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DEVELOPMENT OF FLUORESCENT PROBES FOR IMAGING 
SYNAPTIC ACTIVITY AT INDIVIDUAL PRESYNAPTIC TERMINALS 
Paolomi U. Merchant  
 
This thesis describes the design, synthesis and development of fluorescent probes to 
monitor synaptic transmission at individual presynaptic terminals in the mouse brain. Two 
distinct approaches to accomplish this are discussed.  The first approach seeks to monitor 
synaptic activity by using pH-sensitive endocytic membrane probes to label active presynaptic 
terminals. The second approach seeks to monitor synaptic activity by loading small fluorescent 
molecules into presynaptic vesicles and studying their evoked release upon stimulation.  
The first chapter of this thesis describes currently available techniques that are used to 
study synaptic transmission in the brain. The use of electrochemical techniques is discussed and 
the use of fluorescent reporters is introduced as a means to image single synapses with high 
resolution.  
Chapter II of this thesis describes the rational design of pH-sensitive membrane probes 
for labeling recycling vesicles. The synthesis, photophysical properties and biological 
characterization of these probes are described. Although these probes proved to be too lipophilic 
to work well in the brain tissue and neuronal culture, their use on the cell surface is 
demonstrated. Furthermore, the structure activity relationship established by this library of 
probes can be used to direct the future development of pH-sensing endocytic dyes.   
Chapter III and IV of this thesis describe the development of new generations of 
Fluorescent False Neurotransmitters (FFNs) for imaging vesicular content release from 
individual presynaptic terminals in the brain. Chapter III introduces a novel imaging agent, 
FFN200, for monitoring and quantifying dopamine release from individual synaptic terminals in 
the mouse brain. Chapter IV describes the exploration and screening of small fluorescent 
molecules in the mouse brain for the purpose of developing FFNs at synaptic terminals other 
than dopamine. FFN7122 is introduced as the first FFN to be developed for terminals outside of 
dopamine. FFN7122 is shown to be a marker for glutamatergic terminals in the hippocampus, 
dorsal striatum, and motor cortex of the mouse brain. The evoked release of this probe from 
presynaptic vesicles is demonstrated and two hypotheses for its uptake mechanism are proposed.  
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AN OVERVIEW OF THE MECHANISM AND DETECTION OF 
SYNAPTIC ACTIVITY  
 
I. NEUROSCIENCE: OVERVIEW AND SIGNIFICANCE 
The brain is one of the great frontiers of modern science. Neuroscience, the study of the 
brain, is one of the most rapidly growing areas of biology. The intersection of new developments 
in molecular biology, cell biology, chemistry, electrophysiology, neuroimaging and computer 
modeling has offered unprecedented insights into the fundamental understanding of the brain. 
Consequently, the past two decades have witnessed spectacular conceptual and methodological 
advances in neuroscience. Scientists have uncovered a wealth of information regarding the 
structure of the brain and the role it plays in language, memory, emotional processing, social 
conduct, personality, decision-making, and judgment. However, despite this progress, many 
mysteries still remain unsolved.    
Although existing technologies can measure brain activity ranging from macroscopic 
brain regions to single neurons, they cannot measure those of complex neural circuits. In order to 
address this gap in our understanding of how the brain works, the Federal Government has 
pledged to fund over $100 million for the Brain Research through Advancing Innovative 
Neurotechnologies (BRAIN) Initiative. The BRAIN initiative is a broad, collaborative research 
initiative aimed at accelerating the development and application of technologies needed to 
produce a dynamic picture of how individual cells and complex neural circuits interact in both 
time and space. This picture will fill major gaps in our current knowledge and provide 
unprecedented opportunities to explore how the brain enables the human body to record, process, 
utilize, store, and retrieve vast quantities of information. Ultimately, it is hoped that the BRAIN 
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initiative will improve prevention, diagnosis and treatment of several neuropsychiatric disorders 
such as schizophrenia, Attention Deficit Hyperactivity Disorder (ADHD), drug addiction and 
Parkinson’s Disease (PD). 
 In this chapter, I will provide a broad overview of the existing technologies that are 
currently being used to detect brain activity. I will discuss the advantages and disadvantages of 
each technology, with the aim of providing an understanding of how my work has addressed 





















II. STRUCTURE AND ORGANIZATION OF NEURONS 
The brain consists of a variety of neural cell types. Neurons form the basic information-
processing units of the brain and glia provide the structural framework that allows neurons to 
remain connected through extensive neural networks.  
A typical neuron has four morphologically defined regions: the cell body, dendrites, 
axons, and axon terminals (Fig. 1). The cell body, also called the soma, is the metabolic center of 
the neuron. The nucleus is located in the cell body, and most of the cell’s protein synthesis 
occurs in the cell body.         
A neuron usually has multiple processes called dendrites that extend from the cell body. 
These processes usually branch out and serve as the main regions for receiving input into the 
neuron from other nerve cells.     
The cell body also gives rise to long processes called axons. These carry nerve impulses 
away from the cell body and direct them to other cells. Axons are surrounded by insulating 
material called myelin, which enables electrical signals to travel down the axon at high speeds. 
Near its end, the axon divides into many fine branches that have specialized swellings called 
presynaptic terminals. These presynaptic terminals end in close proximity to the dendrites of 
another neuron. The dendrite of one neuron receives the message sent from the presynaptic 
terminal of another neuron (Fig. 1).  
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Fig. 1. Structure of a neuron showing the cell body, dendrites, axon and axon terminals. Some 
axons are surrounded by the myelinated sheath. Axon terminals form synapses with the dendrites 
or cell body of the post synaptic neuron. Information travels away from the cell body of the 
presynaptic neuron, down its axon and is conveyed to the postsynaptic neuron through the 
synapse. Though this image depicts one neuron connecting to only one other neuron, a single 
neuron can forms synapses with several other neurons. Fig. is adapted from 
http://kvhs.nbed.nb.ca/gallant/biology/neuron_structure.html.  
  
The site where a presynaptic terminal ends in close proximity to a receiving dendrite is 
called the synapse. The cell that sends out information is called the presynaptic neuron, and the 
cell that receives the information is called the postsynaptic neuron. It is important to note that the 
synapse is not a physical connection between the two neurons; there is no cytoplasmic continuity 
between the two neurons. The extracellular space between the presynaptic and postsynaptic 
neurons is called the synaptic space or synaptic cleft.  
Furthermore, synaptic connections are not static. Neurons form new synapses or 
strengthen synaptic connections in response to external and internal stimuli. This dynamic 
change in neuronal connections, called synaptic plasticity, is of immense importance as it forms 




III. SYNAPTIC COMMUNICATION: MECHANISM OF NEUROTRANSMITTER 
RELEASE  
Neurons are the fundamental information processing units of the brain. The process of 
information flow between neurons is known as neurotransmission. Such information flow may 
be either chemical or electrical in nature, but is predominantly chemical in nature in the 
mammalian central nervous system (CNS). The chemical communication between two neurons 
occurs via small molecules called neurotransmitters (NTs).  
NTs are usually synthesized in the neuron and packaged into synaptic vesicles in the 
presynaptic terminals via specific NT transporters. The energy needed to drive this process is 
provided by an electrochemical proton gradient1 across the vesicular membrane. This 
electrochemical gradient is generated by the V-ATPase proton pump2. V-ATPase pumps protons 
into the vesicular lumen3, thereby maintaining its pH at ~5.5. NT transporters couple the efflux 
of protons from the vesicle with the influx of NT into the vesicle4 (Fig. 2). Consequently, pH of 
the vesicle is tightly coupled to NT uptake and thus represents a key contributor to synaptic 
plasticity.  
The process of NT release from a neuron is initiated by the propagation of an electrical 
impulse, the action potential, through the axons.  The action potential depolarizes the axon 
membrane, causing an influx of calcium ions into the neuron. The increase in intracellular 
calcium concentration causes the fusion of NT filled vesicles to the presynaptic membrane. This 
allows the NT to be released into and diffuse across and outside of the synaptic cleft, where it 
binds to and activates its receptors on presynaptic, postsynaptic or extrasynaptic cells, thereby 
effecting the process of chemical synaptic transmission. NT at the synaptic cleft can then be 
taken up into the presynaptic neuron or other surrounding cells through the action of specific 
reuptake transporters or degraded by enzymes at the synaptic cleft (Fig. 2).  
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 Information is transferred via the movement of these small molecule NTs between 
neurons through either point-to-point transmission within synapses or volume transmission, 
which is extrasynaptic. Volume transmission functions quite differently from synaptic 
transmission, which is optimized for high-speed and precise communication. In contrast to 
synaptic transmission, volume transmission provides a communication mode that is temporally 
slower and anatomically broader in reach, and more suited to modulatory functions. Furthermore 
information can also be transferred via retrograde neurotransmission, a process by which a 
retrograde messenger is released by a postsynaptic dendrite or cell body and travels across the 






















Fig. 2. NTs are usually synthesized within the neuron and packaged into synaptic vesicles via 
vesicular membrane transporters. The arrival of an action potential causes the depolarization of 
the neuron and opening of voltage-gated calcium ion channels. The influx of calcium ions 
Presynaptic Neuron
NT Synthesis























Voltage-gated Ca2+ ion channel
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initiates vesicles to fuse with the presynaptic, cause the release of NT into the synaptic cleft. 
Once released, NT can bind to receptors on the postsynaptic, presynaptic (autoreceptors) or 
extrasynaptic membrane to elicit a response. The loading of NT into the synaptic vesicle is 
dependent on the pH of the vesicular lumen which is maintained at ~5.5 due to the action of the 
V-ATPase proton pump.  
 
After exocytosis, the vesicles are recaptured either immediately or via the formation of 
clathrin-coated pits in the membrane so they can be recycled for later use (Fig. 3). Though there 
are several controversial issues that remain regarding this recycling process, the fact that 
exocytosis is closely coupled with endocytosis in nerve terminals is well-established. This was 
first elegantly demonstrated 30 years ago by using uptake markers to label synaptic vesicles6.  
This coupling of endocytosis with exocytosis is important because it enables the rapid re-
supply of the docked pool of vesicles, allowing NT release to keep up with the rate of action 
potential firing. In the CNS, synaptic terminals have only on the order of 100 vesicles per active 
zone, yet neuronal activity in functional circuits often requires sustained action potential firing in 
range of 10-100 Hz. The fidelity of normal circuit function therefore relies on the rate of vesicle 
use as well as recycling at each synapse.   
Fig. 3. A schematic of the endocytosis/exocytosis 
vesicle cycle in a pre-synaptic terminal. After a NT 
is synthesized, it is packaged into vesicles in the 
presynaptic terminal via specific NT transporters. 
The vesicles are transported to the cell membrane 
for docking and priming, after which exocytosis is 
triggered via a combination of several mechanisms. 
Vesicles are retrieved and recycled via one of 













 Much work has contributed to a classical view of an exo-endocytic cycle, where vesicles 
fuse by completely flattening into the plasma membrane, in a process known as full-collapse 
fusion. This leads to complete aqueous continuity between vesicle lumen and external medium 
and to full lipid continuity vesicle membrane and plasma membrane. In contrast to this view, 
there is mounting evidence for a non-classical mode of fusion, termed ‘kiss-and-run’, in which 
vesicles are thought to fuse only transiently with the plasma membrane without complete loss of 
identity6.  
 Furthermore, it is important to note that the strength of a synaptic connection is 
fundamentally dependent on the size of the postsynaptic depolarization caused by NT release 
from a single synaptic vesicle (quantal size) as well as the probability of NT release at each 
synapse (release probability)7. The probability of NT release can be highly variable and is a 
consequence of the inherently stochastic nature of the molecular and cellular processes that drive 
vesicle exocytosis. Thus, for each action potential, NT release has a certain likelihood of 











IV. CLASSES OF NEUROTRANSMITTERS  
 A variety of substances in the CNS serve as NTs. These can broadly be characterized as 
amino acids (AA), derivatives of amino acids called biogenic amines (BA) or neuropeptides 
(NP) (Fig. 4). AA and BA are most the most widely used NTs. Other small molecules as 

















Fig. 4. Three major classes of neurotransmitter signaling molecules – neuropeptides, amino acids 
and biogenic amines.  
 
IV. 1 Amino Acid Neurotransmitters  




























Even though there are several amino acid NTs, glutamate and gamma-aminobutyric acid 
(GABA) are the most widely distributed throughout the brain. Both the NTs are discussed below 
are important for understanding my work in Chapter IV.  
(1) Glutamate 
Glutamate is the primary excitatory NT in the brain and increases the propensity of the 
postsynaptic neuron to fire action potentials. It is packaged into presynaptic vesicles by the 
vesicular glutamate transporters VGLUT1, VGLUT2 and VGLUT38. Though the distinct role of 
each VGLUT in glutamate neurotransmission is not yet well understood, it is known that all 
three VGLUTs have similar affinity for glutamate (all show Kms in the low millimolar range) 
and participate in the uptake of glutamate into presynaptic vesicles.  
After glutamate is released into the synaptic cleft and extrasynaptic space as the result of 
an action potential, it can act postsynaptically through three families of ionotropic receptors, 
named after their preferred agonists, N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-
5methyl-4-isoxazolepropionic acid (AMPA) and kainate. These receptors are ligand-gated ion 
channels9 that are permeable to cations such a Na+ and Ca2+. Glutamate can also act through 
three groups of metabotropic, G protein-coupled glutamate receptors (mGluR) that modify 
neuronal and glial activity on a slower time scale as compared to ionotropic receptors10. When 
activated, mGluRs act indirectly through G protein subunits on other receptors and ion channels 
via a cascade of intracellular signaling11.  
In contrast to other NTs that are recycled directly into the nerve terminals, excess 
glutamate appears to recycle indirectly. Excess glutamate is taken up primarily into glia through 
plasma membrane transporters called excitatory amino acid transporters (EAATs). In humans (as 
well as in rodents), five subtypes of EAATs have been identified and named EAAT1-512. 
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EAAT1-2 are found on membranes of glial cells whereas EAAT3-4 are located on membranes of 
neurons13. Within the glia, glutamate is converted to glutamine and shuttled back to neurons via 
plasma membrane glutamine transporters. Within the neurons, glutamine is converted back into 
glutamate through the enzyme glutaminase (Fig.5). 
 
Fig. 5. Mechanism of glutamatergic neurotransmission in the mammalian central nervous 
system. Within presynaptic neurons glutamine is converted to glutamate by the enzyme 
glutaminase. Glutamate is packed into presynaptic vesicles via the vesicular glutamate 
transporter (VGLUT) and released when the presynaptic vesicles fuse with the presynaptic 
membrane. The glutamate that is released is recycled by excitatory amino acid transporters 
(EAATs) which are expressed on the postsynaptic and presynaptic membrane as well as on the 
surface of astroglia. There are 5 EAAT subtypes. GLAST, GLT-1 and EAAC1 correspond to 
EAAT1, EAAT2 and EAAT3 respectively. In astrocytes, glutamate is converted glutamine via 
glutamine synthetase and exported extracellularly to be taken up by neurons again. Glutamate 
binds to its receptors that are both ionotropic and metabotropic. Glutamate receptor stimulation 
results in not only rapid ionotropic effects but also in synaptic plasticity and long term 
potentiation (LTP, see Chapter IV)). Fig. is adapted from Shigeri et al. (2004) Brain Research 
Reviews 45, 250–65. 
 
Without the activity of glutamate transporters, glutamate would build up and kill cells in 
a process called excitotoxicity, in which an excessive amount of glutamate acts as a toxin to 
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neurons by triggering a number of biochemical cascades. 
(2) Gamma-Aminobutyric Acid (GABA) 
 GABA is the primary inhibitory NT that decreases the postsynaptic neuron’s excitability. 
GABA is synthesized from glutamic acid via the enzyme glutamic acid decarboxylase (GAD)14 
and then packaged into presynaptic vesicles via the vesicular GABA transporter (VGAT)15.  
Depolarization of GABA neurons causes GABA to release into and diffuse across the 
synaptic cleft, where it binds to its target receptors on the postsynaptic surface. There are two 
classes of GABA receptors: GABAA and GABAB. GABAA receptors are fast acting ionotropic 
receptors whereas GABAB receptors are slower acting G protein-coupled metabotropic 
receptors16.  
The action of GABA at the synapse is terminated by its reuptake into presynaptic nerve 
terminals and surrounding glial cells by the action of plasma membrane GABA transporters 
(GATs). GABA taken back up into nerve terminals is available for reutilization, but GABA in 
glia is metabolized to succinic semialdehyde and cannot be resynthesized in this compartment 
since glia lack GAD. Ultimately, GABA can be recovered from this source through the Krebs 
cycle.  
To date, four different GATs have been described, GAT1, GAT2, GAT3, and the 
Betain/GABA transporter type 1 (BGT-1). These transporters are members of a large family of 
12-transmembrane spanning Na+/Cl− coupled transporters17. GAT1 and GAT3 are the two main 
subtypes of GATs responsible for the regulation of extracellular GABA levels in the CNS. 
GAT1 is mainly expressed in neurons and GAT3 is mainly expressed on glia.  
IV. 2  Biogenic Amines  
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 There are five established biogenic amine (also known as monoamines) 
neurotransmitters. These include three catecholamines - dopamine (DA), epinephrine and 
norepinephrine (NE) - the indolamine serotonin (5-hydroxytryptamine; 5-HT), and histamine. 
The biosynthesis of monoamines occurs throughout their corresponding neurons and cells. The 
first step in the synthesis of catecholamines is the hydroxylation of the amino acid tyrosine to 
form DOPA. An analogous reaction, the hydroxylation of tryptophan to 5-hydroxytryptophane, 
is the first step in the synthesis of 5-HT. The next step in the synthesis of monoamines (MAs) 
involves decarboxylation by aromatic amino acid decarboxylase (AADC) to form DA or 5-HT. 
NE is then formed via the hydroxylation of the benzylic carbon of DA18.     
MAs are taken up and stored in vesicles via vesicular monoamine transporters 1 and/or 2 
(VMAT1 and/or VMAT2), in a manner described previously (Fig. 2). The role of this transporter 
in relation to DA uptake is further elaborated upon in Chapter III. MAs are released from the 
presynaptic terminal via calcium-dependent exocytosis in response to action potentials. Once 
released, they bind to and activate their specific receptors on the postsynaptic, presynaptic or 
extrasynaptic membrane. MAs can act on presynaptic or extrasynaptic cells in order to influence 
the cells through a positive or negative feedback mechanism. When a MA binds to its 
presynaptic receptors (autoreceptors), it can either stimulate MA biosynthesis or inhibit further 
NT release.  
The vast majority of MA receptors in mammals are metabotropic G-protein coupled 
receptors (GPCRs) with seven transmembrane domains. An interesting exception to this is the 5-
HT3 receptor, which is ionotropic19. 
Excess MAs can be taken up via plasma membrane transporters. These include DAT for 
DA, NET for NE and SERT for 5-HT20.  
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DA neurotransmission, a broad interest of our lab and the focus of one of my projects, is 
explained in greater detail in Chapter III.   
IV.3 Neuropeptides  
Neuropeptides are small protein-like molecules used by neurons to communicate with 
each other.  They are generally synthesized as precursor proteins that are processed by enzymes 
such as prohormone convertases and carboxypeptidases. These enzymes cleave a peptide 
precursor at specific processing sites in order to generate the bioactive peptides21. Several 
neuropeptides such as Enkephalin, Neuropeptide Y and Substance P have been identified22. Like 
monoamines they are packaged into vesicles and released by exocytosis.  
Once synthesized, neuropeptides are secreted from neurons (or glia for some peptides) 
and signal to neighboring neurons by acting on cell surface receptors. Often, they are co-released 
with other small-molecule NTs. However, they differ from NTs in that they are not recycled 
back into the cell once secreted. Instead, they are cleaved by extracellular peptidases which serve 
to inactivate their biological activity.  
Neuropeptides are involved in a wide range of brain functions, including reward, food 











V. NEUROTRANSMITTER PATHWAYS  
(1) Amino Acid NT Pathways 
 The mammalian brain requires a balance between excitatory and inhibitory 
neurotransmission to sustain proper neuronal function. The two major classes of neurons that 
maintain this intricate balance are the glutamatergic excitatory projection neurons and 
GABAergic inhibitory neurons. Both these types of neurons play important regulatory roles in 
neurotransmission and their synapses are widely spread throughout the brain. The major 
pathways of these two amino acid NTs are briefly described here (Fig. 6) and later elaborated 
upon in Chapter IV.  
 There are five major glutamatergic pathways. (1) The cortico-cortical glutamatergic 
pathways allow pyramidal cortical neurons to communicate with each other via glutamate23. (2) 
The cortical brainstem glutamate projection is a descending pathway that projects from cortical 
pyramidal neurons in the prefrontal cortex to brainstem centers such as the raphe (R) nuclei, 
locus coeruleus (LC), ventral tegmental area (VTA) and the substantia nigra (SN). (3) Another 
descending pathway is known as the corticostriatal glutamate pathway and projects from the 
cortex to the striatum. (4) Thalamocortical glutamate pathways ascend from the thalamus to 
innervate pyramidal neurons in the cortex. (5) Corticothalamic glutamate pathways descend 
from the prefrontal cortex to the thalamus. Notably, three of the five pathways project from the 
frontal cortex and penetrate into deeper brain areas and the spinal cord where they exert control 
over the neuroanatomic structures residing there. 
GABAergic inhibition is seen at all levels of the CNS, including the hypothalamus, 
hippocampus, cerebral cortex and cerebellar cortex24. For the most part, GABA modulates 
neuronal activity locally by release from interneurons (neurons whose relatively short axons 
branch locally to innervate other neurons in the vicinity), though a number of GABAergic 
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projection neurons have also been discovered in the brain. The most well defined GABA  
projection neurons in the CNS have their cell bodies in the basal ganglia and the cerebellum. 
Projection neurons in the basal ganglia arise principally from the striatum and globus pallidus 
and terminate in the substantia nigra25. The Purkinje cells of the cerebellar cortex are also a 
major source of GABAergic projection neurons26.  
 
 
Fig. 6. The glutamate and GABA pathways in the normal human brain are illustrated. Glutamate 
pathways include the following: (1) Cortico-cortical pathways. (2) The pathway between the 
pyramidal neurons in the prefrontal cortex to brainstem NT centers. (3) The corticostriatal 
glutamate pathway that projects from the cortex to the striatum. (4) Thalamocortical glutamate 
pathways that ascend from the thalamus to the cortex. (5) Corticothalamic glutamate pathway 
that descends from the prefrontal cortex to the thalamus. GABAergic pathways consist of 
interneurons as well as projection neurons. Interneurons are abundantly found in the cortex and 
hippocampus as well as the hypothalamus, olfactory bulb and retina. GABAergic projection 
neurons are found mostly in the basal ganglia and cerebellum. Figure is adapted from the 
educational resources of the Lundbeck Institute CNSforum.  
 
                     GLUTAMATE PATHWAYS! ! ! ! !           GABA PATHWAYS!
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(2) Biogenic Amine Pathways  
 
Monoaminergic neurons innervate almost all brain areas. A brief overview of this 
innervation is presented here (Fig. 7). The DA cell bodies in the SN and adjacent VTA project to 
the striatum and to regions in the neocortex. DA pathways play an important role in motor 
control, habit learning, motivation and reward processes. This is further elaborated upon in 
Chapter III.  
The NE cell bodies in the LC project to limbic and cortical regions, and to the thalamus, 
cerebellum, and spinal cord27. The 5-HT cell bodies located in the raphe nuclei project to almost 
all parts of the brain28. 5-HT plays an important role in the regulation of mood and attention and 
has been implicated in several types of behavior, such as appetitive, emotional, motor, cognitive 
and autonomic29.  
 
 
Fig. 7. The DA, NE and 5-HT pathways in the normal human brain are illustrated. DA cells 
bodies are present in the VTA and SN and project to the striatum and prefrontal cortex. NE cell 
bodies are present in the LC and raphe nuclei and project to the thalamus, cortex, cerebellum and 
olfactory bulb. 5-HT cell bodies are present in the raphe nuclei and project to the cortex, 
thalamus, cerebellum and basal ganglia. Figure is adapted from educational resources of the 
Lundbeck Institute CNSforum.  
 
   DOPAMINE PATHWAY                      NOREPINEPHRINE PATHWAY               SEROTONIN PATHWAY!
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VI. METHODS FOR THE STUDY OF SYNAPTIC TRANSMISSION 
Two experimental strategies that have been widely used to study the synaptic basis of 
circuit function are electrochemistry and optical imaging. Electrochemical techniques such as 
cyclic voltammetry and amperometry (elaborated upon in section VI.I of this chapter) are 
excellent methods for studying NT release in brain slices as they provide a temporal resolution 
on the scale of 100 milliseconds or less and in vivo they provide a temporal resolution of about 1 
second or less30.  However, electrochemical techniques do not allow the locations of neurons and 
synaptic connections to be identified. Moreover, they report the release of NT from large 
populations of terminals and do not have the spatial resolution needed (~1 µm) to study 
neurotransmission at the level of individual presynaptic terminals. Electrical capacitance 
measurements that examine membrane retrieval have been used to study vesicle recycling at 
individual terminals, but only in a few instances31. Even though this approach yielded fruitful 
information, it could only applied to select giant synapses (~10 µm in diameter) that are not 
found in the CNS.  
The study of single synapses, as opposed to groups of synapses, is of immense 
importance because in order to understand the bulk behavior of neurons we need to understand 
individual members of the assembly. Furthermore, changes in the strength of connections 
between neurons are widely assumed to play a role in the storage of memories in the central 
nervous system32.  
Optical assays provide vastly improved spatial resolution (~ 1 µm or less) and are thus 
better suited for widely used preparations of the CNS such as neuronal culture and tissue slices, 
where the size of a presynaptic bouton is  ~1 µm. Furthermore, optical assays also allow larger 
areas to be surveyed than is possible with electrochemistry. The different parameters of synaptic 
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transmission that have been targeted for measurement by optical means are described in section 
VI.2.  
VI.1 Electrochemical Methods 
Electrochemical techniques that have traditionally been used to study presynaptic activity 
include cyclic voltammetry (CV) and amperometry.  
(1) Cyclic Voltammetry  
CV relies on the ability of the NTs to change their redox state in response to the 
application of small electrical potentials (~1 Volt). Over the usable potential range most NTs 
(acetylcholine, GABA, glycine, glutamate, aspartate,) cannot be oxidized. Others such as 
endorphins and neuropeptides although electroactive, are ordinarily so low in concentration and 
diffuse so slowly that they do not generate sufficient current to be measurable by CV. Only the 
catecholamines and serotonin, along with their metabolites, are readily detectable by CV33.  
CV provides real-time measurements of changes in the extracellular concentration of 
these NTs with high temporal resolution (100 milliseconds or less). Its spatial resolution is on the 
order of 100 μm or less34. This technique uses carbon-fiber microelectrodes that have a diameter 
of approximately 7-35 μm. The electrodes are aspirated into a glass capillary and then pulled into 
a point that is polished to a smooth surface, with a portion of the fiber (75-200 μm) extending 
from the glass tip. This generates an electrode that is about 20 μm in diameter and 25-400 μm in 
length. The electrode tip is typically placed in the area of interest where neurochemical 
information needs to be measured. The spatial resolution of this technique is limited by the size 
of the electrode. A typical carbon fiber microelectrode measures NT release from hundreds of 
presynaptic release sites35.   
In order to accurately measure DA, NE or 5-HT concentration, electrodes are calibrated 
with concentrations of monoamines that are relevant to the biological sample. For example, in 
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brain slices, since monoamine release is generally ≤1 µM, calibration is done with concentrations 
of DA, NE or 5-HT that are between 0.1 and 1 µM. 
A voltage that is sufficient to oxidize monoamines (Fig. 8) is applied to the carbon fiber 
microelectrode. The oxidation process results in current flow at the electrode surface. The 
amount of current is then measured and can be converted into concentration of monoamine in the 
vicinity of the electrode tip by means of electrode calibration. The current is measured rapidly, 
and when plotted against time, can provide information as to how stimulation parameters and 






Specifically, a triangular waveform is applied to the electrode. This potential is scanned 
from  -0.4 V to 1 V and back to -0.4 V at the rate of 300 V/s. This process generates its own 
background current that masks the current generated by the oxidation of the NT. However, since 
this current is known and constant, it can be subtracted from the overall current to reveal the 
cyclic voltammogram of the NT present in the system. The oxidation and reduction peaks in this 
background-subtracted voltammogram can then be used to detect the identity of the particular 
NT of interest30. For example, in the case of DA, electrical stimulation causes an increase in the 
current detected and then a decrease due to DA reuptake (Fig. 9).     
 
Fig. 8. The redox reaction 
for dopamine initiated by 
the application of a 


































Fig. 9. (A) The triangular waveform of potential applied to the electrode is ramped from -0.4 V 
to 1.0 V and back at a scan rate of 300 V/s. (B) Background current is plotted as a function of 
applied potential. The solid line is the background current, and the superimposed dashed line is 
the current observed in the presence of dopamine. (C) Upon background subtraction, a cyclic 
voltammogram for is generated whose oxidation and reduction peaks can be used to identify the 
NT of interest. (D) Plot shows the changes in dopamine current. The current corresponding to the 
peak oxidation potential of dopamine is plotted. Figure is adapted from Robinson et al. (2003) 
Clinical chemistry 49, 1763–73. 
 
Even though CV can be used to detect a broad range of catecholamines, indolamines and 
NT metabolites, it must be remembered that not all NTs can be differentiated by this technique. 
For example, DA and NE have very similar voltammograms that are indistinguishable by CV. 
Therefore, in order to study DA neurotransmission using CV, experiments can be carried out 
only in brain regions which are known to have high dopaminergic innervation and sparse 
noradrenergic innervation36.  
Nonetheless, CV has proved to be an immensely useful tool to measure NT concentration 
as well as the kinetics of NT release and uptake, both in vivo and in vitro37. Furthermore, it has 
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been used effectively to study the effect of drugs and other pharmacological treatments on DA 
release in both wild type and disease animal models38.  
(2) Amperometry 
 Continuous amperometry involves the application of a constant potential difference 
between a working electrode and a reference electrode. This potential is fixed at a level sufficient 
to oxidize the molecule of interest. During the oxidation process, electrons are transferred to the 
electrode, giving rise to a measurable oxidation current. Molecules are delivered to the electrode 
surface by diffusion, which occurs at a rate proportional to the concentration of the solution 
surrounding the electrode.  
For example, in the case of DA, the carbon electrode is held at +0.4 V versus an Ag/AgCl 
reference electrode. DA molecules that come into contact with the electrode surface are oxidized, 
with each DA molecule transferring two electrons to the surface of the electrode.  
However, any substance present in the solution that oxidizes at or below the potential 
applied to the electrode may contribute to the total oxidation current. For this reason, the total 
oxidation current might include contributions from other oxidizable substances, so amperometry 
is not selective and must be used accordingly. Therefore, the use of continuous amperometry is 
only valid when the compound of interest represents the main oxidizable compound released in 
the vicinity of the carbon fiber electrode. Indeed, this approach has been used in systems that 
meet these requirements.  
For example, amperometry has been used to monitor epinephrine and norepinephrine 
release by single chromaffin cells39 and DA release by single PC12 cells40. The technique can 
also be used for monitoring electrically evoked DA release in brain striatal slices because, in this 
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preparation, oxidizable molecules in the extracellular space of the slice remain below the 
detection limit of amperometry41. 
  The main advantage of amperometry over CV is that it exhibits a higher sampling rate 
and faster temporal response42. However, molecules that are oxidized at the electrode cannot be 
differentiated, limiting the selectivity of this technique.  
VI.2 Optical Methods  
Synaptic activity can be visualized by targeting different parameters involved in synaptic 
transmission. These parameters and their corresponding optical tools that have been used to 
measure them are listed below.  
(1) Voltage Signals – Voltage Sensitive Dyes and Proteins  
(2) Presynaptic and Postsynaptic Calcium Signals – Fluorescent Calcium Indicators and 
Dyes 
(3) Vesicle Fusion with the Presynaptic Membrane – Fluorescent Endocytic FM dyes 
(4) pH Change in the Vesicular Lumen – SynaptopHluorins  
(5) Release of Neurotransmitter – GluSnFr 
(6) Release of Synaptic Vesicle Content – Fluorescent False Neurotransmitters (FFNs)  
(1) Voltage Signals – Voltage Sensitive Dyes and Proteins 
Voltage-sensitive dyes are small amphiphilic molecules that intercalate into cell 
membranes and change their spectral properties in response to membrane potential43.  Even 
though they provide excellent temporal resolution, on the scale of milliseconds, they generate 
large background signals because they stain all membranes in a non-specific manner. 
Furthermore, these dyes are toxic and experiments are limited to only a narrow timeframe after 
their application.  
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Genetically encoded reporters that can be localized to specific regions of a neuron by 
fusion to specific proteins have been used to overcome this unwanted background signal. The 
first generation of genetically encoded voltage sensors was made by fusing fluorescent proteins 
to voltage-gated ion channels. FlaSh, a fusion of green fluorescent protein to the Shaker K+ 
channel, exhibited a maximal fluorescence change of about 5%, but showed a slow decay time44. 
Other voltage sensitive proteins are Voltage Sensor Probe (VSPI)45 and sodium channel protein-
based activity reporting construct (SPARC)46 which were developed by fusing a fluorescent 
protein to a potassium or sodium channel.  
 Unfortunately, all these voltage sensors have a relatively low signal over the background 
and the ΔF/F is too small to be used at the level of individual neurons47.      
(2) Presynaptic and Postsynaptic Calcium Signals – Fluorescent Calcium Indicators and 
Dyes 
 
 Fluorescent calcium indicators detect changes in calcium concentration that result from 
the influx of calcium ions through voltage-sensitive calcium channels which open when the 
neuron is depolarized. These dyes have been applied towards the study of both presynaptic and 
postsynaptic calcium influx.  
 Calcium dyes such as fluo-3 and rhod-2 can be introduced into thousands of neurons by 
bulk loading in the form of an acetoxymethyl ester derivative, both in slices and in vivo48. Dye 
can be introduced into a single cell through a patch pipette. This reduces background signals and 
can increase resolution to the level of single synapses49. Using this technique, it has been 
possible to monitor postsynaptic calcium signals in dendritic spines of excitatory synapses 
mediated by glutamate-gated channels like NMDA or AMPA. Since these calcium dyes can 
image single synapses, they can be used to optically measure the ‘quantal release’ of NTs by 
measuring postsynaptic readouts. Such ‘quantal analysis’ has revealed heterogeneity in synaptic 
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strength at different terminals of the same neuron as well as changes in vesicle release 
probability associated with different forms of synaptic plasticity25.  
 Protein-based calcium indicators have also been developed. These genetically encoded 
sensors improve specificity of labeling and reduce background signals. Some of the most 
sensitive genetically encoded calcium indicators (GECIs) for detecting post synaptic calcium 
influx are D3cpv and GCaMP3. D3cpv generates a fluorescence change of ~8% when the 
fluorescent signal is collected form the soma50. GCaMP3 generates a ΔF/F of ~14% in apical 
dendrites51. One of the first attempts to use a calcium-sensitive protein to monitor the activity of 
individual synapses used synapcam – a fusion of the calcium sensitive Cameleon protein with the 
Shaker potassium channel – expressed at postsynaptic sites in the muscle of Drosophila. 
Synapcam provided single-impulse resolution and also revealed variations in synaptic strength at 
different connections of the same neuron. One of the drawbacks of this approach however, is that 
it cannot be applied to synapses where there is no obvious rise is the postsynaptic calcium signal, 
such as at inhibitory synapses. Presynaptic targeting of calcium indicators has been developed in 
order to address this limitation.  
 Imaging calcium changes at the presynaptic terminal is a promising approach because 
this region has a high density of voltage-sensitive calcium channels. The presynaptic calcium 
signal is larger and faster than the calcium signals in other compartments of the neuron52 and 
therefore provides the possibility of detection with improved time resolution. Furthermore, the 
localization of a GECI to the presynaptic compartment reduces contamination by dendritic and 
somatic fluorescence.    
The first attempt to use a GECI to monitor the activation of presynaptic terminals was 
made by using SyGCaMP253, a fusion of GCaMP2 with synaptophysin, a synaptic vesicle 
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protein. In cultured hippocampal neurons SyGCaMP2 could be used to visualize and measure 
activity of individual synapses. Single action potential induced calcium spikes could be detected 
as a ~11% rise in fluorescent signal at individual presynaptic terminals. The signal to noise ratio 
was sufficient to assess the wide variability in presynaptic calcium signals in different terminals 
of the same neuron.  
Even though calcium indicators have been immensely useful for studying synaptic 
activity, one of their major limitations is the saturation of their response after a few action 
potentials. This is likely due to their high affinity for and slow release of calcium ions at the 
binding sites.  Even though SyGCaMP2 showed a significant improvement in this regard 
compared to previous GECIs, it seems unlikely that a single GECI will provide a solution to this 
problem because neurons in different regions of the nervous system show large variations in 
activity. Furthermore, it is important to note that each spike in calcium concentration does not 
correspond to NT release because NT release is affected by the probability of vesicle fusion at 
each release site (see section III of this Chapter).  
(3) Vesicle Fusion with the Presynaptic Membrane – Fluorescent Endocytic FM dyes 
 Even though the aforementioned voltage sensitive and calcium sensitive dyes have been 
valuable tools for the study of synaptic activity, they cannot provide a precise estimate of the 
kinetics of endocytosis and exocytosis, which is inherently a function of membrane fusion. In 
order to address this limitation, fluorescent membrane dyes, called FM dyes, have been 
developed. The most commonly used FM dye is FM1-4354.  
FM dyes are styryl pyridinium molecules with a lipophilic group and a divalent cationic 
group. According to the mechanistic model for FM dyes, the lipophilic group of the dye inserts 
into the outer leaflet of the cell membrane but does not cross over into the cytosol due to the 
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dicationic charge. They are incorporated into and label synaptic vesicles in response to 
stimulated endocytosis. They have been used in various preparations including cell culture, 
neuronal culture and brain slices. The excitation and emission maxima which occur at 474 nm 
and 580 nm respectively, are well suited to biological imaging.  
 FM dyes are directly relevant to my work regarding the development of a new class of 
pH-responsive endocytic dyes, which is the focus of Chapter II, and hence are described in 
further detail there.  
 (4) pH Change in the Vesicular Lumen – SynaptopHluorins  
Fluorescent proteins (FPs) such as green fluorescent protein (GFP) are widely used in 
biological imaging. FPs are genetically encoded labels and thus can be ‘built into’ a biological 
system using transgenic and viral approaches. As FPs are synthesized within the cell, there is no 
need for labeling with exogenous agents, or for the fixation and permeabilization procedures that 
are required for immunofluorescence. Furthermore, FPs can be fused to their protein targets, so 
that they are expressed in a 1:1 ratio with the target protein.  
Proteins that are pH sensitive, called pHluorins, were developed by mutating GFP in 
order to enhance its pH sensitivity and thus report changes in pH as a function of fluorescence 
intensity. These proteins have been especially useful for measuring NT exocytosis and vesicle 
recycling because they can report the difference in pH between the vesicular lumen (pH 5.5) and 
the extracellular milieu (pH 7.4). Most notably, SynaptopHluorin (spH), a fusion protein made 
up of the synaptic vesicle protein synaptobrevin-2 and a pH sensitive protein, has been used 
extensively to study presynaptic activity in a variety of systems.  
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The concept of exploiting pH differences to study synaptic activity is directly relevant to 
my work regarding the development of a new class of pH-responsive endocytic dyes. Therefore, 
the protocols for and uses of spH are described in further detail in Chapter II. 
(5) Release of Neurotransmitter – GluSnFr 
  
 Efforts to detect synaptic activity by optically monitoring NT release have focused on 
imaging glutamate, as this is the most widespread NT in the brain. Spatial resolution of 
individual synapses has been achieved by two genetically encoded reporters that can be anchored 
to the cell membrane – FLIPEO55 and GluSnFR56.  Both these sensors are based on the concept 
of Förster resonance energy transfer (FRET) and are built around the glutamate binding protein 
GltI from Escherichia coli. A fluorescent signal is generated when glutamate is released into the 
synaptic cleft and binds to the sensor, which is widely expressed on the surface membrane. A 
variant of GluSnFR, SuperGluSnFr, has allowed direct measurements of the time course of 
glutamate release onto the dendrites of cultured hippocampal neurons, with a spatiotemporal 
sensitivity sufficient to measure a single action potential.  
 The development of GluSnFr and other techniques for visualizing glutamate release is of 
importance to my work regarding the development of fluorescent small molecules to visualize 
NT release at gutamatergic synapses. This work is the focus of Chapter IV and therefore 
techniques to image glutamate release are further elaborated upon there.    
(6) Release of Synaptic Vesicle Content – Fluorescent False Neurotransmitters (FFNs) 
 The concept of FFNs to optically monitor exocytosis by imaging release of synaptic 
vesicle contents was introduced by our lab in 200957. The general concept of a FFN was to 
develop a small fluorescent molecule that could serve as a substrate for plasma membrane NT 
transporters and/or vesicular membrane NT transporters. Inspired by the fact that the vesicular 
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membrane transmporter 2 (VMAT2), which is responsible for monoamine uptake, is known to 
be somewhat promiscuous for its substrates, a library of fluorescent molecules was synthesized 
in order to imitate the structure of endogenous monoamines. The overall design of these 
molecules preserved key functional groups of the endogenous NTs in order to maintain 
recognition by VMAT2, and added additional aromatic functionality in order to confer the 
molecules with fluorescent properties. From this library, FFN102 emerged as DA transporter 
substrate and a selective marker for DA presynaptic terminals in the mouse dorsal striatum. It 
was taken up by presynaptic vesicles and released in response to electrical stimulation at a 
frequency of 10Hz, allowing for the first time the direct visualization of NT specifically from 
DA terminals.  
The design and structure of FFNs is applicable to my work in Chapter III, which involves 
the development of a second generation of a DA-specific FFN, and thus this concept is further 
explained there.  The idea of FFNs is also discussed in Chapters IV and V, which focus on the 












VII. POSITRON EMISSION TOMOGRAPHY FOR IMAGING SYNAPTIC 
ACTIVITY  
 Positron emission tomography (PET) is a powerful non-invasive imaging technique that 
uses probes radiolabelled with a short-lived positron emitting radionuclide. PET probes can be 
imaged and quantified in vivo by detection of the gamma rays that are formed as a result of 
annihilation of the positrons emitted. PET has been particularly important in the quantification of 
biochemical and pharmacodynamic processes in healthy and diseased human patients because it 
provides a deeper understanding of these processes in vivo.  
The most commonly used radioisotopes are 11C, 13N, 15O and 18F which have half lives of 
20, 10, 2 and 110 minutes respectively. PET measurements are extremely sensitive and can 
detect picomolar level these radioisotopes radiotracers in the body. The spatial resolution for 
PET in clinical applications is in the range of 4-8 mm, whereas the resolution for use in small 
animals is 0.5-2 mm58.  
When introduced clinically in the 1970s, PET provided a fundamentally new opportunity 
to explore the parts of the brain that were activated while undertaking specific tasks. This clinical 
application of PET is based upon the observation that changes in regional neural activity are 
coupled to changes in regional cerebral blood flow and metabolism. However, more recently the 
applications of PET have mainly focused on the study of neurotransmitters, the actions of 
pharmaceutical drugs, and the study of diseased states of the brain such as in Alzheimer’s and 
Parkinsons disease.  
PET is used to study NTs by incorporating radioisotopes into either endogenous NTs or 
molecules that are known to mimic endogenous NTs. Using this strategy, PET probes provide a 
way to identify and study specific neurons and networks in the brain and also assess whether 
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abnormally high or low transmitter levels are associated with specific brain conditions. Such 
studies have been successfully performed in vivo.  
For example, to study DA in vivo, PET tracers have been developed to measure DA 
synthesis and transport. For the former, the most commonly used tracers are 6-[18F]FDOPA and 
6-[18F]FMT (Fig. 10) , whereas for the latter several 11C/18F-labeled tropane analogues are being 
clinically used59. These tracers have been used in the study of diseases such as Parkinson’s 
disease, which is characterized by low levels of DA, in order to assess the effects of experimental 




Fig. 10. Structures of 6-[18F]FDOPA and 6-[18F]FMT, commonly used PET tracers for studying 
in vivo DA synthesis.  
 
Due to its high sensitivity, noninvasive nature and ability to measure various molecular 
processes in vivo, PET imaging has been widely used to study neural activity and neuroplasticity 
in the brain in both animal models and human subjects. Indeed, it is one of the most selective and 
sensitive methods for measuring biological processes in vivo60. However, despite these 
advantages, PET imaging has important limitations. Currently, in human subjects, the spatial 
resolution of PET (4-8mm) is too poor to visualize changes at the cellular level. In small animals, 
the spatial resolution of PET (0.5-2mm) is not high enough to enable the detailed study of 
changes in regional activity within certain brain structures. Furthermore, PET requires long 
acquisition times and therefore has low temporal resolution (tens of seconds to minutes)61. Since 
only trace amounts of radioactive elements with short half-lives are injected into patients, the 











Another problem is the partial-volume effect62. This refers to the incorrect estimation of 
radiotracer concentration in a voxel due to the finite spatial resolution of PET imaging. 
Therefore, complicated algorithms must be used in order to correct for this in human brain 
imaging63. Finally, the short half-life of positron-emitting nuclei limits the availability of the 
technology, as radiotracers must be synthesized at a site close to the clinical facility.  
The concept of PET probes for studying NT release is relevant to our work regarding the 
development of both DA-specific and DA-nonspecific FFNs. This is because one long-term goal 
of our lab is to incorporate radionuclides into the structure of FFNs, so as to visualize NT release 
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DEVELOPMENT OF FLUORESCENT pH SENSITIVE ENDOCYTIC 
PROBES FOR IMAGING SYNAPTIC ACTIVITY 
 
I. INTRODUCTION 
As mentioned in Chapter I, several electrical and optical techniques have been developed 
to study synaptic activity. Both techniques have been used in a number of preparations such as in 
live cells, brain tissue slices and in vivo. Electrical techniques to measure and quantify 
neurotransmitter (NT) release have traditionally involved cyclic voltammetry and carbon fiber 
amperometry. Even though these electrical techniques have excellent temporal resolution, (on 
the time scale of milliseconds) they study release of NT from large populations of terminals and 
do not have the necessary spatial resolution needed (~1 µm) to study exocytic events at 
individual presynaptic terminals.  
Optical assays provide vastly improved spatial resolution (~1 µm or less) and are thus 
better suited for studying individual presynaptic terminals which are ~1 µm in size. Two widely 
used fluorescent reporters have been developed for studying synaptic activity at the presynaptic 
terminal. These include (1) FM dyes – fluorescent dyes that can be added to membranes to study 
endocytic capture and re-release and (2) pHluorins – genetically encoded pH-sensitive 
fluorescent proteins that are targeted to synaptic vesicles.  
While both FM dyes and pHluorins have been immensely useful in the study of 
presynaptic activity, each tool has its own set of limitations. FM dyes photobleach easily and 
cannot be easily used in time course experiments that require repeated excitation. Furthermore, 
prolonged illumination results in phototoxic effects to biological preparations. pHluorins require 
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viral infection for use in cell or neuronal culture and generation of transgenic animals for use in 
tissue slices.  
In order to address these limitations, we sought to develop a novel class of pH-sensitive 
endocytic dyes that would be suitable for studying presynaptic activity in brain tissue, thereby 
eliminating the need for viral infection, transfection or the generation of transgenic animals. As 
such, our goal was to design and synthesize a library of putative membrane probes that would be 
photostable and sufficiently bright for use in two-photon microscopy and characterize the probes 
in increasingly complex biological systems (from cell culture to the brain tissue).   
This chapter provides an overview of the two aforementioned tools, FM dyes and 
pHluorins, and our efforts towards synthesis and characterization of pH sensitive membrane 
dyes.  
(1) Fluorescent Styryl Membrane Dyes 
 To label vesicle membranes, fluorescent styryl pyridinium molecules with a lipophilic 
group and a dicationic group, have been widely used. In this context, one of the most commonly 
used styryl dyes is FM1-431. The lipophilic group of the dye inserts into the outer leaflet of the 
cell membrane but does not cross over into the cytosol due to the dicationic charge (Fig. 1a and 
Fig. 1b). When the dye is inserted into the membrane, the fluorescence intensity significantly 
increases compared to the fluorescence of the dye in the surrounding solution. This is 
advantageous as it allows the fluorescence in the membrane to be exclusively studied without 
significant interference from the dye in the surrounding solution. Another important 
characteristic of FM1-43 to note is its chain length. When styryl dyes like FM1-43 are used to 
label the membrane, the chain length determines its partitioning into the membrane (whether it 
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partitions at all and if it does, whether it can be reversibly washed out). Several dyes with 
varying chain length were initially prepared before the optimal chain length was determined2. 
 FM1-43 has been used in various preparations including cell culture, neuronal culture and 
tissue slices. The excitation and emission properties of FM dyes are well suited to biological 























Fig. 1. A) The structure of styryl pyridinium dyes FM1-43 and FM4-64 showing the lipophilic 
tail that inserts into and has affinity for the cell membrane. Note that the dyes differ in the length 
and structure of their lipophilic tails. B) Graphic illustrating the mechanism of labeling of the FM 
dyes in a cell. The lipophilic tail shown in green inserts into the outer leaflet of the cell 
membrane and is prevented from further crossing the cell membrane due to the charged 
quaternary amines represented by the red end of the molecule. C) The steps involved in the 
endocytosis/exocytosis protocol for FM1-43. (1) Neurons are at rest and no membranes are 
labeled. (2) FM1-43 labels the plasma membrane. (3) Upon stimulation, exocytosis occurs and 
the vesicles fuse with the plasma membrane, establishing continuity between the inner leaflet of 
the vesicle membrane and the outer leaflet of the plasma membrane. (4) Rapid endocytosis 
occurs and now the luminal side of the vesicle as well as the plasma membrane is labeled with 
the dye. (5) The dye bound to the plasma membrane is washed away with ADVASEP-7, a 
derivative of β-cyclodextrin that is used as carrier molecule to remove non-specifically bound 
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FM1-43. (6) A second round of stimulation causes exocytosis and dye unloading. Fig. is adapted 
from Gaffield, M.A. et al. (2006) Nat. Protoc. 1, 2916– 2921.  
 
The general protocol for FM1-43 (Fig. 1C) involves stimulation of exocytosis while the 
preparation (cell culture, neuronal culture or tissue slice) is subjected to the dye in bulk solution. 
This exocytosis causes the rapid formation of newly endocyosed vesicles. These newly 
endocytosed vesicles encapsulate the stained plasma membrane. The dye bound to the outer 
plasma membrane is then washed away.   
 The presynaptic terminals that contain the stained recycled vesicles can then be 
monitored as small, distinct fluorescent points (puncta). In a second round of exocytosis (via 
electrical stimulation or stimulation with high calcium or high potassium solutions), the vesicular 
membrane labeled with FM1-43 fuses with the plasma membrane and the dye is dispersed.  
Due to the lipophilicity of FM1-43 and its affinity for lipid bilayers, it could not be easily 
washed away from the outer plasma membranes. For a long time, this precluded its use in brain 
slice preparations where nonspecific binding resulted in an elevated background. This problem 
was addressed by the use of a sulfobutylated derivative of β-cyclodextrin (ADVASEP-7). 
ADVASEP-7 was shown to have a higher affinity for FM1-43 than for the plasma membrane 
and was used as a carrier molecule to remove FM1-43 that was non-specifically bound to the 
outer leaflet of the plasma membrane, thus significantly reducing background staining3.  
The uptake of FM1-43 into recycled vesicles enables the study of the vesicle movement 
from the point at which vesicle regeneration starts all the way through its life cycle until the 
vesicle reaches the readily releasable pool. In this way, by labeling part of the vesicle pool in a 
synaptic terminal, FM1-43 has been used to uncover an array of interesting properties of synaptic 
vesicle edocytosis and exocytosis1-7.  
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Firstly, the kinetics of vesicle staining and destaining can be studied. Using FM1-43, the 
complete cycle of vesicle recycling at the frog neuromuscular junction has been studied by 
comparing dye loss and NT release during a single period of uninterrupted stimulation of 20 Hz. 
Under these conditions, one complete cycle of release of NT, recycling of a vesicle, and rerelease 
of NT has been found to be 1 minute long1. The kinetics of exocytosis and endocytosis at 
individual synapses in cultured hippocampal neurons has also been studied using FM1-43. In this 
preparation, the time constant for endocytosis was studied by measuring the rates of dye uptake 
in response to stimulation of 20 Hz. Under these conditions, the time constant for endocytosis 
was determined to be 20 s4 and that for a full cycle to be about 40 s5.  
Secondly, styryl dyes have been widely used to determine the release probability (see 
Chapter I) of vesicles at individual synapses in relation to the size of the recycling vesicle pool in 
the terminal6. In this context, Murthy and co-workers studied the uptake of FM1-43 into synaptic 
vesicles in cultured hippocampal neurons. Their findings showed that the size of the recycling 
pool of vesicles was strongly correlated with release probability. Synapses with higher release 
probabilities had more vesicles.  
Additionally, styryl dyes have been used to monitor the different modes of both 
exocytosis and endocytosis in cultured hippocampal neurons. To study different modes of 
exocytosis, the kinetics of dye release were studied during electrical stimulation and were 
demonstrated to be composed of both a fast and relatively slower component. During various 
forms of stimulation (high frequency versus low frequency), both fast and slow modes of vesicle 
endocytosis were observed and slow endocytosis was linked with full exocytosis (see Chapter I) 
and fast endocytosis was linked with kiss and run (see Chapter I) type exocytosis7. 
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Furthermore, FM1-43 has been used along with calcium dyes in order to study the effects 
of calcium concentration on the fusion mechanisms involved in exocytosis8. It was found that 
calcium accumulation promotes the full fusion of synaptic vesicles over kiss and run at 
moderately high frequencies. This evidence was used to propose that the duration of fusion pore 
opening is modulated by calcium, causing the release of FM dye to occur faster (full fusion) or 
slower (kiss and run). 
 (2) pH Sensitive Fluorescent Proteins   
Fluorescent proteins (FPs) such as green fluorescent protein (GFP) are widely used in 
biological imaging. FPs are genetic labels and thus can be ‘built into’ a biological system using 
transgenic approaches. As labels are created within the cell, there is no need for labeling with 
exogenous agents, or the fixation and permeabilization procedures that are required for 
immunofluorescence. FPs can be fused to their protein targets, so that they are expressed in a 1:1 
ratio with the target protein.  
Proteins that are pH sensitive derivatives of GFP, called pHluorins, were developed by 
mutagenesis of GFP. These proteins have been especially useful for measuring NT exocytosis 
and vesicle recycling because they can report the difference in pH between the vesicular lumen 
(pH ~5.5) and the extracellular milieu (pH ~7.4) by changes in their fluorescence emission or 
excitation or both.  
As mentioned in Chapter I, the pH of synaptic vesicles is maintained at ~5.5 through the 
action of the V-ATPase proton pump9 which pumps protons from the cytosol into the vesicular 
lumen10. This generates a proton electrochemical gradient11 across the vesicular membrane that 
provides the driving force for NT uptake into synaptic vesicles. The NT is taken up from the 
cytosol into the vesicle lumen, against its own concentration gradient by substrate/proton 
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antiporters that utilize the energy generated by this proton electrochemical gradient (see Fig. 
3A). Experimental evidence has shown that NT transporters such as the vesicular monoamine 
transporter (VMAT) and the vesicular glutamate transporter (VGLUT) are proton-coupled 
transporters12. They couple the efflux of protons from the vesicle with the influx of NT into the 
vesicle. Therefore, it is imperative that the synaptic vesicles maintain an acidic pH (usually ~5.5) 
in order to enable refilling. Finally, when the vesicle fuses with the presynaptic membrane, it 
comes in contact with the extracellular milieu (pH ~7.4) and experiences a jump in pH to ~7.25.  
 
Fig. 2. Fluorescence excitation spectra of wild-type GFP (A), 
ratiometric pHluorin (B) and ecliptic pHluorin (C). The 
ordinate scales reflect normalized differences in fluorescence 
intensity. Fig. is adapted from Miesenbock, G. et al. (1998) 
Nature 394, 192–196. 
 
The pHluorins have been exploited for measurements of 
exocytosis in the pH range of 5.5 to 7.4. It is known that 
wild-type GFP has a bimodal excitation spectrum with peaks 
at 395 and 475nm. Underlying these two maxima are the 
protonated and deprotonated states of Tyrosine 66 which is a 
part of the chromophore. However, the excitation spectrum 
of GFP is only mildly altered between pH 5.5 and 10 (Fig. 2), 
rendering it almost insensitive to pH in the range necessary to 
study synaptic vesicle recycling13.  
Therefore, Miesenbock and co-workers14 converted GFP to a pH sensor by amino acid 
substitutions that coupled changes in bulk pH with changes in the electrostatic environment of 
the chromophore. Since histidine has the appropriate pKa  (~6 for the imidazole side chain) for a 
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sensor for exocytosis, it was introduced at key positions in wild-type GFP. After several rounds 
of mutagenesis, two classes of pH sensitive proteins emerged – ratiometric and ecliptic 
pHluorins.  
Ratiometric pHluorins display a reversible excitation ratio change between pH 7.5 and 
5.5. Thus, at one wavelength (395 nm), the fluorescence intensity increases in response to 
increasing pH and at another wavelength (475 nm) the fluorescence intensity decreases in 
response to increasing pH. Ecliptic pHluorin, in contrast, does not show this reversible excitation 
ratio change when excited at 395 nm and 475 nm. For excitation at both 395 nm and 475 nm, it 
loses fluorescence when pH is lowered, until pH values of lower than 6, where it emits only 
weakly when excited at 395 nm and undetectably (eclipsed) when excited at 475 nm (see Fig. 2).  
In order to image endocytosis and exocytosis, the pHluorins have been linked to the 
luminal side of synaptic vesicle membrane proteins. Upon stimulation, vesicles fuse with the 
plasma membrane and expose their intralumenal proteins to the neutral extracellular medium 
(pH7.4), resulting in an increase in fluorescence. During endocytosis, the rapid reacidification of 
the vesicles leads to a decrease in the fluorescence as the pHluorin gets quenched. Since the pKa 
value of the pHluorin is 7.1, it results in changes in fluorescence of ~20 fold per vesicle fusion 
event15. It is this property which confers the pHluorins sufficient sensitivity to measure the 
release of small pools of vesicles. 
In their seminal work, Miesenbock and coworkers14 demonstrated the use of ratiometric 
and ecliptic pHluorins to study synaptic vesicles and secretory vesicles respectively. They used 
ratiometric pHluorins to determine the pH of synaptic vesicles in hippocampal neurons. They 
used the all-or-nothing fluorescence response of ecliptic pHluorins to image exocytosis of single 
secretory vesicles in a transfected mast cell line. In the mast cells, acidic granules at rest 
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appeared only at 410 nm excitation but not at 470 nm excitation. After initiating a secretory 
response, an increase in fluorescence signal was easily visualized at 470 nm excitation.  
SynaptopHluorin (spH)14 has come to be the most widely used pHluorin based reporter. 
This is a fusion protein, made up of the transmembrane synaptic vesicle protein synaptobrevin-2 
(also called VAMP-2) and the ecliptic pHluorin, with the pHluorin targeted to the luminal side of 
the vesicle. spH has been used to study presynaptic activity in a variety of systems, including 
Drosophila melanogaster olfactory neurons16, neurons in Caenorgabditis elegans17 and 
hippocampal slices18 as well as dissociated hippocampal neurons (in culture)19 from transgenic 
mice that express spH. 
 
Fig. 3. A) Protons are pumped into the vesicle lumen via the V-ATPase pump using the energy 
generated by the hydrolysis of ATP. This creates an acidic environment in the lumen. The 
vesicular transporter (in this image VMAT) is a proton-coupled transporter that pumps NT in as 
the protons move down their electrochemical gradient. The figure is adapted from Lee, M et al., 
(2010) Journal of the American Chemical Society 132, 8828–30. B) SynaptopHluorin is fused to 
the luminal side of synaptobrevin and is quenched in the acidic environment of the vesicle. When 
it fuses with the extracellular space, it fluoresces at the more alkaline pH and is quenched again 
upon reacidification of the vesicle.  
 
While studying spH at individual neurons in hippocampal cultures, Sankranarayanan and 
Ryan15 found that the synaptic vesicle protein synaptobrevin-2 was present in the plasma 
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membrane even in neurons at rest, suggesting that this vesicular protein fully incorporates into 
the vesicle membrane during exocytosis. Furthermore, they found that this protein freely diffuses 
within the plasma membrane and is not completely recycled back into the vesicle during 
endocytosis.  
Fernando-Alfonso and Ryan20 combined the use of FM4-64 with hippocampal neurons 
expressing spH in order to study the balance between endocytosis and exocytosis at the nerve 
terminal. This endocytosis-exocytosis balance is of fundamental importance in neuroscience 
because it determines how quickly the vesicle pool is depleted, and thus strongly influences 
presynaptic activity. In order to simultaneously study both processes, FM4-64 destaining was 
used to measure kinetics of exocytosis, while the speed of vesicle membrane retrieval in spH 
positive terminals was used to measure kinetics of endocytosis. They concluded that the rate of 
endocytosis is sufficiently fast to avoid vesicle pool depletion during continuous action potential 
firing at 10 Hz. Thus, by harnessing the power of both FM dyes and pHluorins, they were able to 
answer a key question regarding synaptic transmission.  
Clearly, as seen from these examples, FM dyes as well as spH have been valuable tools in 
the field of synaptic imaging. They have been used to study the kinetics and probability of NT 
release as well as to help understand the role of different molecules on NT exocytosis. Moreover, 
they have been applied to a broad range of preparations such as cell culture, neuronal culture and 
tissue.  
 However, as mentioned previously, FM1-43 photobleaches easily and thus cannot be 
easily used in experiments that require repeated excitation. Furthermore, prolonged illumination 
results in phototoxic effects2. Additionally, the spectra of the dicationic styryl dyes reveal no 
sensitivity in the required pH range of 5 to 9. Even though there are three nitrogen atoms in the 
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FM dye structure, the two quaternary nitrogens do not have lone pairs of electrons to act as bases 
and the third nitrogen in the tail is only weakly basic as its lone pair participates in conjugation 
with the pi system of the aromatic ring.   
SynaptopHluorin requires transient transfection for use in cell or neuronal culture and 
generation of transgenic animals for use in tissue slices. Moreover, its pKa of 7.1 is too high to 
accurately measure the acidity of the synaptic vesicles which have a pH of ~5.5.   
Therefore, we sought to address these limitations by designing and developing pH 
sensitive fluorescent membrane dyes. Our goal was to develop a pH sensitive endocytic probe 
that would behave similarly to FM1-43. Specific studies we sought to carry out with successful 
probes were as follows: 
(1) Measure pH in specific types of terminals in the brain: Distal electrical stimulation would 
be used to induce the selective uptake of the membrane probe into glutamate terminals21.   
(2) Measure pH over the time course of NT release: This would allow us to study pH 
changes at individual terminals over the life cycle of vesicle exocytosis, recycle and 
reuse.  
(3) Measure the alteration of parameters (1) and (2) mentioned above in mouse models of 








II.  RESULTS AND DISCUSSION 
 
II.I Rational Design of pH Sensitive Membrane probes  
 
In order to address the limitations posed by FM dyes (phototoxicity and pH insensitivity) 
and spH (generation of transgenic animals), we sought to design small molecule pH-sensitive 
endocytic membrane dyes. For this purpose, the following design factors were considered.  
(1) Lipophilicity: The molecule had to be lipophilic enough to bind to the membrane 
but not so lipophilic as to irreversibly lodge into the plasma membrane. That 
is, it had to be able to reversibly partition into the membrane.  
(2) Polarity: The polar head had to be able to prevent the molecule from crossing the 
plasma membrane.  
(3) Fluorescence: The fluorophore of choice needed to display a fluorescence signal 
which was dependent on pH. 
(4) pKa: The pKa needed to be in the optimal range for sensing pH differences 
between the vesiclar lumen and the extracellular space. Since this range was 
5.5-7.4, we decided to incorporate a fluorophore with a pKa close to 6. 
Keeping in mind these requirements, it became apparent that two essential components 
needed to be incorporated in to the design - a lipophilic tail for membrane attachment and a 
charged polar “head” to prevent the molecule from further crossing across the plasma membrane. 
Furthermore, pH sensitivity needed to be incorporated into the charged polar “head”, since it 
would be this part that would not be embedded in the membrane, and hence free to sense changes 
in pH in the vesicular lumen. The rationales used to design each part of the molecule are 
explained in the sections below and illustrated in Fig. 4B.  
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Fluorophore and pH Sensor: For the fluorophore, we chose the well-known compound 7-
hydroxycoumarin or umbelliferone whose fluorescence excitation spectrum is strongly 
dependent on pH. When excited at 370 nm, umbelliferone shows an increase in fluorescence 
intensity with increasing pH. The pKa of this compound however, is too high (~7.8) to accurately 
sense pH differences in the required pH range.  
pKa Modulator: We chose to install an electron withdrawing chloride group adjacent to the 7-
hydroxy group in order to act as a pKa modulator. The chloro group would serve to decrease the 
pKa by stabilizing the negative charge on the deprotonated hydroxyl group, thereby yielding a 
pKa of ~6, which would be appropriate for sensing the pH in the lumen of the vesicle (~5.5). 
Furthermore, this strategy for decreasing the pKa of umbelliferone had already been used 
successfully by our group. Previously, we had demonstrated that the agent Mini102 (Fig. 4A) 
could be used as a pH sensor in cell culture22 as well as in brain slice preparations23.  
Lipophilic Tail: Secondly, the length of the alkyl chain for membrane attachment was chosen 
based on the known length of the lipid tail that constitute the phospholipid bilayer24 (14-24 
carbons long for each leaflet) as well as the length of other small molecule probes that are known 
to partition into the cell membrane25.  
  
 
Fig. 4. A) Mini102 is a known pH sensitive fluorophore with a desired pKa of 6.2. The 
numbering scheme used for the coumarin core is also shown. B) The general design of pH 
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sensitive endocytic probes. The charges on the hydroxyl and amine groups represent the 
expected protonation and deprotonation state of the molecule at physiological pH. Colors 
highlight the different parts that were considered in the probe design such as membrane 
attachment and lipophilicity, polarity, pH sensitivity, and pKa.  
 
II.2  Overview of Scaffolds Used in Each PM Series  
  
 Based on the criteria mentioned above, 4 different pH responsive series were designed 
and synthesized. These included PM100, PM200, PM400, and PM500. The 7-hydroxy core was 
conserved across each series, but the polarity and lipophilicity of each series varied. The series 
were synthesized chronologically (from 100 to 500), allowing insights gained from the initial 
series to be applied to the design of the next series. This process allowed us to optimize the 
balance between lipophilicity and polarity that was needed in order to find a probe that would 
selectively label the membrane. An overview of the scaffolds in each library are illustrated in 
Fig. 5. 
A detailed description of the rational design of each series is presented in the sections that 
follow. Besides polarity and lipophilicity, the ease of synthesis was also considered as new 
designs were developed.  
During the synthesis of PM200 series, a new design for a non-pH sensitive membrane 
probe became apparent to us. This design is encapsulated in the PM300 series. Even though this 
series lacked pH sensitivity, we synthesized it in order to develop a coumarin based membrane 











































Fig. 5. The general scaffolds for PM100, 200, 400 and 500 series are shown. The coumarin core, 
high-lighted in green, was conserved across all the series. The pH sensitive group, highlighted in 
red, on the 7-position of the coumarin was also conserved in all series. The hydroxyl group is 
expected to be deprotonated at physiological pH. The variable length of the lipophilic tail 
(squiggly lines) in each series is highlighted in orange. The cationic charge of the amine in 
PM100 is highlighted in purple and differentiated from the cationic charges in PM200, 400 and 
500 by which are highlighted in pink. This is because the secondary amine in PM100 relies on 
the physiological pH in order to maintain its cationic charge but the amines in the other series 
carry a permanent cationic charge. A non-pH sensitive endocytic probe was also designed in 











 PM101-103 were designed as alkylated derivatives of Mini102 (Fig. 6). The alkyl chains 
were varied in order to determine the chain length needed to afford the desired affinity for the 
cell membrane. The primary amine of the ethylamine was chosen as the site for alkylation 
because this allowed facile access to several derivatives without needing to alter the synthetic 
route. Mini102 could be used as a common intermediate and a simple variation of the alkylating 
agent would yield the derivatives. Furthermore, it was hypothesized that at physiological pH of 
7.4, the ethylamine would be protonated (given that the pKa of phenylethyl amine is 9-1026) and 
would thus likely serve as one of the charged sites in the molecule. This charge would help 
prevent the probe from crossing the plasma membrane. It was of key importance to incorporate 
this charged site into the molecule in a way that would allow the lipophilic tail to insert into the 
membrane but prevent the pH sensing group (at 7-position of the coumarin) from inserting into 
the membrane. Therefore, it was imperative to have a charged atom right at the end of the 


















Fig. 6. The design of PM100 series is also shown. PM101–103 were designed as alkylated 
derivatives of the known fluorophore Mini102.   
   
Synthesis 
 
First, Mini102 was synthesized via an established procedure22 and PM101-103 were 
synthesized by monoalkylation of Mini102. This was carried out via a one pot, two-step 
reductive amination involving first imine formation and secondly, reduction of the imine with 
sodium borohydride27 (Fig. 7). This two-step approach needed to be used because in the presence 
of both excess hexanal (an excess was needed to drive the reaction forward) and the reducing 
agent, it was possible to observe the dialkylated product. Indeed, when this reaction was carried 
out with sodium borohydride at the start of the reaction, the dialkylated product was observed. 
This indicated that after the first round of alkylation (via imine formation) and reduction, a 
second round of alkylation and reduction were taking place, as expected. The two-step approach 
avoided this problem by ensuring that the imine was reduced only for a short time (15-30 
minutes) in the presence of excess hexanal, reducing the chance that a second alkyation would 
occur. The synthesis of PM101 is shown below as a representative example. The low yields of 
compounds in this series could be attributed to low conversion of the starting material into the 
imine. An increase in conversion was not seen even when a 5 fold excess of the aldehyde was 
used. Since a large volume of solvent needed to be used in order to dissolve the polar starting 
material, the concentration of the starting material was very low (~0.004 M). Therefore, the low 
conversion could be a reflection of the low rate of reaction expected in dilute solutions. We did 
not try to optimize this conversion since only a few milligrams of these compounds were needed 













Fig. 7. Representative synthesis for PM100 series. Monoalkylation of Mini102 with the 
appropriate aldehyde (in this case hexanal) was carried out in a one pot, two-step reaction to 





As expected, compounds belonging to the PM100 series shared the same fluorophore as 
Mini102 and displayed similar photophysical properties. The excitation spectra were strongly pH 
dependent and exhibited two fully resolved maxima at 335 and 370 nm. The peak at 335 nm 
excitation corresponds to the protonated phenolic form of the coumarin and the peak at 370 nm 
excitation corresponds to the deprotonated phenolate form of the coumarin. All compounds in 
this series displayed ratiometric excitation spectra. There was a reversible excitation ratio change 
between pH 7 and 5. At wavelength 335 nm, the fluorescence intensity decreases in response to 
increasing pH and at wavelength 370 nm, the fluorescence intensity increases in response to 
increasing pH. The fluorescence emission peaks occurred at roughly 450 nm for all three probes. 
Representative excitation/emission spectra and absorption spectra are shown in Fig. 8. The pKa 
of the hydroxy compounds were determined to be in the range of 5.5 to 6.1. The pKa were 
determined by plotting the ratio of absorbance at 370 nm and the isosbestic point at each pH 







Fig. 8. Excitation/Emission spectra of 10 µM PM101 at pH 7.4 shows an excitation peak at 370 
nm and an emission peak at 450 nm. The absorption spectra of 10 µM PM101 show ratiometric 




HEK293T cells were used for the preliminary studies of the PM100 series. The cells were 
incubated with 20 µM of the probe for 30 minutes, washed with buffer and then imaged using 
standard epifluorescence microscopy. Images were taken at two time points after removal of the 
media containing the probe – time point 0 minutes and 15 minutes. This was done in order to 
assess the lipophilicty and wash out kinetics of the probes. The commercially available 
membrane probe FM1- 43 was used as a positive control for membrane labeling. The results are 




Fig. 9. PM100 Series imaged in HEK293T cells at two different time points using an 
epifluoresence microscope equipped with filter cube of λex 350/50 FWHM nm and λem 460/50 
FWHM nm. Images were acquired at 1000 millisecond exposure time. 20 µM probe was 
incubated for 30 minutes, washed, and imaged at time point 0 and 15 minutes after washing. All 
probes, PM101 (A), PM102 (B), PM103 (C), showed a dispersed labeling pattern at time point 0 
minutes and diffused out of the cells by time point 15 minutes. D) Imaging 5 µM FM1-43 in the 
presence of the dye after a 30 minute incubation period showed membrane staining. Individual 
round/ellipsoidal structures of 10-15 µm in size are single cells. Scale bar 25 µm. 
 
 
As seen in Fig. 9, FM1-43 labeled the cell membrane and did not diffuse into the 
cytoplasm. PM101-103 all showed a diffuse staining pattern in the cells that markedly differed 
from the pattern seen in FM1-43, indicating that they were able to enter the cells. This uptake 
pattern can be explained either by lipophilic diffusion of the probes across the cell membrane, 
via spontaneous endocytosis or uptake via a transporter. However, uptake via spontaneous 
endocytosis seems less likely. This is because the time scale for spontaneous endocytosis in 
HEK293T occurs on the time scale of hours28, which is much longer than the time scale for 
incubation and imaging (~30 minutes) used in these experiments. Furthermore, the lack of 
spontaneous endocytosis at the 30 minute point was confirmed by the low extent of intracellular 
labeling by FM1-43. Small punctate structures indicating endocytosed vesicles were seen in the 
FM1-43 experiments only around 4 hours.  
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In order get a more accurate picture of the structures being labeled by these probes, we 
imaged them in PC12 cells using two-photon microscopy. Two-photon microscopy generates 
clearer images because two-photon excitation only excites the fluorophore at the focal plane, as 
opposed to epifluorescence microscopy where the entire sample is illuminated by the excitation 
light, generating a large amount of background fluorescence due to excitation above and below 
the focal plane. FM1-43 was imaged as a positive control. For FM1-43, confocal imaging with 
one photon microscopy was used as FM1-43 can easily be excited and visualized in cell culture 
with a one-photon excitation of 488 nm. The longer two-photon excitation was needed only for 
the coumarin-based fluorophores because the available confocal microscopes are not equipped 
with laser sources appropriate for exciting coumarins with one-photon excitation (~ 340 to 380 
nm). Confocal microscopy is a method of optical sectioning of samples less than 200 µm in 
thickness.  
It is important to note that PC12 cells were chosen for further imaging experiments 
because we ultimately sought to investigate our probes for the study of endocytosis/exocytosis in 
these cells since they were found to be a good model system for this purpose and they had 
previously been used with the membrane probe FM1-4329. Furthermore, PC12 cells, which are 
derived from a pheochromocytoma of the rat adrenal medulla, have small vesicles that contain 
catecholamines and can be differentiated into neurons by treatment with nerve growth factor, 
making them a useful model system for neurobiological studies30.  
In these experiments, the same labeling protocol was used as mentioned earlier. The cells 
were incubated with 20 µM probe for 30 minutes, washed, and then immediately imaged.  A 
two-photon excitation wavelength of 760 nm and an emission range of 440 to 490 nm was used 
to image the PM100 probes. A representative two-photon image of PM100 series labeling in 
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PC12 cells is shown in Fig. 10. Images were taken immediately after the experimental medium 
containing the probe was removed and replaced with probe-free media.  
As a positive control, labeling with FM1-43 was carried out. As mentioned previously, 
FM1-43 can be imaged in the continuous presence of the dye and does not need the additional 
wash out step. Therefore, images were taken in the presence of the dye after a 30 minute 
incubation period.  
Fig. 10. A) A representative image 
of PM100 series imaged in PC12 
cells using two-photon microscopy 
with λex  760 nm and λem 440-490 
nm. The image shown here is 
PM101. 20 µM probe was 
incubated for 30 minutes, washed, 
and then immediately imaged. B) 
Confocal image of 2 µM FM1-43 
which was used a positive control for membrane labeling. FM1-43 was incubated for 30 minutes 
and images were taken in the continuous presence of FM1-43 using λex of 488 nm and emission 
of 550-650 nm. Scale bar 25 µm. 
 
Probes in the PM100 series crossed the cell membrane and showed a punctate staining 
pattern with nuclear exclusion in PC12 cells. These puncta likely represented acidic 
compartments in the cell that accumulated the dye. The large black, unlabeled circular structures 
within the cells were the nuclei, which remained unlabeled. We did not investigate structures of 
the labeled intracellular compartments further, because the labeling pattern clearly differed from 
the positive control of FM1-43.  
Since images were not taken at a time point of 15 minutes after the wash in PC12 cells, as 
was done in HEK293 cells, it is possible that the probes had different patterns of uptake and 
wash out in HEK293 and PC12 cells. Furthermore, since two-photon imaging was not done in 
HEK293 cells, it is not clear whether the probes accumulated in acidic compartments in HEK293 
cells or simply diffused into cytosolic spaces in the cell. However, since we were primarily 
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interested in using PC12 cells as a model system, we focused on the staining patterns of the 
probes in PC12 cells.  
We concluded that these probes were too lipophilic in PC12 cells to serve as endocytic 
membrane probes and hence engineered a more polar series to help overcome this problem. The 










































The PM200 series was designed to be more polar than the PM100 series. This was done 
by incorporating a quaternary amine into the PM200 core scaffold. In this manner, the cationic 
charged was fixed, unlike in PM100 where the charged state of the amine/phenol could vary 
depending on the pH of the surrounding environment.  
As seen in Fig. 11, we attempted to install a permanent charge at two possible sites. First, 
we attempted to incorporate the permanent charge on the amine belonging to the ethylamine of 
Mini102. The quaternary amine derivative of PM100 could not be synthesized because the 
Hofmann elimination took place to yield the tertiary amine and terminal alkene. We next 
attempted to incorporate a quaternary amine on the 3 position of the coumarin ring. This strategy 
also proved unfruitful. We were only able to install a tertiary amine on 3-position of the 
coumarin. The exhaustive methylation of the tertiary amine to yield a quaternary amine could not 
be accomplished, likely because the amino group was too close to the electron withdrawing ester 
group.  
 
Fig. 11. Possible sites that were initially considered for installing a permanent cationic charge 
into the endocytic probe. Sites were chosen based on the synthetic ease as well the required 
condition for the pH sensor to be located near the outer leaflet of the cell membrane. A) This 
design was chosen due its easily accessible synthetic route. B) This site was chosen in order to 
test whether it was feasible to install a quaternary amine directly on the coumarin ring.  
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In order to tackle the issues of the Hofmann elimination, as well as the proximity of the 
charge to the ester group, we next decided to insert an aromatic ring between the coumarin and 
the permanent cationic charge. The permanent charge was installed on an aromatic amine located 
in the para position of the arene ring attached at the 3-position of the coumarin ring. 
Furthermore, we hypothesized that a cationic charge in this position would increase the 
brightness of the probe by stabilizing the phenolate form of the coumarin (through resonance of 

















Fig. 12. Design of PM200 series with the permanent charge on the aromatic amine. PM200 
shows the electron donating/withdrawing properties of the hydroxy and quaternary amine group 





First, PM200 was synthesized to examine a single permanent cationic charge would be 
sufficient to keep it from crossing the plasma membrane. After imaging experiments determined 
that PM200 was indeed polar enough to prevent its crossover through the plasma membrane, 
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PM201-203 were synthesized. In this series, we did not incorporate the chlorine atom at the 6-
position of the coumarin ring since we were primarily interested in optimizing the lipophilicity 
and polarity of the membrane probes. We only incorporated the chlorine atom into PM203.  
PM200 and PM201 were synthesized using a standard synthetic sequence shown in Fig. 
13. The shared intermediate 3, 3-{4nitrophenyl}-7-hydroxy coumarin), was used for the 
synthesis of both PM200 and PM201. In order to synthesize 3, 2,4-dihydroxybenzaldehyde was 
benzyl-protected at the 4-position via a standard procedure22 to yield intermediate 1. The 
Pechmann condensation of 1 with 2-(4-nitrophenyl)acetic acid yielded the desired coumarin 2. 
The nitro group in 2 was reduced to the amino group with Raney Ni to yield 3. The exhaustive 
alkylation of the amine in 3 with methyl iodide followed by deprotection of the benzyl group 
yielded PM200.  
To synthesize PM201, 3 was dialkylated using butanal and sodium triacetoxyborohydride 
as the reducing agent. Unlike the monoalkylation reaction which needed to be carried out in two 
steps, the dialkylation reaction reaction could be carried out in a single step, with the reducing 
agent present at the start of the reaction. Sodium triacetoxy borohydride was used as the reducing 
agent because it was found to be milder than sodium borohydride and more selective for imine 
reduction as compared to aldehyde reduction27. Methylation of the tertiary amine with methyl 
iodide followed by deprotection of the benzyl group yielded PM201.  
One of the difficulties in this synthetic route was that intermediate 2 was very insoluble 
and conversion of 2 to 3 showed several side products, leading to a low yield. Furthermore, 
intermediate 3 was also highly insoluble and difficult to purify either by recrystallization or 





Fig. 13. Synthesis of PM200 and PM201. Intermediate 3 was used as a shared intermediate for 
the synthesis of both PM200 and PM201.   
 
Due to the low solubility of 2 in both polar and nonpolar solvents, as well as the low 
conversion of 2 to 3, the synthetic route to access PM202 and 203 was modified (Fig. 14). 
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Fig. 14. Synthesis of PM202. The synthetic scheme for PM202 was modified due to the 
difficulties encountered in the synthesis of PM201.  
 
To synthesize PM202, first, a Pechmann condensation of 2,4-dihydroxybenzaldehyde 
was carried out with 2-(4-(dimethylamino)phenyl)acetic acid, using acetic anhydride as a solvent 
and sodium acetate as a base. This yielded the appropriate 3-(4-(dimethylamino)phenyl)-7-
acetoxy-coumarin or intermediate 6. This strategy allowed both coumarin formation as well 
installation of two methyl groups on the amine in one step. This condensation procedure could 
not be used to access a corresponding derivative with chlorine atom in the 6-position of the 
coumarin because the chlorine atom prevented the acetylation of the 4-hydroxy group on 2,4-
dihydroxybenzaldehyde, which was critical for the coumarin formation via the Pechmann 
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condensation. Therefore, a different approach using DCC coupling was developed to access 
intermediate 11, which was needed for synthesis of PM203 (Fig. 15).  
It is important to note that the alkylation of the dimethyl amine could not be achieved 
when the acetoxy protecting group was installed on the 7-position of the coumarin. This was 
possibly due to the reduced nucleophilicity of the amine when the phenol was acetylated. 
Therefore, the acetoxy protecting group was switched to an electron donating benzyl group. This 
increased the nucleophilicity of the amine and aided the exhaustive alkylation of the amine. It is 
also important to note that when the dimethyl amine was alkylated with hexyl bromide, the high 
temperatures needed for this alkylation reaction resulted in the loss of one methyl group from the 
amine. The reaction did not take place at lower temperatures presumably due to the steric 
hindrance on the amine as well as the relatively low nucleophilicity of the aniline amine. Re-
alkylation with methyl iodide to yield the quaternary ammonium salt compensated for the loss of 
the methyl group.  Finally, deprotection of the benzyl group yielded the PM202. 
The synthesis of PM203 is shown below. In this probe, we explored a strategy to install a 
chloro group on the 6-position of the coumarin ring. As mentioned before, the Pechmann 
condensation could not be used to synthesize the coumarin ring. Therefore, we used a one pot, 
two-step reaction to gain access to this probe, including an ester formation followed by an aldol 
condensation. N,N'-Dicyclohexylcarbodiimide (DCC) coupling was used to accomplish the 




Fig. 15. Synthesis of PM203. PM203 incorporated a chloro group at the 6-position of the 
coumarin ring. Trifluoroacetic acid is abbreviated as TFA. Acetonitrile is abbreviated as ACN. 
 
It is important to note that the alkylation of the dimethyl amine in this case also proved to 
be very difficult and required harsh temperatures which caused the loss of one methyl group 
from the amine. This was compensated in the same way by realkylation with MeI. 
Photophysical Properties  
Since the PM200 series contained essentially the same fluorophore as PM100 series, the 
photophysical properties were similar. However, one marked difference was that the absorption 
peaks were slightly red shifted as compared to the PM100 series. The absorption maxima 
occured at 340 nm and 390 nm, a opposed to 335 and 370 nm in PM100 series. This result is a 
reflection of the longer conjugation system in PM200. The photophysical properties of PM201 
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are shown as a representative for the PM200 series. The absorption spectra as well as 
fluorescence emission spectra at varying pH are shown in Fig. 16.  
 
Fig. 16. Photophysical properties of PM201. The absorption spectrum of 10 µM PM201 showed 
two absorption peaks with maxima at 340 nm and 400 nm respectively. The emission spectrum 
of 2 µM PM201 showed an emission peak with a maximum at 465 nm when excited at 340 nm. 
The legend shows the varying pHs at which both the absorption and fluorescence spectra were 
measured.   
 
Fluorescence Imaging  
First, PM200 was examined in cells to test whether it was sufficiently polar so as to not 
cross the cell membrane. Imaging was carried out in HEK293T cells using two-photon 
microscopy as described previously. The imaging was carried out in the presence of 10 µM 
probe. PM200 was found not to cross the cell membrane, as seen in Fig. 17. PM200 was also 
washed out and then imaged (data not shown). The probe showed to residual staining upon 
washing out, indicating that that it did not bind to the membrane or that that any potential 























Fig. 17. The bright field and fluorescence imaging of PM200 in HEK293T cells. Images were 
taken in the presence of 10 µM probe after a 15 minute preincubation. λex was 780 nm and λem 
was 440-500 nm. PM200 was not taken up by cells. Scale bar 25 µm. 
 
Next, PM201-203 were tested in HEK293T cells using two-photon microscopy. A 
representative image is shown in Fig. 18. All three probes readily crossed the cell membrane, 
indicating that the addition of a lipophilic tail to PM200 caused a drastic reduction in polarity. 
Therefore, we decided to pursue the synthesis of endocytic probes with two quaternary amines 
and alkyl chains of similar length. It should be noted that the labeling for PM201-203 showed a 




Fig. 18 An image of PM202 in HEK293T cells 
acquired by two-photon microscopy is shown as a 
representative of the staining pattern observed in 
PM201-203. 10 µM probe was incubated for 15 
minutes, washed, and then imaged immediately. 
Exciation and emission conditions used were the same 
as for PM200 (See Fig. 17). A similar punctate pattern 
was seen as with the  PM100 series. Circular 
unlabeled structures within the cells represent nuclei. 
Scale bar 25 µm.  
Brightfield            Fluorescence                    Overlay 
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Before moving on to the synthesis of a dicationic probe, we explored the synthesis of a 
non-pH sensitive membrane probe because we realized that this would be very easily 
synthetically accessible, given the synthetic route for PM200 series. Moreover, we thought that 
despite the lack of pH sensitivity, these probes would still be useful tools because we had 
observed that coumarin-based probes were much less susceptible to photobleaching compared to 
FM dyes.  
This series involved the O-alkylation of PM200. It was hypothesized that the alkyl chain 
would allow for membrane attachment and the quaternary amine would provide the necessary 
charge to prevent the probe from crossing the membrane. Fig. 19 shows the design of this series.  
 
Fig. 19. PM300 Series was designed as a mono-cationic series with a lipophilic tail attached to 





PM300 series was synthesized using 6a as an intermediate which was synthesized as 
described previously. O-Alkylation with the appropriate alkyl iodide at 50°C (higher 
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temperatures were avoided to prevent N-alkylation) yielded intermediate 14 which upon N-
methylation gave the desired probes. The general synthetic scheme for the PM300 series is 





Fig. 20. General synthetic scheme for PM300 series. Acetonitrile is abbreviated as ACN. 
 
Photophysical Properties  
PM301-303 all showed excitation/emission spectra similar to the PM200 series, the only 
difference being that the excitation/emission spectra did not depend on pH. The absorption 
maximum was at 385 nm and the emission maximum was at 465 nm.  
Fluorescence Imaging 
As before, the HEK293T cells were incubated for 30 minutes with the probes. Imaging 
was carried out in the presence of the probes using two-photon microscopy. It was possible to 
skip the additional wash step because these probes showed an enhanced fluorescence in 
lipophilic environments, and a dimmer fluorescence in aqueous solutions and growth media (as 
is seen with FM1-43). Two-photon images with their corresponding bright field images are 













PM301 did not show membrane staining or any labeling of intracellular organelles. 
PM302 demonstrated membrane staining but also showed some cross over into the cytosol as 
was seen from a small amount of diffused labeling within the cells. PM303 emerged as an 
excellent stain for membrane labeling, as seen in Fig. 22.  
 
 
Fig. 22. PM303 (5 µM) showed excellent membrane labeling in HEK293T cells after 30 minutes 
of incubation. Images were taken in the continuous presence of the dye. Imaging conditions used 
were the same as for the PM200 series (See Fig. 17). Scale bar 10 µm. 
PM303 Brightfield Overlay 
Fig. 21. PM301 and 
302 labelling in 
HEK293T cells. Cells 
were incubated with 
the probe for 30 
minutes and then 
imaged in the 
continuous presence of  
5 µM probe. Imaging 
parameters used were 
similar to those for 
PM200 (See Fig. 17). 







Fluorescence  Brightfield 
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The shorter alkyl chain on PM301 was not sufficient to achieve affinity for the 
membrane. PM303 showed the optimal balance of polarity and lipophilicity to serve as a 
membrane probe. Next, the washout kinetics of PM303 were investigated. We found that PM303 
bound too tightly to the cell membrane to be rinsed out by washing with only PBS. However, 
rinsing with ADVASEP-7 helped to resolve this issue by dislodging the probe from the 
membrane. Since this probe proved to have promising properties (membrane affinity, 
photostability etc.) in cell culture to serve as an endocytic dye, we decided to investigate it 
further in a more complex biological system – primary neuronal culture.  
Primary neuronal cultures derived from rodents are widely used to study basic 
physiological properties of neurons. They are typically prepared by obtaining primary neurons 
from the rodent cortex, hippocampus, or striatum. Neuronal culture significantly differs from cell 
culture in that it does not consist of single cell type. It comprises not only neurons but also 
astrocytes and glia. As such, there are several lipophilic membranes that are available for 
labeling by membrane probes. Consequently, the ability to wash out an endocytic probe from 
lipophilic structures is of great importance in order to avoid high background fluoresence.  
Dr. Yvonne Schmitz in the Sulzer group (Columbia University Medical School) carried 
out the imaging experiments in cortical neuronal culture. Unfortunately, PM303 proved to be too 
lipophilic for neuronal culture and could not readily be washed out of the membranes, despite 









II. 6 Design Synthesis, Photophysical Properties and Fluorescence Imaging of PM400 
Series 
 
 Before moving on to the synthesis of the dicationic probes with two quaternary amines, 
we investigated another series of probes in which the cationic charge would be placed on an 
alkylated pyridine. The PM400 series was designed with to be structurally more similar to FM-
143. Furthermore, we were interested in investigating how charged pyridinium nitrogens would 
change the photophysical properties as well as the polarity of the probes. Moreover, it is easier to 
alkylate pyridine nitrogens in comparison to anilines (such as the ones in intermediate 5 in 
Fig.13, intermediate 7 in Fig. 14 and intermediate 11 in Fig. 15) as their lone pair of electrons are 
not conjugated with the extended pi system. Additionally, the pyridine nitrogen was chosen to be 
in the para position so that when alkylated, the permanent charge would be able to serve as a sink 
for the pi system of the deprotonated phenolate in the 7-position of the coumarin. The structures 
for compounds in the PM400 are shown below in Fig. 23.  
This series included monocationic and dicationic probes. PM401 was synthesized first in 
order to determine whether the methylated pyridinium motif would be sufficiently polar to 

















The synthetic scheme for the PM400 Series is shown in Fig. 24 and Fig. 25. Intermediate 
15 was synthesized via a Perkin reaction using 4-(benzyloxy)-5-chloro-2-hydroxybenzaldehyde 
(intermediate 10) and commercially available ethyl 2-(pyridin-4-yl)acetate. Coumarin formation 
using ethyl 2-(pyridin-4-yl)acetate was carried out according to known procedures31. Alkylation 
of 14 with MeI or octyl-bromide followed by deprotection of the benzyl group with TFA 




Fig. 24. Synthesis of PM400 sereis.  
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For the synthesis of intermediate 17, excess 1,3-dibromopropane was used to alkylate 
N,N-dimethyloctan-1-amine. A ten-fold excess of the dibromopropane was used in order to 






Fig. 25. Synthesis of intermediate 17. 
 
 
Photophysical Properties  
 
 The PM400 series displayed unexpected photophysical characteristics. The quaternized 
pyridyl coumarins showed absorption and emission spectra that were significantly red shifted as 
compared to their quaternized amino counterparts (PM200 series). In PBS buffer, they showed 
two absorption maxima at 375 and 450 nm and an emission maximum at 545 nm. The two 
maxima could reflect absorption by two different species – the protonated and deprotonated 
phenol. The absorption of these probes at 450 nm did not display a large dependence on pH. At 
this wavelength, the absorption at pH 5 was almost identical to that in alkaline solution. 
 Additionally, the PM400 series displayed a low absorption intensity as well as low 
fluorescence intensity. Therefore, a high concentration of 10 µM had to be used to detect 
emission, as opposed to 2 µM, which was sufficient for measuring emission of the previous PM 
series 100-300. The fluorescence intensity was much stronger in methanol than in phosphate 
buffered saline (PBS). One likely explanation for the decrease in fluorescence is this is that the 
resonance structure of the deprotonated phenolate anion is described by a quinone-type structure. 
In comparison to their parent aromatics, quinones are known to show intense phosphorescence at 
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the expense of fluorescence. The quinoid structure of the phenolate anion is shown in Fig. 27.  




Fig. 26. Absorbance spectrum of 10 µM PM401 at varying pH is shown as a representative for 
the PM400 Series. The legend displays the various pHs used. Emission spectrum of 10 µM 
PM401 is shown in PBS buffer (pH 7.4) as well as in a PBS/MeOH mixture. Emission spectrum 





















PM401 and 402 were incubated with HEK293T cells for 30 minutes and then imaged 
using two-photon microscopy. For the PM400 series, images were taken in the presence of the 
probe instead of washing out. This was possible because the fluorescence was quenched in 
aqueous environment, thereby diminishing background fluorescence from the media.  
Probes were excited at two different wavelengths, corresponding to the two peaks seen in 
the absorbance spectra. Two-photon images were taken at both 750 nm (approximately 
corresponding to 375 nm peak for one photon excitation) and 900 nm (approximately 
corresponding to the 450 nm peak excitation). At both excitation wavelengths, a similar staining 
pattern was seen and representative images of this are shown in Fig. 28. PM401 and 402 diffused 





Fig. 28. PM401 and 402 (5 µM) were incubated in HEK293T cells for 30 minutes and imaged 
using two-photon microscopy. Excitation wavelengths of both 750 and 900 nm were used and an 
emission range of 500-600 nm was used. At both wavelengths, PM401 and 402 showed a 
punctate staining pattern. The representative image shown here uses an excitation wavelength of 
750 nm. Scale bar 25 µm.   
 
Imaging PM403 was carried out similarly and the results are shown in Fig. 29. 
Interestingly, PM403 showed labeling of intracellular organelles only when excited at 750 nm 
but excellent membrane labeling when excited at 900 nm. This could be explained by the 
simultaneous presence of both the phenol and phenolate species. The phenol (750 nm excitation), 
with one less charge, was more likely to cross the cell membrane, but the phenolate (900 nm 
excitation), with an additional charge, was more likely to be prevented from crossing the 
membrane. It is also possible that the probe labels both the plasma membrane and intracellular 



















Fig. 29. PM403 in HEK293T cells showed a punctate staining pattern when excited at 750 nm 
and membrane staining when excited at 900 nm. 5 µM probe was incubated for 30 minutes and 
imaging was carried out in the presence of the probe. Scale bar 25 µm. 
 
We concluded that that even though PM403 looked promising as a membrane probe, as 
seen with excitation at 900 nm, the species excited by 750 nm would interfere with the 






















Brightfield                          750 nm                 900 nm 
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PM500 series was designed as the dicationic series. In this design, we incorporated a 
quaternary benzylic amine, as it would be easier to alkylate than its corresponding aromatic 
amine (see synthesis of PM200). Even though the pyridine series (PM400) was easy to alkylate, 
it resulted in probes with decreased fluorescence. Therefore, PM500 was designed (Fig. 30) in 
order to generate a probe that would not only be straightforward to alkylate but also be 
sufficiently fluorescent.  
 
Fig. 30. Design of PM500 Series 
Synthesis 
The benzyl bromide intermediate 20 was designed so that the final quaternary amine 
could be installed via substitution in the benzylic position. An alternative approach to accomplish 
this goal would have been to have to perform the Pechmann condensation with 2-(4-
((dimethylamino) methyl)phenyl) acetic acid, and then further alkylate this tertiary amine. 
However, this approach was not followed due to the excessive cost of this commercially 
available phenyl acetic acid. 
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The synthesis of PM501 is shown as a representative example (Fig. 31) for the 500 
series. PM502 was synthesized similarly with a longer alkyl chain.   
 
Fig. 31. Synthetic scheme for PM500 series. N-Bromosuccinimide is abbreviated as NBS and 




PM500 series displayed similar photophysical properties to PM200 series, showing 
ratiometric, pH dependent fluorescence with two fully resolved absorption peaks with maxima at 
340 nm and 390 nm. The emission maximum occurred at 480 nm.  
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Fluorescence Imaging  
PM501 and 502 were initially imaged in HEK293T cells as described previously (not 
shown here). PM502 showed excellent membrane staining and was further investigated in PC12 
cells using the same labeling protocol. As discussed previously in section II.3, PC12 cells were 
chosen because they are a good neuronal model and have been widely used in neurobiological 
studies.  
Once we established that PM502 was able to serve as a membrane probe, we studied its 
fluorescence in response to varying pH at the cell surface. This was done by varying the pH of 
the external buffer from a basic pH of 8.9 to acidic pH of 5.3. As seen in Fig. 32, when PM502 is 
at the cell surface, it is relatively bright at basic pH and dim at acidic pH. 
 
 
Fig. 32. PM502 imaged in PC12 cells shows clear membrane staining. The fluorescence was 
studied at the cell surface in response to varying external pH. A) Acetate buffer was used to set 
the external pH to 5.3. B) 2-(N-morpholino)ethanesulfonic acid (MES) buffer was used to set the 
external pH to 7.3. MES has a pKa 6.15 and is commonly used to prepare buffers in the pH range 
of 5.2 - 7.3. C) 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer was used to 
set the external pH to 8.9. HEPES has a pKa of 7.5 and is commonly used to prepare buffers in 
the pH range of 6.8 to 8.8. Scale bar 10 µm. 
 
PM502 emerged as a promising pH sensitive membrane dye. Its fluorescence change in 
response to external pH indicated that the pH sensor was appropriately placed on the outside of 
the membrane. This orientation was necessary in order for the pH sensing group to be 
appropriately placed within the lumen of the vesicle following endocytosis (see section II.1).  
 84 
Next, PM502 was imaged in cortical neuronal culture and its washout kinetics were 
studied. This work was done by Dr. Yvonne Schmitz. Unfortunately, PM502 proved to be too 
lipophilic in neuronal culture and showed poor washout even with ADVASEP-7. The inability of 
the probe to reversibly partition into the membrane was a hindrance in its further development as 
an endocytic dye. This is because the dye bound to the outer plasma membrane would interfere 




































III. CONCLUSIONS AND FUTURE DIRECTIONS 
 
We designed and synthesized a number of novel coumarin based compounds and carried 
out a systematic study on their lipophilicity and membrane binding properties by investigating 
their labeling patterns in HEK293T cells, PC12 cells and cortical neuronal culture. Through this 
study, we were able to gain insights into the structure-activity relationship of these novel 
membrane probes. Through consecutive rounds of synthesis, we were able to optimize the length 
of the alkyl chain as well as the number of cationic charges needed for membrane binding. For a 
pH sensitive membrane probe which incorporates a pH sensor on the outer side of the plasma 
membrane, we established that a chain length of 12 carbons and two cationic charges are needed.  
PM502, which incorporated the structural characteristics mentioned above, was able to 
bind appropriately to the plasma membrane and sense pH changes of the external environment. It 
proved to be synthetically easily accessible and sufficiently bright and photostable for two-
photon microscopy.  Even though this probe satisfied the two critical conditions of membrane 
binding and pH sensing, it did not successfully meet the third criteria of reversible partitioning 
into the membrane. That is, it proved to be too lipophilic to wash away from the plasma 
membrane (in neuronal culture), resulting in non-specific staining and high background. 
Therefore, even though PM502 may not be suitable for studying synaptic vesicle recycling, it 
could still find other applications where the washout of the dye is not critical. For example, it 
could find applications in the imaging of the endocytic pathways in cells where the organelles 
undergo a change in pH along the pathway. One such example is the pathway involved in 
receptor-mediated endocytosis in which one of the first events is the acidification of the newly 
formed endosomes. The internalization of transferrin by human erythrolukemia cells involves the 
formation of an acidic endocytic vesicle.  Changes in pH also occur further along the endocytic 
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pathway as the early endosomes form late endosomes or lysosomes32. Thus PM502 can be used 
to investigate pH changes along these pathways, using protocols similar to the ones used for 
other pH sensitive dyes such as LysoSensor Yellow and LysoSensor Red33.    
Through the optimization of the lipophilic tail, we also developed a non-pH sensitive 
membrane probe, PM303. Like PM502, even though this dye showed selective binding to the 
plasma membrane and was sufficiently bright and photostable for two-photon microscopy, the 
washout kinetics of this dye were not suitable to study synaptic vesicle endocytosis/exocytosis. 
This dye can also find other applications where the washout from the plasma membrane is not 
critical. For example, it could be used for long term tracking and labeling of intracellular 
membranes and to study liposomes and endosomes. Furthermore, it could be used as a tracer in 
neurons to study retrograde axonal transport34, a phenomenon which involves the transport of 
vesicles from the axon terminals towards the cell bodies.  It could be used in conjunction with 
other dyes such as True Blue (TB) and Nuclear Yellow (NY)35 that have been developed for this 
purpose. Furthermore, since its fluorescence is enhanced when bound to the cell membrane (as 
also seen with FM1-43), it can be imaged in the continuous presence of the dye without needing 
an extra wash out step.  
In order to further develop these coumarin-based membrane probes, a suitable washout 
carrier molecule will have to be found. While ADVASEP-7 has proved to be a useful carrier 
molecule for FM1-43, it is certainly possible that it may not work well for our coumarin-based 
dyes. This is because the hydrophobic interior of ADVASEP-7, a derivative of the cyclic β-
cyclodextrin consisting of 7 glucopyranose units, can only accommodate specific molecules with 
appropriate dimensions. α-Cyclodextrins or γ-cyclodextrins that consist of 6 and 8 
glucopyransose units respectively can accommodate molecules with a different set of 
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dimensions. These cyclodextrins could be used as starting points in the exploration of new 
carrier molecules for the coumarin dyes.   
In summary, our findings indicate that the development of an endocytic pH probe that 
will selectively bind to the plasma membrane will require incorporation of at least two 
permanent cationic charges in order to prevent the probe from crossing the cell membrane. These 



















IV. EXPERIMENTAL SECTION 
IV.1 General Information  
All manipulations of air and/or water sensitive compounds were performed using standard 
Schlenk techniques under an atmosphere of argon passed through Dririte. All chemicals were 
purchased from Sigma-Aldrich and used as received unless otherwise noted. Flash 
chromatography was carried out on SILICYCLE silica gel (230-400 mesh).  Nuclear Magnetic 
Resonance spectra were recorded at 300 K on Bruker Advance DPX 300 or 400 Fourier 
transform NMR spectrometers in CDCl3, CD3OD and DMSO. Proton chemical shifts are 
expressed in parts per million (ppm, δ scale). Proton spectra were referenced to the solvent 
residual peak (CDCl3, δ 7.26; CD3OD, δ 3.30; DMSO, δ 2.49). Data for 1HNMR are reported as 
follows: chemical shift, integration, multiplicity, (s = singlet, d = doublet, t = triplet, m = 
multiplet, and coupling constant in Hertz (Hz). Carbon chemical shifts are expressed in parts per 
million (ppm, δ scale) and are referenced to the carbon resonance of the NMR solvent (CDCl3, δ 
77.0; CD3OD, δ 49.0; DMSO, δ 39.5) Mass spectra were recorded on a JEOL LCmate 
(Ionization mode: APCI+). HPLC was performed on a Waters 600 Controller on a Vydac C18 
Protein and Peptide column (#218TP1022); fractions were detected at 254 nm with a Waters 
2487 Dual λ Absorbance Detector.  Data was analyzed using OpenLynx software. For HPLC, 
either isocratic or linear elution gradients were used of solvents A and B (A = HPLC grade 
MeOH; B = de-ionized water containing 0.1% (v/v) trifluoroacetic acid (TFA) (ReagentPlus 





IV.2 Synthesis of PM100 Series 
Mini102: The HCl salt of Mini102 was synthesized according to established procedures22. 
PM101-103: PM101-103 were synthesized by monoalkylation of Mini102. The synthesis of 
PM101 is shown and described below as a representative example. 
 
PM101: 200 mg (0.724 millimoles) of Mini102 was added to an 
oven-dried two-neck round bottom flask. 100 mL of andyhrous MeOH was added under argon. 
The solution was sonicated and mildly heated until all Mini102 was dissolved. 50µl (0.362mmol) 
of dried triethylamine was added under argon. The mixture turned yellow and was allowed to stir 
for half an hour at room temperature. 3Å sieves were added. 267µl (2.172 millimoles) of hexanal 
were added and allowed to stir overnight at room temperature. After 24 hours, 306 mg (1.448 
mmol) of sodium borohydride were added and allowed to stir for 15 minutes. The reaction was 
quenched with sodium bicarbonate and then filtered. The filtrate was extracted twice with 100 
mL of ethyl acetate, dried over MgSO4, filtered and concentrated under vacuum to yield a 
brownish-yellow oil. The oil was purified by flash chromatography over a silica gel column 
using an elution gradient ranging from 5% to 20% methanol in dichloromethane. The product 
was obtained as a light yellow oil. 1H NMR (300 MHz, DMSO) δ 7.70 (s, 1H), 6.61 (s, 1H), 5.99 
 90 
(s, 1H), 2.92 (m, J = 4.7 Hz, 4H), 2.71 (t, J = 6.4 Hz, 2H), 1.48-1.44 (m, 2H), 1.33-1.21 (m, 6H), 
0.86 (t, 3H). LRMS (APCI+): Calc’d for C17H22ClNO3 323.1 m/z, measured 323.79 (MH+). 
PM102: PM102 was obtained in 15% yield as a yellow oil.  
1H NMR (300 MHz, DMSO) δ 7.75 (s, 1H), 6.69 (s, 1H), 6.05 (s, 1H), 3.03 – 2.87 (m, 4H), 2.75 
(t, J = 7.0 Hz, 2H), 1.52-1.49 (m, 2H), 1.33-1.25 (m, 10H), 0.85 (t, J = 6.3 Hz, 3H). LRMS 
(APCI+): Calc’d for C19H26ClNO3 351.16 m/z , measured 351.71 (MH+). 
PM103: PM103 was obtained in 21% yield as a light 
yellow oil. 1H NMR (300 MHz, DMSO) δ 7.68 (s, 1H), 6.56 (s, 1H), 5.95 (s, 1H), 2.90 (dd, J = 
4.5 Hz, 4H), 2.68 (t, J = 7.0 Hz, 2H), 1.45 (m, 2H), 1.33-1.21 (m, 14H), 0.86 (t, 3H). LRMS 









V.3 Synthesis of PM200 Series   
4-(benzyloxy)-2-hydroxybenzaldehyde: 1 was synthesized according to 
established procedures22. 1H NMR (300 MHz, CDCl3) δ 11.45 (s, 1H), 9.71 (s, 1H), 7.42 (m, 
5H), 7.25 (d, J = 4.0 Hz, 1H), 6.6 (d, 1H), 6.51 (s, 1H), 5.10 (s, 2H). 
7-(benzyloxy)-3-(4-nitrophenyl)-2H-chromen-2-one: 0.442 g (1.9 
mmol) of 1 was added to a round bottom flask with 0.31 grams (1.9 mmol) of 2-(4-
nitrophenyl)acetic acid, 3 mL of acetic anhydride and 0.204 g of sodium hydride (as a 60% 
suspension in oil).  The mixture was allowed to stir overnight at room temperature. After 24 
hours a yellow suspension was obtained which was filtered to yield the product as a yellow solid. 
The solid was washed with cold ether and dried under vacuum. The product was obtained in 92% 
yield and used without further purification. 1H NMR (400 MHz, DMSO) δ 8.45 (s, 1H), 8.32 (d, 
J = 9.0 Hz, 2H), 8.03 (d, J = 9.0 Hz, 2H), 7.76 (d, J = 8.7 Hz, 1H), 7.51 – 7.33 (m, 5H), 7.18 (d, 
J = 2.3 Hz, 1H), 7.11 (dd, J = 8.6, 2.4 Hz, 1H), 5.27 (s, 2H). LRMS (APCI+): Calc’d for 
C22H15NO5 373.36 m/z, measured 374.39 (MH+). 
3-(4-aminophenyl)-7-(benzyloxy)-2H-chromen-2-one: 1.5 g of 2 
(4.0 mmol) was added to 200 mLs of a solution of MeOH/THF (50%v/v) and dissolved in a 
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round bottom flask. Sonication with heating was necessary in order to fully dissolve the starting 
material. 20 mLs of MeOH was added to another round bottom flask containing Raney Ni (used 
as a slurry in H2O).  1 mL of hydrazine was added to the MeOH/Raney Ni mixture and refluxed. 
The MeOH/THF solution containing 2 was slowly added to the refluxing MeOH/Raney Ni 
mixture. The combined solution was allowed to reflux for 2 hours after which 1 mL of hydrazine 
was added and allowed to reflux for another 20 minutes. The reaction was monitored by TLC. 
The mixture was then cooled, filtered over celite to remove Raney Ni, and dried over MgSO4. 
This was filtered again and concentrated under vacuum to yield a yellow solid that was filtered 
over a short silica column using an elution of 5:1 Hexanes: Ethyl acetate. 3 was obtained as a 
yellow solid in 50% yield. 1H NMR (400 MHz, DMSO) δ 8.02 (s, 1H), 7.66 (d, J = 8.7 Hz, 1H), 
7.51 – 7.36 (m, 7H), 7.10 (d, J = 2.4 Hz, 1H), 7.04 (dd, J = 8.6, 2.4 Hz, 1H), 6.60 (d, 2H), 5.39 
(s, 2H), 5.23 (s, 2H). LRMS (APCI+): Calc’d for C22H17NO3 343.36 m/z, measured 344.39 
(MH+). 
7-(benzyloxy)-3-(4-(trimethyl-λ4-azanyl)phenyl)-2H-chro - men-
2-one: 100 mg (0.3 mmol) of 3 were added to 30 mLs of anhydrous MeOH under argon. Then 
124.4 mg (0.9 mmols) of potassium carbonate were added to the solution. Excess MeI was added 
portion-wise to the solution under argon. A total of 9 equivalents, 168 µl (2.7 mmol) were added. 
The solution was allowed to reflux at 60°C for 3 days. A yellow solution was obtained which 
was concentrated under vacuum to yield a yellow solid. This was washed with H2O to remove 
potassium carbonate and then dried under vacuum to yield the product as a yellow powder in 
95% yield. This was used without further purification. 1H NMR (400 MHz, DMSO) δ 8.33 (s, 
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1H), 8.05 (d, J = 9.2 Hz, 2H), 7.96 (d, J = 9.2 Hz, 2H), 7.74 (d, J = 8.7 Hz, 1H), 7.54 – 7.33 (m, 
6H), 7.17 (d, J = 2.2 Hz, 1H), 7.10 (dd, J = 8.6, 2.4 Hz, 1H), 5.27 (s, 2H), 3.64 (s, 9H). LRMS 
(APCI+): Calc’d for C25H24NO3+ 386.47 m/z, measured 372.39 (MH+).(ionization of one methyl 
group on amine leads to lower measured mass).  
 PM200: 50 mg (0.13 mmol) of 4 were added to 10 mL of MeOH 
and 2 mL of EtOH (to aid solubility). Raney Ni was added to the solution (used as a slurry in 
water). 4 was then reduced under H2 at 50 psi for 4 hours. The mixture was filtered over celite 
and dried over MgSO4. It was filtered again and concentrated under vacuum to yield a yellow 
solid in 88% yield. 1H NMR (400 MHz, MeOD) δ 8.18 (s, 1H), 8.06 – 8.01 (m, 2H), 8.01 – 7.97 
(m, 2H), 7.60 (d, J = 8.6 Hz, 1H), 6.89 – 6.84 (m, 1H), 6.79 (d, J = 2.2 Hz, 1H), 3.73 (s, 9H). 
LRMS (APCI+): Calc’d for C18H18NO3+ 296.34 m/z, measured 297.04 (MH+)  
7-(benzyloxy)-3-(4-(dibutylamino)phenyl)-2H-chro - men 
-2-one: 200 mg (0.58 mmol) was added to 5 mL of anhydrous MeOH in an oven-dried round 
bottom flask under argon. The starting material was dissolved in the solvent at room temperature 
and 200 µl (2.32 mmol) of butanal was added. 145.8 mg (2.32 mmol) of sodium 
cyanoborohydride was added and the reaction was allowed to stir at room temperature for 24 hrs. 
The reaction was quenched with 1M NaOH and the product was extracted with ethyl acetate. The 
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organic layer was dried over MgSO4, filtered and then concentrated under vacuum to yield a 
yellow oil. The crude oil was filtered through a silica gel column to remove baseline impurities 
and excess aldehyde. A mixture of 15:1 hexanes: ethyl acetate was used for the flash 
chromatography. The yellow powder obtained was subjected to the next step of methylation and 
then purified.  
4-(7-(benzyloxy)-2-oxo-2H-chromen-3-yl)-N,N-dibutyl-N-
methylbenzenaminium: 80 mg (0.175 mmol) of 5 were added to a vial and dissolved in 
acetonitrile under argon. 500 µl (5.3 mmol) of MeI were added to the vial under argon. The 
reaction was heated to 50OC in the enclosed vial. After 48 hours, the reaction was cooled down 
to room temperature and a white salt crashed out which was filtered and washed with 1 ml of 
cold acetonitrile. The product was obtained in 43% yield over two steps. 1H NMR (400 MHz, 
MeOD) δ 8.25 (s, 1H), 8.07 (d, J = 9.1 Hz, 2H), 7.88 (d, J = 9.2 Hz, 2H), 7.73 (d, 1H), 7.54 – 
7.32 (m, 5H), 7.13 – 7.04 (m, 2H), 5.25 (s, 2H), 4.06 (td, J = 12.6, 4.2 Hz, 2H), 3.85 (td, J = 
12.4, 5.0 Hz, 2H), 3.63 (s, 3H), 1.75 (ddd, J = 17.9, 9.8, 4.9 Hz, 2H), 1.47 – 1.18 (m, 6H), 0.94 
(t, J = 7.3 Hz, 6H). 13C NMR (101 MHz, MeOD) δ 162.69 (s), 160.81 (s), 155.52 (s), 142.18 (s), 
141.40 (s), 137.41 (s), 136.26 (s), 130.24 (s), 129.71 (s), 128.26 (s), 127.87 (s), 127.37 (s), 
121.41 (d, J = 14.3 Hz), 113.54 (s), 113.26 (s), 101.06 (s), 70.32 (s), 68.83 (s), 46.53 (s), 24.59 
(s), 19.11 (s), 12.40 (s). Calc’d for C31H36NO3+ 470.27 m/z, measured 456.04 (MH+) (the extra 
methyl group was not detected likely due to ionization).  
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PM201: 20 mg (0.04 mmol) of 5a was dissolved in 10 mL of 
MeOH. Raney Ni (as a slurry in water) was added to the mixture and the starting material was 
reduced with H2 at 50 psi for 24 hrs at room temperature. The reaction mixture was filtered over 
celite and concentrated under vacuum to yield a light yellow oil. This was purified using HPLC 
with a MeOH/H2O gradient starting from 0% MeOH to 40% MeOH over 30 minutes and from 
40% MeOH to 100% MeOH for the following 30 minutes. The product was obtained as a light 
yellow oil in 53% yield. 1H NMR (400 MHz, MeOD) δ 8.49 (s, 1H), 8.21 (s, 1H), 8.05 (d, J = 
9.0 Hz, 2H), 7.85 (d, J = 9.1 Hz, 2H), 7.60 (d, J = 8.6 Hz, 1H), 6.87 (dd, J = 8.5, 2.3 Hz, 1H), 
6.79 (d, J = 2.2 Hz, 1H), 4.04 (td, J = 12.6, 4.2 Hz, 2H), 3.82 (td, J = 12.6, 4.9 Hz, 2H), 3.62 (s, 
3H), 1.73 (dt, J = 12.5, 6.0 Hz, 2H), 1.48 – 1.22 (m, 6H), 0.94 (t, J = 7.3 Hz, 6H). 13C NMR (101 
MHz, MeOD) δ 163.12 (s), 161.16 (s), 155.83 (s), 142.60 (s), 141.16 (s), 137.67 (s), 130.02 (d, J 
= 19.1 Hz), 121.24 (s), 119.94 (s), 113.89 (s), 111.95 (s), 101.78 (s), 99.99 (s), 68.80 (s), 46.44 
(s), 24.57 (s), 19.10 (s), 12.37 (s). Calc’d for C24H30NO3+ 380.51 m/z, measured 366.41 (MH+) 
(the methyl group was not detected as seen previously, likely due to ionization).  
3-(4-(dimethylamino)phenyl)-2-oxo-2H-chromen-7-yl -     
acetate: 300 mg (1.45 mmol) of 2,4-dihydroxybenzaldehyde was added to 100 mL reactor along 
with 390 mg (1.45 mmol) of 4-(dimethylamino)phenylacetic acid. 10 mL of acetic anhydride 
 96 
was added and the contents were stirred for 15 minutes. 360 mg of sodium acetate was added and 
the reactor was closed and heated to 150OC for 6 hours in an oil bath. The reaction was then 
cooled to room temperature and further cooled to -20OC for 2 hours. A brownish-yellow solid 
crashed out which was filtered and washed with cold H2O. This solid was recrystalized from 
ethylacetate to give the product in 95% yield as brownish-yellow crystals. 1H NMR (300 MHz, 
DMSO) δ 8.13 (s, 1H), 7.78 (d, J = 7.9 Hz, 1H), 7.65 (d, J = 7.9 Hz, 2H), 7.28 (s, 1H), 7.16 (d, J = 8.2 
Hz, 1H), 6.79 (d, J = 8.0 Hz, 2H), 2.97 (s, 6H), 2.32 (s, 3H). Calc’d for C19H17NO4 323.12 m/z, 
measured 324.2 (MH+) 
3-(4-(dimethylamino)phenyl)-7-hydroxy-2H-chromen-2 - one :  
300 mg (0.928 mmol) of 6 was dissolved in 20mL of MeOH. 2 mL of 13M HCl was added and 
the mixture was allowed to reflux overnight. The MeOH was them evaporated under vacuum and 
and 1.5M NaOH was added to the flask. The NaOH mixture was allowed to cool overnight at -
20OC. Greenish-brown crystals crashed out of the mixture and were recovered in 62% yield. 1H 
NMR (300 MHz, DMSO) δ 7.87 (s, 1H), 7.57 (d, J = 8.9 Hz, 2H), 7.36 (d, J = 8.7 Hz, 1H), 6.75 
(d, J = 9.0 Hz, 2H), 6.55 (d, 1H), 6.41 (s, 1H), 2.93 (s, 6H). Calc’d for C17H15NO3 281.11 m/z, 
measured 281.2 (MH+) 
7-(benzyloxy)-3-(4-(heptyl(methyl)amino)phenyl) - 2H -
chromen-2-one: 200 mg (0.618 mmol) of 6a was added to a round bottom flask. 5 mL of DMF 
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was added to dissolve the starting material. 101 µl (0.851) of benzylbromide and 147 mg (1.058 
mmol) was added to starting material. The flask was sealed and the reaction was stirred for 6 hrs 
at room temperature.  The reaction was cooled -20OC for 2 hours and yellow crystals formed. 
These were recovered by filtration and washed with H2O. The product was obtained as a yellow 
solid in 85% yield. 1H NMR (300 MHz, DMSO) δ 8.06 (s, 1H), 7.69-7.9 (m, 3H), 7.54 – 7.32 
(m, 5H), 7.10 (s, 1H), 7.04 (d, J = 8.6 Hz, 1H), 6.77 (d, J = 8.6 Hz, 2H), 5.23 (s, 2H), 2.95 (s, 
6H). Calc’d for C24H21NO3 371.15 m/z, measured 371.9 (MH+) 
7-(benzyloxy)-3-(4-(heptyl(methyl)amino)phenyl)-2H -
chromen-2-one: 200 mg (0.54 mmol) of 7 was added to 15 mL of acetonitrile in a reactor and 
heated mildly to aid dissolution. 1 mL (6.74 mmol) of hexyl iodide was added. The reactor was 
sealed and heated to 110OC for 24 hrs in an oil bath. The reaction was cooled to room 
temperature and the acetonitrile was evaporated under vacuum. A brownish-yellow sludge was 
obtained to which a few mL of hexanes and MeOH was added. The solid that crashed out was 
recovered by filtration and recrystalized from a mixture of ethyl acetate, MeOH and EtOH. This 
solid was subjected to the next step of methylation without isolation of the product.  
4-(7-(benzyloxy)-2-oxo-2H-chromen-3-yl) - N-hexyl-
N,N-dimethylbenzenaminium: 50 mg (0.11 mmol) of 8 was added to a 50 mL reactor and 
dissolved in 5 mL of acetonitrile. 700 µl of MeI was added to the reactor. It was sealed and 
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heated to 60oC in an oil bath for 6 hrs. The reaction was then cooled to room temperature and the 
solvent was removed under vacuum to yield a yellow solid. The crude 1H-NMR showed ~15% 
impurities. The yellow solid was used in the next step without further isolation.  
PM202: 50 mg (0.109 mmol) of 9 was dissolved in 1 
mL of EtOH in a vial. 3 mL of TFA was added and the vial was sealed and heated to 90oC for 24 
hours. The reaction mixture was cooled to room temperature and the solvent was concentrated 
under vacuum. The crude concentrated mixture was purified by HPLC using a MeOH/H2O 
gradient starting from 0% MeOH to 40% MeOH over 30 minutes and from 40% MeOH to 100% 
MeOH for the following 30 minutes. The product was obtained as a light yellow oil in 23% yield 
over three steps. 1H NMR (400 MHz, MeOD) δ 8.37 8.20 (s, 1H), 8.04 (d, J = 9.1 Hz, 2H), 7.91 
(d, J = 9.2 Hz, 2H), 7.60 (d, J = 8.6 Hz, 1H), 6.87 (dd, J = 8.5, 2.3 Hz, 1H), 6.79 (d, J = 2.2 Hz, 
1H), 3.99 – 3.88 (m, 2H), 3.68 (s, 6H), 1.50 (d, J = 7.5 Hz, 2H), 1.37 – 1.26 (m, 6H), 0.95 – 0.84 
(m, 3H). Calc’d for C23H28NO3+ 366.25 m/z, measured 363.01 (MH+). 
5-chloro-2,4-dihydroxybenzaldehyde: This compound was synthesized 
according to a previously described procedure22. 
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4-(benzyloxy)-5-chloro-2-hydroxybenzaldehyde: This compound was also 
synthesized according to a previously described procedure22.  
7-(benzyloxy)-6-chloro-3-(4-(dimethylamino)phenyl) 
-2H-chromen-2-one: A reflux condenser was attached to an oven-dried three-neck round bottom 
flask under argon. 170 mg (0.648 mmol) of 10, 115.6 mg (0.64 mmol) of 2-(4-
(dimethylamino)phenyl)acetic acid,  147 mg ( 0.713 mmol) of N,N'-dicyclohexylcarbodiimide 
(DCC) was added to this flask argon. The contents was dissolved in 5 mL of methylene chloride 
and a small crystal of 4-dimethylaminopyridine (DMAP) was added and allowed to stir at room 
temperature for two hours. At this point, all the starting materials had been completely consumed 
to form the ester as monitored by TLC. 213 µl (1.52 mmol) of triethyl amine was added to 
reaction and it was heated up to 60oC using an oil bath.  After 4 hours, the reaction was cooled 
and the DCC byproducts were filtered out. The filtrate was concentrated under vacuum to yield a 
crude yellow oil. 2 mL of acetonitrile was added to this and a yellow solid crashed out which 
was recovered by filtration to yield a yellow solid in 73% yield. 1H NMR (400 MHz, DMSO) δ 
8.03 (s, 1H), 7.88 (s, 1H), 7.60 (d, J = 9.0 Hz, 2H), 7.53 – 7.37 (m, 5H), 7.36 (s, 1H), 6.78 (d, J = 





yl) amino)phenyl)-2H-chromen-2-one: 100 mg (0.246 mmol) of 11 was added to 10 mls of 
acetonitrile. 2 mL (2.514 g or 9.36 mmol) of 1-iododecane was added to a microwave reactor 
and the reaction was allowed to proceed for 4 hrs at 150oC. The crude reaction mixture was 
evaporated onto silica gel which was loaded onto a silica gel column and filtered through a short 
silica column, using an elution of 8:1 Hexanes: Ethylacetate. The recovered material was 
obtained as a yellow oil and contained the desired product and ~ 10% iododecane as an impurity. 
This was not purified further and the crude mixture was used in the next step.  
4-(7-(benzyloxy)-6-chloro-2-oxo-2H-chro- 
men-3-yl)-N-decyl-N,N-dimethylbenzenaminium:  10 mg of the crude mixture from 12 was 
dissolved in 2 mL of acetonitirile in a vial. 500 µl of MeI was added to the vial which was then 
sealed and heated to 90oC for 24 hrs. The reaction was cooled -20oC for 12 hrs. Yellows crystals 
crashed out which were recovered by filtration. These were subjected to the next step without 
further purification. 
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PM203: 5 mg (0.0018 mmol) of 13 was 
added to a vial and dissolved in 3 mL of EtOH. 0.5 mL of TFA was added and the vial was 
sealed and heated to 90oC for 4 hours. The solvent and acid were evaporated under vacuum to 
give a yellow oily solid. This was dissolved in hot acetonitrile and allowed to cool for at -20oC 
for 24 hrs. The product was obtained as yellow crystals in 31% yield over three steps. 1H NMR 
(400 MHz, MeOD) δ 8.17 (s, 1H), 8.05 (d, J = 9.2 Hz, 2H), 7.92 (d, J = 9.2 Hz, 2H), 7.77 (s, 
1H), 6.94 (s, 1H), 3.99 – 3.88 (m, 2H), 3.68 (s, 6H), 1.56-1.49 (s, 2H), 1.30 (m, J = 15.8 Hz, 














IV.4 Synthesis of PM300 Series:  
 
3-(4-(dimethylamino)phenyl)-7-ethoxy-2H-chromen-2-one: 
100 mg (0.355 mmol) of 6a was added to 10 mL of acetonitrile in a round bottom flask and 
mildly heated to help it to dissolve in the solvent. 50 µl (0.639 mmol, 1.8 eq) of iodoethane was 
added to solution. 123 mg (0.8575 mmol, 2.5 eq) of K2CO3 was added. The flask was fitted with 
a reflux condenser. The reaction was heated to 50oC for 6 hr. It should be noted that the reflux 
was condenser was used simply to cool any small amounts of solvent that may have evaporated. 
The reaction was not carried out at the boiling point of the solvent (82oC) in order to prevent N-
alkylation. The reaction was cooled and the crude mixture was concentrated under vacuum to 
yield a yellow solid. This was washed with water to get ride of salts. A second wash was carried 
out with hexanes to get rid of excess alkyl iodide. The yellow solid was filtered to give the 
product in 92% yield. No further purification was needed. 1H NMR (400 MHz, DMSO) δ 8.07 
(s, 1H), 7.66 (d, J = 8.6 Hz, 1H), 7.62 (d, J = 8.9 Hz, 2H), 6.99 (d, J = 2.3 Hz, 1H), 6.95 (dd, J = 
8.6, 2.4 Hz, 1H), 6.78 (d, J = 9.0 Hz, 2H), 4.15 (q, J = 7.0 Hz, 2H), 2.96 (s, 6H), 1.38 (t, J = 7.0 






one: The procedure followed was similar to that of 14a, except that DMF was used as the 
solvent. When the reaction was complete, it was poured into H2O and the product crashed out of 
solution. It was recovered by filtration and stirred vigorously with hexanes for 30 min to wash 
away excess alkyl iodide. The product was obtained as a yellow solid in 95% yield. No further 
purification was needed. 1H NMR (400 MHz, DMSO) δ 8.07 (s, 1H), 7.66 (d, J = 8.6 Hz, 1H), 
7.62 (d, J = 8.9 Hz, 2H), 7.00 (d, J = 2.3 Hz, 1H), 6.96 (dd, J = 8.6, 2.4 Hz, 1H), 6.78 (d, J = 9.0 
Hz, 2H), 4.10 (t, J = 6.5 Hz, 2H), 2.96 (s, 6H), 1.82 – 1.69 (m, 2H), 1.56 – 1.40 (m, 2H), 0.96 (t, 
J = 7.4 Hz, 3H). Calc’d for C21H23NO3 337.14 m/z, measured 338.04 (MH+).  
3-(4-(dimethylamino)phenyl)-7 -(octyloxy)-2H-
chromen-2-one: This was prepared by the same procedure followed for 14b. The product was 
obtained as a yellow solid in 90% yield. No further purification was needed. 1H NMR (400 MHz, 
DMSO) δ 8.06 (s, 1H), 7.64 (d, J = 8.7 Hz, 1H), 7.61 (d, J = 9.0 Hz, 2H), 6.98 (d, J = 2.3 Hz, 
1H), 6.94 (dd, J = 8.6, 2.4 Hz, 1H), 6.77 (d, J = 9.0 Hz, 2H), 4.07 (t, J = 6.5 Hz, 2H), 2.95 (s, 
6H), 1.79 – 1.70 (m, 2H), 1.44 – 1.22 (m, 10H), 0.90 (t, 3H). Calc’d for C25H31NO3 393.23 m/z, 




PM301: 60 mg (0.19mmol) of 14a was added to 5 mL of 
acetonitrile in a vial. 100 µl (1.5 mmol) of MeI was added and the vial was sealed and heated to 
80oC for 24 hrs. The mixture was cooled and concentrated under vacuum to give a yellow solid 
that was recrystalized from acetonitrile to give a whitish-yellow solid in 92% yield. 1H NMR 
(400 MHz, DMSO) δ 8.34 (s, 1H), 8.05 (d, J = 9.3 Hz, 2H), 7.98 (d, J = 9.2 Hz, 2H), 7.73 (d, J = 
8.7 Hz, 1H), 7.06 (d, J = 2.3 Hz, 1H), 7.02 (dd, J = 8.6, 2.4 Hz, 1H), 4.19 (q, J = 7.0 Hz, 2H), 
3.65 (s, 9H), 1.39 (t, J = 7.0 Hz, 3H). 13C NMR (101 MHz, MeOD) δ 142.17 (s), 130.10 (s), 
119.67 (s), 113.25 (s), 100.40 (s), 68.27 (s), 56.39 (s), 30.82 (s), 12.71 (s). Calc’d for C20H22NO3 
323.15 m/z, measured 323.25 (MH+) 
PM302: The same procedure was used that for the 
synthesis of PM301. 1H NMR (400 MHz, DMSO) δ 8.33 (s, 1H), 8.06 (d, J = 9.1 Hz, 2H), 7.97 
(d, J = 9.1 Hz, 2H), 7.72 (d, J = 8.6 Hz, 1H), 7.06 (s, 1H), 7.02 (d, J = 8.6 Hz, 1H), 4.12 (t, J = 
6.5 Hz, 2H), 3.64 (s, 9H), 1.80 – 1.71 (m, 2H), 1.51 – 1.42 (m, 2H), 0.96 (t, J = 7.4 Hz, 3H). 13C 
NMR (101 MHz, MeOD) δ 163.22 (s), 160.87 (s), 155.62 (s), 146.49 (s), 142.17 (s), 137.57 (s), 
130.10 (s), 129.63 (s), 121.27 (s), 119.67 (s), 113.25 (s), 112.91 (s), 100.40 (s), 68.27 (s), 56.39 
(s), 30.82 (s), 18.82 (s), 12.71 (s). Calc’d for C22H26NO3 352.19 m/z, measured 353.29 (MH+) 
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PM303: The same procedure was used as that 
for the synthesis of PM 301 and PM 302. 1H NMR (400 MHz, DMSO) δ 8.36 (s, 1H), 8.07 (d, J 
= 9.3 Hz, 2H), 7.99 (d, J = 9.2 Hz, 2H), 7.74 (d, J = 8.7 Hz, 1H), 7.08 (d, J = 2.3 Hz, 1H), 7.04 
(dd, J = 8.6, 2.4 Hz, 1H), 4.13 (t, J = 6.5 Hz, 2H), 3.67 (s, 9H), 1.83 – 1.72 (m, 2H), 1.51 – 1.41 
(m, 2H), 1.36-1.30 (m, 8H), 0.89 (t, 3H).13C NMR (101 MHz, MeOD) δ 163.18 (s), 160.85 (s), 
155.59 (s), 146.49 (s), 142.17 (s), 137.51 (s), 130.09 (s), 129.67 (s), 121.22 (s), 119.72 (s), 
113.23 (s), 112.92 (s), 100.40 (s), 68.57 (s), 56.46 (s), 31.57 (s), 29.01 (d, J = 6.6 Hz), 28.75 (s), 














IV. 5 Synthesis of PM400 Series  
7-(benzyloxy)-6-chloro-3-(pyridin-4-yl)-2H-chromen-2-one:  200 mg 
(0.763 mmol) of 10 was added to 10 mL of isopropyl alcohol. 129 µl (0.839 mmol, 1.1 eq) of 
ethyl 2-(pyridin-4-yl)acetate and 83 µl (0.839 mmol) of piperidine was added. The mixture was 
refluxed overnight. The reaction was cooled to room temperature. A white solid crashed out 
which was recovered by filtration in 65% yield. 1H NMR (400 MHz, DMSO) δ 8.68 (d, J = 6.0 
Hz, 2H), 8.41 (s, 1H), 7.97 (s, 1H), 7.77 (d, 2H), 7.56 – 7.32 (m, 6H), 5.38 (s, 2H). Calc’d for 








methylpyridin-1-ium: 60 mg (0.165 mmol) of 14 was added to 10 mL of acetonitrile in a 50 mL 
reactor. 0.5 mL (7.5 mmol) of MeI was added to the solution. The reactor was sealed and heated 
to 100oC for 24 hrs. The reaction was cooled and the solvent and MeI was evaporated under 
vacuum. The product was obtained in 91% yield was a yellow solid. 1H NMR (400 MHz, 
DMSO) δ 9.02 (d, J = 6.9 Hz, 2H), 8.77 (s, 1H), 8.48 (d, J = 7.0 Hz, 2H), 8.02 (s, 1H), 7.62 – 




yl)-1-octylpyridin-1-ium: 50 mg (0.1375 mmol) of 14 was dissolved in 40 mL of acetonitirile in 
a reactor. 400 µl (2.30 mmol) of 1-bromooctane was added to the solution. A catalytic amount of 
NaI was added. The reactor was sealed and heated to 100oC for 24 hr using an oil bath. The 
reaction was cooled and concentrated under vacuum. The crude mixture was washed with 
hexanes. A yellowish-orange solid crashed out which was filtered and recovered. The crude 1H-
NMR showed ~10% impurity of octyl bromide. The product was not isolated and was used in the 
next step without purificaiton.  
PM401: 20 mg (0.0896 mmol) of 15i was added to a reactor with 4 
mL of TFA. The reactor was sealed and heated to 100oC for 10 hrs. The TFA was evaporated 
under vacuum to yield an orange solid. The product was recrystalized from a mixture of H2O, 
TFA and MeOH. 1H NMR (400 MHz, MeOD) δ 8.89 (d, J = 6.9 Hz, 2H), 8.69 (s, 1H), 8.58 (d, J 
= 6.9 Hz, 2H), 7.87 (s, 1H), 6.96 (s, 1H), 4.42 (s, 3H). 13C NMR (101 MHz, MeOD) δ 159.65 
(s), 159.01 (s), 155.17 (s), 151.33 (s), 145.69 (s), 144.65 (s), 130.36 (s), 125.38 (s), 119.20 (s), 





PM402: 15ii was used as a starting material and 
the same procedure was used for deprotection of the benzyl group as was used for PM 401. The 
product was obtained as an orange powder in 66% yield over two steps. 1H NMR (400 MHz, 
DMSO) δ 9.12 (d, J = 7.0 Hz, 2H), 8.79 (s, 1H), 8.51 (d, J = 7.0 Hz, 2H), 7.93 (s, 1H), 7.05 (s, 
1H), 4.59 (t, J = 7.4 Hz, 2H), 1.96 (t, J = 6.5 Hz, 2H), 1.30 – 1.25 (m, 10H), 0.87 (t, 3H). Calc’d 
for C22H25ClNO3+ 386.15 m/z, measured 387.8 (MH+).  
N-(3-bromopropyl)-N,N-dimethyloctan-1-aminium:  2 mL 
(9.7 mmol) of N,N-dimethyloctan-1-amine was added to 10 mL of MeOH. 5 mL (49 mmol) of 
1,3-dibromopropane was added to the mixture. The mixture was heated in a reactor for 48 hr at 
30oC. The reaction mixture was concentrated under vacuum to yield a light green oil. 200 mL of 
Methyl tert-butyl ether (MTBE) was added to this mixture and stirred vigorously. A white oil 
precipitated from the solution. The MTBE was decanted to leave behind the white oil. Fresh 
MTBE was added and the process was repeated three times. MTBE was removed from the oil by 
evaporation under vacuum for 24 hrs. 1H NMR (400 MHz, CDCl3) δ 3.82 - 3.8 (m, 2H), 3.61 – 
3.49 (m, 4H), 3.45 (s, 6H), 2.45-2.40 (m, 2H), 1.76 (m, 2H), 1.44 – 1.21 (m, 10H), 0.88 (t, J = 




- men-3-yl)-1-(3 -(dimethyl(octyl)ammonio)propyl)pyridin-1-ium: 200 mg (0.55 mmol) of 14 
was dissolved in 90 mL of acetonitirle in a reaction vessel. Sonication and heating was required 
to dissolve 14. 1 g (3.6 mmol) of 17  was added to the solution. The reaction vessel was sealed 
and the reaction was heated to 80oC for 24 hrs. The reaction was cooled and concentrated under 
vacuum to yeild a brown sludge. MeOH was added to the brown sludge until a yellow solid 
precipitated out which was recovered by filtration. This solid contained the required product as 
well as some excess of 17. The solid was carried to the next step without further purification.      
PM403: 18 was deprotected with TFA 
using the same procedure as mention for the deprotection of 15i. The solid obtained was purified 
on the HPLC using a MeOH/H2O gradient starting from 0% MeOH to 40% MeOH over 30 
minutes and from 40% MeOH to 100% MeOH for the following 30 minutes. The product was 
recovered as an orange solid in 63% yield over two steps. 1H NMR (400 MHz, MeOD) δ 8.63 (d, 
J = 7.1 Hz, 2H), 8.58 (d, J = 7.1 Hz, 2H), 8.50 (s, 1H), 7.57 (s, 1H), 6.25 (s, 1H), 4.55 (t, J = 7.4 
Hz, 2H), 3.55 – 3.48 (m, 2H), 3.40 (m, 2H), 3.17 (s, 6H), 2.50-2.52 (m, 2H), 1.80 (m, 2H), 1.49 – 
1.27 (m, 10H), 0.91 (t, 3H). Calc’d for C27H37ClN2O32+ 473.05 m/z, measured 458.35 (MH+) 
(ionization of a methyl group).  
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IV. 6 Synthesis of PM500 Series  
2-oxo-3-(p-tolyl)-2H-chromen-7-yl acetate:  100 mg (0.725 
mmol) of 2,4-dihydroxybenzaldehyde was added to 108.8 (0.725 mmol) and dissolved in 10 mL 
of acetic anhydride in a reaction vessel. 119 mg (1.45 mmol) of sodium acecate was added. The 
vessel was sealed and heated to 180oC for 3 hrs. The reaction was cooled to room temperature 
and then cooled to -20oC. White crystals were formed. H2O was added to the reaction mixture 
and the product was filtered out and recovered as white crystals in 55% yield. 1H NMR (400 
MHz, CDCl3) δ 7.80 (s, 1H), 7.6 (d, 2H), 7.56 (d, J = 8.5 Hz, 1H), 7.30 (s, 1H), 7.28 (s, 1H), 
7.17 (d, J = 2.2 Hz, 1H), 7.10 (dd, J = 8.4, 2.2 Hz, 1H), 2.43 (s, 3H), 2.38 (s, 3H). Calc’d for 
C18H14O4 294.09 m/z, measured 295.1 (MH+) 
3-(4-(bromomethyl)phenyl)-2-oxo-2H-chromen-7- yl acetate:  
100 mg (0.34 mmol) of 19 was dissolved in 5 mL of anhydrous methylene chloride under argon 
in an oven-dried round bottom flask. 60 mg (0.34 mmol) of N-bromosuccinimide (NBS) and a 
catalytic amount of azobisisobutyronitrile (AIBN) was added. The reaction was heated in an oil 
bath to 55oC for 8.5 hrs. The reaction was concentrated under vacuum. The recovered solid was 
recrystalized from a mixture of methylene chloride, methanol and hexanes. The product was 
obtained as a white powder in 79% yield. 1H NMR (400 MHz, CDCl3) δ 7.81 (s, 1H), 7.66 (d, 
2H), 7.55 (d, J = 8.4 Hz, 1H), 7.48 (d, J = 8.3 Hz, 2H), 7.16 (d, J = 2.2 Hz, 1H), 7.08 (dd, J = 
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8.4, 2.2 Hz, 1H), 4.53 (s, 2H), 2.35 (s, 3H). Calc’d for C18H13BrO4 372.0 m/z, measured 372.5 
(MH+) 
N-(3-(dimethylamino)propyl)-N,N-dimethyl -  
decan-1-aminium: 4.83 mL (28.9 mmol, 10 eq ) of N1,N1,N3,N3-tetramethylpropane-1,3-diamine 
was added to 0.638 mL (2.89 mmol, 1 eq) of 1-bromodecane and dissolved in 10 mL of MeOH. 
The reaction was heated to 30oC in a reactor for 24 hrs. The MeOH was removed under vacuum 
to leave a light yellow oil. 30 mL of hexanes was added to dissolve the excess N1,N1,N3,N3-
tetramethylpropane-1,3-diamine. A yellow oil remained at the bottom of the solution. The 
hexanes were decanted. Excess hexanes were removed under vacuum and the product was 
obtained as a yellow oil in 75% yield. 1H NMR (400 MHz, CDCl3) δ 3.63 – 3.49 (m, 4H), 3.43 
(s, 6H), 2.41 (t, J = 6.4 Hz, 2H), 2.19 (s, 6H), 1.95 – 1.87 (m, 2H), 1.79 – 1.68 (m, 2H), 1.36 – 
1.31 (m, 14H), 0.85 (t, 3H). Calc’d for C17H39N2+ 271.31 m/z, measured 256.2 (MH+) (ionization 
of a methyl group).  
N-(3-(dimethylamino)propyl)-N,N-di-methyldo 
-decan-1-aminium: 21ii was synthesized using the same procedure as for 21ii with 1-
dodecyldecane as the alkylating agent. The product was obtained in 66% yield as a yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 3.60 – 3.46 (m, 4H), 3.39 (s, 6H), 2.37 (t, J = 6.4 Hz, 2H), 2.19 (s, 
6H), 1.91 – 1.83 (m, 2H), 1.76 – 1.63 (m, 2H), 1.25 - 1.19 (m, 18H), 0.86 (t, J = 6.8 Hz, 3H) 






30 mg (0.08 mmol, 1 eq) of 20 was dissolved in 5 mL of acetonitrile in a reactor. 60 mg (0.24 
mmol, 3 eq) of 21i was added to this solution. The reactor was sealed and heated up to 100oC for 
10 hrs. The solvent was concentrated under vacuum to give a yellowish white oil which was 
dissolved in a mixture of MeOH/Hexanes (50%v/v). This was heated to 50oC to aid dissolution 
and then and cooled to -20oC for 12 hrs. The product crashed out as a white solid and was 
recovered in 88% yield. 1H NMR (400 MHz, CDCl3) δ 7.95 (s, 1H), 7.75 (s, 4H), 7.61 (d, J = 8.6 
Hz, 1H), 7.10 (d, J = 2.1 Hz, 1H), 7.04 (dd, J = 8.5, 2.2 Hz, 1H), 5.02 (s, 2H), 3.91 (t, J = 7.5 Hz, 
2H), 3.86 – 3.75 (t, 2H), 3.57 – 3.46 (m, 2H), 3.37 (s, 6H), 3.30 (s, 6H), 2.86 (s, 2H), 2.34 (s, 
3H), 1.77 (m, 2H), 1.39 – 1.17 (m, 14H), 0.85 (t, J = 6.9 Hz, 3H). Calc’d for C35H52N2O4+ 
564.38 m/z, measured 564.9 (MH+).   
N1-(4-(7-acetoxy-2-oxo-
2H-chromen-3-yl)benzyl)-N3-dodecyl-N1,N3-dimethanidyl-N1,N3-dimethylpropane-1,3-
diaminium: The same procedure was followed as for synthesis of 22i, using 15ii. The product 
was recovered as a white powder in 95% yield. 1H NMR (400 MHz, CDCl3) δ 7.91 (s, 1H), 7.79 
(d, J = 8.3 Hz, 2H), 7.72 (d, J = 8.3 Hz, 2H), 7.61 (d, J = 8.5 Hz, 1H), 7.16 (d, J = 2.1 Hz, 1H), 
7.09 (dd, J = 8.4, 2.2 Hz, 1H), 4.94 (s, 2H), 4.04 (t, 2H), 3.91 (t, 2H), 3.50 (t, 2H), 3.33 (d, J = 
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25.7 Hz, 12H), 2.95-2.90 (m, 2H), 2.36 (s, 3H), 1.85 - 1.80 (m, 2H), 1.29 - 1.22 (m, 18H), 0.88 
(t, J = 6.9 Hz, 3H). Calc’d for C37H56N2O4+ 592.41 m/z, measured 528.9 (MH+). 
 PM501: 25 mg (0.044 
mmol, 1 eq) of 22i was dissolved in 5 mL of MeOH. 8.2 mg (0.06 mmol, 1.5 eq) was added to 
the solution and stirred at room temperature for 1 hr. The solvent was concentrated under 
vacuum to yield a light yellow solid. A mixture of acetonitrile and H2O (30%/70% v/v) was 
added to this and cooled to -20oC for 2 hrs. A white solid crashed out which was further purified 
by HPLC using an elution gradient of MeOH/H2O starting from 0% MeOH to 40% MeOH over 
30 minutes and from 40% MeOH to 100% MeOH for the following 30 minutes. The product was 
obtained as a white salt in 69% yield. 1H NMR (400 MHz, MeOD) δ 7.97 (s, 1H), 7.84 (d, J = 
8.3 Hz, 2H), 7.59 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.7 Hz, 1H), 6.63 (dd, J = 8.6, 2.2 Hz, 1H), 
6.45 (d, J = 2.0 Hz, 1H), 4.65 (s, 2H), 3.46 (dq, J = 13.3, 6.8, 6.3 Hz, 6H), 3.20 (d, J = 9.7 Hz, 
12H), 2.53 – 2.36 (m, 2H), 1.86 – 1.80 (m, 2H), 1.51 – 1.22 (m, 14H), 0.97 – 0.85 (t, 3H). 13C 
NMR (101 MHz, MeOD) δ 173.67 (s), 162.35 (s), 157.12 (s), 142.97 (s), 138.72 (s), 132.67 (s), 
129.54 (s), 128.39 (s), 125.72 (s), 118.27 (s), 115.39 (s), 108.50 (s), 103.19 (s), 67.97 (s), 65.02 
(s), 60.49 (s), 60.22 (s), 50.28 (s), 49.46 (s), 48.51 (s), 31.63 (s), 29.21 (s), 28.95 (d, J = 10.8 





PM502: The same 
procedure was used as the deprotection of 22i. The product was obtained as a white powder in 
65% yield. 1H NMR (400 MHz, MeOD) δ 8.15 (s, 1H), 7.93 (d, J = 8.2 Hz, 2H), 7.67 (d, J = 8.3 
Hz, 2H), 7.60 (d, J = 8.6 Hz, 1H), 6.88 (dd, J = 8.5, 2.3 Hz, 1H), 6.80 (d, J = 2.3 Hz, 1H), 4.67 
(s, 2H), 3.46 – 3.38 (m, 6H), 3.18 (d, J = 6.1 Hz, 12H), 2.41 - 2.38 (m, 2H), 1.85 - 1.80 (m, 2H), 
1.40 - 1.35 (m, 18H), 0.92 (t, 3H).13C NMR (101 MHz, MeOD) δ 175.29 (s), 162.63 (s), 157.35 
(s), 143.12 (s), 139.00 (s), 132.51 (s), 129.37 (s), 128.37 (s), 125.45 (s), 118.94 (s), 114.60 (s), 
108.01 (s), 103.42 (s), 68.27 (s), 64.99 (s), 60.18 (s), 31.64 (s), 29.42 – 28.78 (m), 26.00 (s), 














IV. 7 Photophysical Characterization  
Absorption: Ultraviolet absorption spectra were measured on a Molecular Devices 
SPECTRAmax plus 384 UV-Visible spectrophotometer operated through a Dell Pentium PC by 
SOFTmax software. Solutions for UV absorption spectra were prepared by adding 2 µl of 10 
mM stock solution (in DMSO) of probe to 998 µl of PBS buffer of different pH values, to get a 
final probe concentration of 20 µM. The spectra were recorded in quartz cuvettes. PBS buffer 
with pH 7.4 was made first, and the pH was then adjusted to the desired pH using 1 M HCl or 
NaOH. The raw data was exported to and plotted in Excel software.   
Excitation/Emission: Fluorescence measurements (excitation/emission) were carried out on a 
Jobin Yvon Fluorolog fluorescence spectrofluorometer. Solutions for excitation/emission spectra 
were taken by adding 20 µl of 0.1mM stock solution in DMSO to 980 µl of PBS buffer of 
varying values, to get a final probe concentration of 2 µM. All spectra were recorded using a 
quartz cuvette. PBS buffers of different pH values were prepared as described above. The raw 
data was exported to and plotted in Excel software.   
pKa: The pKa values of the probes were determined from the absorption spectra. The ratio of 
the absorbance at λmax (370 nm for the PM100 series) and absorbance at the isosbestic point 
(ratio = absorbance at 370/ absorbance at isosbestic point) at each pH value was calculated and 
plotted against pH pf the buffer. The graph was fitted to a sigmoid curve using KaleidaGraph or 






IV.8 Fluorescence Imaging in HEK 293T Cells  
HEK293T Cells obtained from ATCC were grown in DMEM + Glutamax (Invitrogen #10569) 
with 10% fetal bovine serum (FBS) obtained from Atlanta Biologicals), 100U/ml penicillin 
(Invitrogen), and 100 µg/ml streptomycin (Invitrogen). For fluorescence microscopy 
experiments, cells were plated on poly-D- lysine (Sigma Aldrich, conc. 0.1 mg/ml) coated six 
well plates at a density of approximately 1.0 X 105 cells per well and grown at 37°C in 5% CO2. 
After 5-6 days, when the cells reached confluence, the medium was removed by aspiration, and 
the cells were washed twice with PBS (2 mL per well). The growth medium was replaced with 1 
ml of experimental medium per well. This medium was DMEM without phenol red and with 
4mM L-glutamine, obtained from Invitrogen. 1% Charcoal dextran-treated FBS was added to the 
experimental medium. The cells were allowed to equilibrate in the experimental media for one-
half hour before the probe was added. The probe uptake was initiated by adding 1 ml of 
experimental media containing 20 µM of the probe (solution was prepared from a 10 mM or 20 
mM stock solution in DMSO), for a final concentration of 10 µM probe. The probe was allowed 
to incubate for 30 minutes or 10 minutes (as specified for each probe). The probe-media was 
then aspirated, washed with PBS and replaced with probe-free experimental media. Fluorescence 
images were acquired using a Leica FW4000 microscope equipped with Chroma custom filter 
cube (ex 350/50 nm FWHM, em = 460/50 nm FWHM) and Hamamatsu digital camera C4742-
95. Fluorescence images were acquired with 1000 milliseconds exposure time. The images were 
taken at various time points after wash (0, 15, 30 etc., minutes) as specified for each probe. The 




IV.9 Fluorescence Imaging in PC12 Cells 
PC12 cells were purchased and maintained according to the protocols provided by American 
Type Culture Collection (ATCC, CRL-1721). PC12 cells (non adherent) were grown in RPMI-
1640 (Invitrogen # 11875) with 10% horse serum (Invitrogen #160-50-11), 5% fetal bovine 
serum (FBS, Atlanta Biologicals), 100 U/ml penicillin/streptomycin (Invitrogen). The non-
adherent PC12 cells were plated on poly-D-lysine (Sigma-Aldrich concentration = 0.1 mg/ml) 
coated 35X10 mm tissue culture dishes (Becton Dickinson Labware) at a density of 5 X 105 cells 
per well and grown at 37°C in 5% CO2. After 6 days, when the cells had reached 70% 
confluence, experiments were carried out on the cells. The probe uptake was initiated as 
described previously for HEK293T cells. The experimental medium contained RPMI 1650 
without phenol red with 2 mM L-glutamine (Invitrogen #11835). It was supplemented with 0.5% 
charcoal/dextran treated FBS (Atlanta Biologicals), 1% charcoal dextran treated horse serum 
(Invitrogen), 100U/ml penicillin/streptomycin (Invitrogen). For imaging experiments, growth 
medium was aspirated, cells were washed with PBS, and 1 ml experimental medium was added 
to the cells. The cells were allowed to equilibrate for 1 hour. 1 ml of experimental media 
containing 20 µM, 10 µM or 2 µM (solution was prepared from a 10 mM or 20 mM stock 
solution in DMSO) probe was added to the culture dish for a final concentration of 10 µM, 5 µM 
or1 µM. Concentrations were chosen and optimized depending on brightness and lipophilicity of 
the probe. The probes were allowed to incubate for 30 minutes. The probe-media was then 
washed with PBS and replaced with probe free experimental media. Images were taken at 
various time points after washing out of the probe (0, 5, 10 minutes) as described for each probe. 
Some images, where specified, were taken in the presence of the probe. The fluorescence 
imaging for PC12 cells was carried out using two-photon fluorescence microscopy on a Leica 
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SP5 confocal laser scanning microscope with titanium-sapphire MaiTai laser (Spectra Physics) 
equipped with a 60X, 0.9 N.A. objective. pH Sensitivity of the fluorophores which labeled 
membranes was tested by first labeling the cell membrane with the probe, and then applying 
buffers of varying pH to the external environment of the cells. First, the growth medium was 
aspirated, and the probe uptake was initiated as described previously. After aspiration of the 
probe-media, the pH buffers were applied to the cells. pH calibration buffers contained 125 mM 
KCl, 20 mM NaCl, 0.5 mM CaCl2, 0.5 mM MgCl2, and 25 mM of the buffering salt (acetate for 
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CHAPTER III 
FFN200: DEVELOPMENT OF A SECOND GENERATION DOPAMINE-
SELECTIVE FFN  
 
I. INTRODUCTION 
 Dopamine (DA) neurotransmission plays a key role in habit learning, motivation, reward 
processes and motor function. The abnormal regulation of DA is associated with several 
neurodegenerative and neuropsychiatric disorders such as Parkinson’s disease, schizophrenia, 
attention deficit hyperactivity disorder (ADHD), and drug addiction1. Therefore, it is of great 
importance to have tools to measure changes in DA concentration as well as density and function 
of DA synapses in healthy and diseased brains. 
 As discussed previously in Chapter I, electrochemical techniques such as cyclic 
voltammetry and amperometry, which use oxidation of DA to measure its release, have been 
invaluable tools to study dopaminergic neurotransmission. Although these techniques have 
excellent temporal resolution (on the time scale of milliseconds), they measure DA release from 
large populations of synapses and lack the spatial resolution required to study synaptic 
transmission at the level of individual synapses2.  
The study of single synapses, as opposed to large populations of synapses, is of immense 
importance because it can uncover mechanisms involved in information processing and storage 
in the brain. Optical methods provide vastly improved spatial resolution (~1 µm or less) as well 
as signal sensitivity, which allows for the study of individual presynaptic terminals. As such, the 
previous decade has seen the development of a series of optical probes to study synaptic activity. 
Two optical techniques that have been widely used to study synaptic activity are fluorescent 
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endocytic dyes, exemplified by FM1-43, and genetically encoded pHluorins. While these two 
techniques have uncovered valuable information about synaptic transmission, they are membrane 
probes and thus cannot be used to directly measure a very important presynaptic parameter - 
neurotransmitter release.  Therefore, they provide only indirect information about the uptake and 
release of neurotransmitters or the functioning of transporters associated with this uptake and 
release.  
Furthermore, these membrane probes do not specifically label monoamine synapses and 
therefore gleaning information particular to monoamine synapses using these approaches has 
been difficult. For example, comparative studies of glutamatergic and dopaminergic neurons in 
culture using fluorescent vesicle fusion reporters have been done3, but since these probes were 
not specific for dopaminergic synapses, post hoc immunostaining against tyrosine hydroxylase or 
VMAT2 was necessary to identify dopaminergic structures, a difficult approach to apply to brain 
slice imaging.  
Some monoamine-specific fluorescent probes, which preclude the need for post hoc cell 
identification, have been developed. The serotonin analogue 5,7-dihydroxytryptamine (5,7-dHT) 
was used to monitor somatic VMAT-mediated serotonin release but problems with weak 
fluorescence, instability due to oxidation, toxicity and long incubation times have complicated its 
application to studying exocytosis kinetics from individual synapses4. Analogs of 1-methyl-4-
phenylpyridinium (MPP+) such as 4-(4-dimethylamino)phenyl-1-methylpyridinium (APP+) and 
neurotransmitter transporter uptake assay (NTUA) are transported by monoamine plasma 
membrane transporters but, in addition to localizing in VMAT2-containing vesicles, they 
accumulate in mitochondria and their activity-induced destaining appears to be negligible5.  
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With these limitations in mind, our group developed fluorescent reporters called 
Fluorescent False Neurotransmitters (FFNs)6 that mimicked the functioning of endogenous 
monoamine neurotransmitters. This approach involved morphing the design of an aromatic 
fluorophore with the structure of an endogenous neurotransmitter. It was hoped that this strategy 
would allow the optical probes to closely mimic the behavior of endogenous neurotransmitters 
and serve as substrates for known neurotransmitter transporters. 
FFNs were designed to be substrates of the neurotransmitter transporter VMAT2, which 
is the key transporter required for the uptake of the biogenic amine neurotransmitters DA, 
serotonin (5-HT), norepinephrine (NE), and histamine into synaptic vesicles. A quick survey of 
known VMAT2 substrates (Fig. 1.) revealed that they all share a characteristic ethylamine group 
that is attached to an aromatic ring. Therefore, this “recognition” group was preserved in our 
VMAT2-substrate candidates. Coumarins were chosen as the fluorophore because they are small, 
photostable, and sufficiently bright molecules. Fusing the ethylamine “recognition” group with 
the coumarin “core” resulted in the generation of a library of probes that incorporated a hydroxy 










































Fig. 1. Endogenous amines such as dopamine, norepinephrine and serotonin all possess a 
characteristic ethylamine group recognized by vesicular monoamine transporter 2 (VMAT2). 
Exogenous VMAT2 substrates such as amphetamine and neurotoxins such as 6-
hydroxydopamine (6-OHDA) also possess this group. VMAT2 also transports methyl 
pyridinium analogs such as 1-methyl-4-phenylpyridinium (MPP+). 
 Screening this 7-hydroxy coumarin library in HEK cells transfected with VMAT2 
revealed a few promising probes which demonstrated VMAT-dependent uptake.  These were 
chosen for further investigation in mouse brain tissue. These efforts resulted in the development 
of a DA selective probe FFN1027. Even though FFN102 is highly selective for DA terminals in 
the mouse brain tissue, it cannot label dopaminergic synapses in cultured mouse neurons. 
Furthermore, since FFN102 possesses a hydroxy group at the 7-position, its fluorescence 
emission spectrum is pH-dependent. Its fluorescence increases above pH 6, when it is in its 
phenolate form. Therefore, when FFN102 is released from vesicles and comes in contact with the 
basic pH (~ 7.4) of the extracellular milieu, the background fluorescence increases, complicating 
the analysis of destaining kinetics in the brain tissue.  
Consequently, we sought to develop a pH-independent DA-selective FFN for use in the 
mouse dorsal striatum as well as neuronal culture. We began by replacing the hydroxy group on 
the 7-position of FFN102 with an amino group, effectively rendering the fluorescence emission 
spectrum of the coumarin unresponsive to pH in the range of 3-10. This change in photophysical 
properties was in accordance with the observed fluorescence properties of 7-hydroxy and 7-
amino coumarins8. The ethylamine group was preserved in the 7-amino derivative in order to 
retain “recognition” by VMAT2. The chloro group on the 6-position of FFN102, which served as 
a pKa modulator was no longer needed for the development of the pH-independent probe and 
hence was not incorporated in its design. These modifications to FFN102 resulted in the 






Fig. 2. (A) FFN102 has a pH-sensing hydroxy group at the 7-position of the coumarin and a pKa 
modulator at the 6-position. (B) FFN200 has an amino group at the 7-position of the coumarin 
and lacks the chloro group at the 6-position which is used as pKa modulator in FFN102. Even 
though FFN102 and FFN200 differ in their structure at the 6 and 7 positions of the coumarin 
ring, they both possess the ethylamine group for recognition by VMAT2. (C) A pH profile for 7-
amino and 7-hydroxycoumarin is shown. The fluorescence intensity ratio is plotted on the y-axis. 
Compounds were excited at 370 nm and fluorescence emission was detected at 460 nm. The 
fluorescence intensity ratio is calculated by dividing the fluorescence intensity, I, of the 
compound, by the maximal fluorescence intensity of the compound, Imax. The fluorescence of 7-
hydroxy coumarin increases sharply at a pH value of ~ 7 whereas that of -7amino coumarin 
remains fairly constant across the pH range of 3-10.  Fig. C is adapted from Jin et al. (2011) 
Chembiochem 12, 65–70. 
 
Furthermore, in order to explore how the position of the ethylamine group affected 
VMAT2 affinity, we synthesized two regioisomers of FFN200, AH180 and GH180, which 

























respectively (Fig. 3). These regioisomers displayed photophysical properties similar to that of the 
parent compound FFN200.  
 
 
Fig. 3. (A) The structures of FFN200 and its regioisomers AH180 and GH180. Each compound 
is a 7-amino coumarin with the ethylamine group located at different positions. (B) The 
excitation and emission spectra of FFN200 are shown as a representative example of the photo 
physical properties of this series of compounds.  
 
The study of the three amino compounds FFN200, GH180 and AH180 in HEK cells 
transfected with VMAT2 revealed that they were all VMAT2 substrates. However, their affinity 
for VMAT2 differed. GH200 and AH180 displayed strong VMAT2-dependent uptake and 
GH180 displayed weak VMAT2-dependent uptake. Changing the position of ethylamine group 
on the coumarin ring thus revealed an interesting structure-activity relationship for VMAT2. 
These VMAT2-dependant uptake experiments in HEK cells were performed by Dr. Gang Hu and 
Dr. Adam Henke, postdoctoral researchers in the Sames laboratory.  
Even though GH180 showed weak VMAT2-dependent uptake in cell culture, it was still 
chosen for study in the mouse brain tissue along with GH200 and AH180. This is because we 
wanted to study the correlation between a compound’s VMAT2 affinity in a simple cell-based 
system and a complex tissue-based system. Establishing such a correlation was critical to the 
development of new 7-amino FFNs because we wanted to know if cell-based systems could be 













strategy of using simple systems to predict selectivity in more complex systems is commonly 
used, it may not always produce accurate results. For example, the expression of certain genes 
has been found to inhibit tumor growth in in vivo models but not in simpler in vitro models9. 
Investigating this correlation was also important because if cell-based systems could 
indeed reliably predict a compound’s selectivity in the tissue slice, it would hasten the process of 
screening new FFNs. Screening molecules in the tissue slice is inherently a low throughput 
processes as every experiment must be performed several times to ensure reproducibility from 
animal to animal. Moreover, selectivity studies require the use of precious transgenic animals 
possessing fluorescent markers. Additionally, the data analysis and for images gathered from the 
mouse tissue is much more complex and time consuming than that for images gathered from cell 
culture.    
Thus, with this in mind, we investigated all three aforementioned 7-amino coumarins 
(FFN200, GH180 and AH180) in the mouse dorsal striatum. Interestingly, all three compounds 
showed selectivity towards dopaminergic presynaptic terminals in the mouse dorsal striatum. 
Remarkably, the selectivity of these compounds towards presynaptic dopamine terminals in the 
mouse brain tissue showed trends that were similar to trends in their VMAT2-dependent uptake 
in HEK cell culture. AH180 and GH200 which had strong VMAT2-dependent uptake in HEK 
cells showed ~ 85% colocalization with dopaminergic terminals in the brain tissue and GH180 
which had weak VMAT2-dependent uptake in HEK cells showed a slightly lower colocalization 
of 70% with dopaminergic terminals in the brain tissue.   
AH180 and GH200 were both further explored in neuronal culture. GH200, unlike 
AH180, was also found to label dopamine cells in neuronal culture and was thus further 
characterized in the tissue slice. This chapter describes our efforts of studying the three 7-amino 
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coumarins FFN200, GH180 and AH180 in the mouse brain tissue. This chapter further describes 
the development of FFN200 as the first DA-selective pH-independent FFN to study the release 
of vesicular content from individual presynaptic terminals. Since FFN200 displayed the 
necessary properties of an FFN (labeling of presynaptic terminals and evoked release upon 
stimulation), we refer to it as FFN200. GH180 and AH180 were not investigated for their ability 
to release from presynaptic terminals upon stimulation, and are therefore not referred to as FFNs.    
A Computational Strategy for FFN Design:  
In the initial stages of our FFN program, we considered generating FFNs through 
computational designs. However, that approach proved to be very challenging, given that 
transporter systems at both the plasma membrane and vesicular membrane are involved in the 
uptake of FFNs. Moreover, computational simulation of new substrates, as opposed to 
ligands/inhibitors, for neurotransmitter transporters is very complex because it must take into 
account not just the affinity of the substrate for the transporter, but also the dynamic interactions 
involved during the uptake/transport of the substrate. This complexity becomes more apparent 
when considering a recent mechanistic model for DA transport by DAT (developed by Drs. 
Weinstein and Javitch)10. According to this model, one DA molecule binds to a site situated deep 
in the transporter protein, followed by binding of a second DA molecule to a distinct binding site 
closer to cell surface. The allosteric effects caused by the binding of this second DA molecule 
cause the opening of the cytoplasmic portion of the transporter, enabling the first DA molecule to 
be released into the cytoplasm. Thus, given the complexity of the process (two binding sites, 
sodium and chloride ion binding sites, substantial conformational changes), we decided to use an 
empirical approach to explore the substrate scope of VMAT2. 
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II. RESULTS AND DISCUSSION 
Since FFN200 showed VMAT-dependent uptake in HEK cells transfected with VMAT2, 
it seemed possible it could potentially label monoaminergic presynaptic terminals in the mouse 
brain tissue. Therefore, we decided to begin exploring this probe in the dorsal striatum, a region 
that is highly innervated by DA terminals11.  
In the dorsal striatum and nucleus accumbens (NAc), approximately 95% of the neurons 
are medium spiny projection neurons that use γ-amino butyric acid (GABA) as their main 
neurotransmitter. These GABAergic neurons receive glutamatergic inputs from cell bodies 
located in the cerebral cortex and dopaminergic inputs from cell bodies located in the ventral 
tegmental area (VTA) and substantia nigra (SN). The location of and inputs into the dorsal 



















Fig. 4. (A) A whole mouse brain. (B) Schematic of a sagittal slice of the mouse brain showing 
the different regions of the brain. (C) Dopamine and glutamate projections into the dorsal 
striatum from the cortex and VTA respectively. Through the striatum also receives inputs fron 
the substantia nigra, this pathway is not shown here. Fig. A and B are adapted from the Allen 
 154 
Brain atlas. Fig. C is adapted from Hyman et al. (2001) Nature reviews. Neuroscience 2, 695–
703. 
 
II.1 Loading and Imaging of GH180, AH180 and FFN200   
In order to load compounds into the mouse brain tissue, we prepared coronal 
corticostriatal slices (Fig. 5) of the mouse brain and incubated them in 10 µM probe for 30 
minutes. Images were taken at different time points after continuous washing (15 minutes, 30 




Fig. 5. The three major orientations in which the brain is cut to typically prepare brain tissue 
slices. Below each plane is shown a representative tissue slice prepared by cutting the brain in 
that particular plane. Images are adapted from the Allen mouse Brain Atlas. Scale bar 1 mm.    
  
Once the tissue slices were prepared, they were kept alive for 4-5 hours by means of a 
buffer called Artificial Cerebrospinal Fluid (ACSF), which mimics the physiological conditions 
in terms of pH, osmolarity and glucose content.  Furthermore, the ACSF was constantly 






brain slice was placed in an imaging chamber and constantly perfused with oxygenated ACSF. 
The flow rate of the buffer through the imaging chamber was kept constant at about 2-3 mL/min 
with the help of a pump to control the rate of flow of the buffer. A platinum harp was used to 























Fig. 6. The typical set up for FFN imaging in acute brain tissue slices. The three syringes on the 
right represent the perfusion system used to store the appropriate buffers (1, 2 or 3) needed to 
keep the slice alive. These are connected via a common valve to the imaging chamber. Buffer 
flows into the imaging chamber and flows out with the aid of a vacuum. The imaging chamber is 
placed on the stage of the microscope and contains the tissue slice. The harp placed above the 
tissue slice prevents it from moving during imaging. The water immersion objective is placed on 
top of the slice.   
 
Images were taken using two-photon microscopy with the appropriate excitation and 
emission wavelengths for the probes. These were determined to be 740 nm for excitation and 440 
to 490 nm for emission for all three probes. Images were taken a depth of 30 microns or greater 
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below the surface of the slice. Further details about imaging parameters are given in the 
experimental section of this chapter.    
II.2 GH180, AH180 and FFN200 Label Presynaptic Dopamine Terminals In Mouse 
Brain Tissue To Varying Extents  
 
 Upon loading 10 µM probe into the dorsal striatum, we observed a punctate fluorescent 
staining pattern, in which the size (~1 µm) and shape (spherical) of the puncta closely resembled 
individual presynaptic terminals (Fig. 7). This staining pattern was similar for all three probes. 
The number and intensity of fluorescent puncta decreased considerably throughout the washing 
period, prompting us to investigate the specificity of the probes towards dopaminergic synapses 










Fig. 7. The staining pattern of FFN200 is shown in the mouse dorsal striatum as a representative 
image of all three probes. Mouse striatal slices were incubated with 10 µM FFN200 for 30 
minutes incubation and then continuously perfused with oxygenated buffer for 45 minutes before 
imaging. FFN200 accumulated in presynaptic terminals as represented by round fluorescent 





In order to assess the selectivity of each probe towards DA terminals, we compared its 
labeling pattern with the labeling pattern of a known marker of dopaminergic structures – 
Tyrosine Hydroxlase (TH). TH is the enzyme responsible for catalyzing the conversion of the 
amino acid L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA), which is a precursor for DA. 
The gene for TH is expected to be expressed in all neurons that produce catecholamines (DA and 
NE). Therefore, slices from mice expressing GFP under the TH promoter12 were used for 
colocalization experiments with the three coumarin probes. In these mice, the GFP positive 
structures observed in the striatum are dopaminergic axons since these are the predominant 
monoaminergic inputs into the striatum13. Consequently, the degree of colocalization between 
the probe and TH-GFP in the striatum of these mice provides a measure of its selectivity towards 
dopamine terminals.  
When carrying out these colocalization experiments, it is crucial to image the 
fluorescence of each of the two reporters (GFP and the 7-amino coumarin probe) without 
interference from the other. Therefore, it was of critical importance to minimize the crossover of 
signal of the fluorophores between the two detector channels. Since the two-photon excitation 
wavelength of the 7-amino coumarins are shorter than that of GFP, they can be spectrally 
resolved from that of GFP. The peak two-photon excitation wavelength for coumarins is 740  nm 
which yields negligible GFP fluorescence. Conversely, the two-photon excitation peak of GFP at 
910 nm yields negligible fluorescence from any of the 7-amino coumarins. Furthermore, distinct 
emission windows of 440-490 nm for the 7-amino coumarin and 510-600 nm for GFP also 
helped differentiate the fluorescence signals.  
A lack of crossover of the 7-amino coumarin into the GFP channel was confirmed by 
imaging wild type slices incubated with the probe under conditions used for GFP (no signal was 
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seen in the GFP channel). Similarly, a lack of crossover of GFP into the 7-amino coumarin 
channel was confirmed by imaging GFP slices lacking probe under the conditions used for the 
FFN (no signal was seen in the FFN channel).  
Another factor that is crucial for the success of these colocalization experiments is lack of 
movement in both the xy and z planes. Shifts in the slice due to perfusion of the ACSF buffer can 
cause an underestimation in the colocalization of the two reporters. In order to account for this 
and ensure that there was minimal slice movement during the period of image acquisition, a 
second FFN image was taken after the GFP image. Only images in which the co-localization 
between the first and second FFN images was greater than 89% were further analyzed. Thus, 
images were taken in the order FFN-GFP-FFN.  
Once the appropriate imaging parameters were established, the level of colocalization 
between the probes and TH-GFP could be investigated. Before we carried out experiments with 
these new probes, we wanted to ensure that our experimental set up was working well. 
Therefore, we used FFN102 a positive control for colocalization between FFN102 and TH-GFP. 
While imaging the positive control, we uncovered an important detail in the experimental set up.  
When using the 63X 0.9 NA water immersion objective from Leica Microsystems, FFN102 
showed only 57 ± 1.5% (mean  ± SEM, n = 3) colocalization with TH-GFP in the dorsal 
striatum. This was in stark contrast to results obtained previously by Rodriguez et al. that showed 
~89% colocalization between FFN102 and TH-GFP. It was uncovered that a 40X 0.8 NA water 
immersion objective from Olympus was used by Rodriguez et al. while performing the initial 
colocalization experiments with FFN102. Accordingly, the control experiments were repeated 
with the Olympus objective and revealed 88 % (average of two independent experiments 
showing 86% and 90% colocalization) colocalization between FFN102 and TH-GFP, as 
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expected. It became clear to us that the poor colocalization observed with the 63X 0.9 NA Leica 
objective was due to chromatic aberration, a type of distortion in which a lens fails to focus 
colors of different wavelengths to the same convergence point. Therefore, even though there was 
a high colocalization between the first and second FFN images (over 90%) indicating minimal 
movement in xy and z planes, the GFP image was misregistered with the amino coumarin signal 
because of their different excitation and emission wavelengths, leading to low colocalization of 
FFN102 with TH-GFP. Consequently, the 63X 0.9 NA Leica objective was not used for further 
colocalization experiments with FFNs. Only a 40X 0.8NA Olympus objective was used for 
further experiments as this objective was appropriately corrected for chromatic abberation. This 
discovery highlights the importance of using the appropriate lenses while performing 
colocalization experiments, since small aberrations in focal points can lead to false negative 
results, especially when imaging fluorescent objects as small as presynaptic terminals. The 
control colocalization experiments with FFN102 were performed in collaboration with Dr. 
Daniela Pereira in David Sulzer’s laboratory at the Columbia University Medial Center 
(CUMC).    
Since the number of puncta labeled by these 7-amino coumarins decreased with washing, 
we were prompted to study their percentage of colocalization with TH-GFP as a function of 
wash time. The number and intensity of TH-GFP puncta should remain constant over the 
washing period. We began by investigating the colocalization of FFN200 with TH-GFP. We 
found that with washing, the number of FFN200 puncta diminished, but the percentage of 
FFN200 puncta that were GFP-positive increased.  From 10 to 50 min of washing, the 
percentage increased from 55 ± 1.8% (mean ± SEM, n = 3) to 84.6 ± 2.6% (mean ± SEM, n = 3). 
Our data indicated that while FFN200 initially labeled a significant fraction of non-dopaminergic 
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punctate structures, the probe became more selective towards dopamine terminals after washing 
for 45 minutes. We therefore used 45-50 min washing periods for all of the following brain slice 
experiments with FFN200. The colocalization experiments of FFN200 with TH-GFP were 
performed by Dr. Daniela Pereria, a postdoctoral scientist in David Sulzer’s laboratory at 
CUMC.  
Next, we performed colocalization experiments with GH180 and AH180 in the dorsal 
striatum. Since we wanted to directly compare their percentage colocalization with that of 
FFN200, we also used a 45-minute wash period for these two probes. We found that AH180 
showed 83%  (average of two independent experiments showing 79% and 87% colocalization) 
colocalization with TH-GFP and GH180 showed 70% (average of two indepndent experiments 
showing 66% and 74% colocaliztion) colocalization with TH-GFP at the 45-minute wash time 
point (Fig. 8). Interestingly, the trends seen for the level of colocalization of the three 7-amino 
coumarins with presynaptic dopamine terminals was in accordance with trends seen in their the 
VMAT2-dependent uptake in HEK293 cells.  That is, the two coumarins (FFN200 and AH180) 
which showed strong VMAT2-dependent uptake in HEK-VMAT2 cells, showed a higher 
colocalization with presynaptic dopamine terminals in the brain as compared to GH180, which 
showed weak VMAT2-dependent uptake in HEK-VMAT2 cells and only 70% colocalization 
with presynaptic dopamine terminals in the brain.  
In order to get an idea about how we analyze and interpret the colocalization data, a clear 
explanation of the process of data analysis is provided here. First, puncta in each fluorophore 
channel are identified. The puncta are identified and defined by a number of parameters. First, a 
threshold for intensity for the entire image is set and only pixels above this intensity are 
considered as signal. Everything below this intensity is considered as background. Next, pixels 
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above the threshold intensity are filtered by specifying the size and shape of the puncta. Only 
those objects that meet the appropriate criteria for intensity, size and shape are considered as 
puncta or regions of interest. The intensity, size and shape parameters are based upon visual 
inspection as well as the known size and shape of the presynaptic terminals of interest (in this 
case, presynaptic dopamine terminals).  
Once the appropriate threshold intensity, size and shape for pucnta selection are defined, 
we can move on to the colocalization analysis. The colocalization is determined for FFN and 
GFP channels by using the “measure colocalization” task that is built into the Volocity software 
we use for data analysis.  It is important to note how colocalization is defined using this task. In 
order to calculate how many FFN puncta also have GFP, first, the previously determined criteria 
of puncta intensity, size and shape are applied to the FFN channel. Next, the predetermined GFP 
intensity threshold is applied to the GFP channel. The program calculates the percentage of the 
area in each FFN positive puncta that has GFP pixels above the set GFP intensity threshold.  This 
is called the “colocalization coefficient”. It should be pointed out here that the criteria for size 
and shape of puncta are not applied to the GFP channel. The threshold intensity is the only 
criteria used for filtering pixels in the GFP channel. As such, the FFN channel is set as the 
“anchored” channel for puncta identification.  FFN200 which have a colocalization coefficient of 
0.5 or higher are considered as pucnta which positively colocalize with GFP. Since no size or 
shape guide is applied to the GFP channel, care must be taken to ensure that FFN puncta which 
show positive colocalization with GFP are not false positives. It is conceivable that an FFN 
puncta may show positive colocalization with GFP if there is a large area of diffused GFP 
staining which is above the set GFP intensity threshold, but which does not match the size guide 
for the FFN puncta. Therefore, in order to avoid this, manual inspection of FFN puncta is 
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performed to ensure that the puncta considered as positive colocalization by Volocity match the 
GFP signal in size and shape.    
 In order to assay the number of GFP puncta which also have FFN, the same analysis is 
performed keeping the GFP channel as the “anchored” channel for puncta identification. Details 









Fig. 8. The colocalization of FFN200 (10 µM, top panel), AH180 (10 µM, middle panel) and 
GH180 (10 µM, bottom panel) with TH-GFP in the dorsal striatum of the mouse brain. Images 
were taken at a wash time point of 45 minutes. Since all three probes have emission spectra in 
the blue region, they could easily be spectrally separated from the GFP emission in the green 
region. The 7-amino coumarin probes were excited at 740 nm and detected in the range of 440 to 
490 nm. GFP was excited at 910 nm and detected in the range of 510 to 600 nm. FFN200 
showed 84.6 ± 2.6% (mean ± SEM, n = 3) co-localization with TH-GFP. AH180 and GH180 
showed 83% (average of two independent experiments having 79% and 87% colocalization) and 
70% (average of two independent experiments having 66% and 74% colocalization) 





independent experiments and AH180 and GH180, images are representative of 2 independent 
experiments. The FFN200 image is courtesy of Dr. Daniela Pereira. Scale bar 10 µm.  
 
II.3 FFN200 Selectively Labels Dopamine Neurons in Neuronal Culture 
 Since AH180 and FFN200 both showed a higher degree of colocalization with TH-GFP 
in the dorsal striatum as compared to GH180, they were both explored as putative DA-selective 
probes in neuronal culture. There are currently no DA-specific optical probes to monitor 
exocytosis in cultured dopaminergic neurons. Our previously published probes FFN102 and 
FFN511 do not accumulate in cultured dopamine neurons and are only applicable for use in brain 
slices.  
First, we incubated TH-GFP ventral midbrain neuronal cultures12 with FFN200 and 
imaged neurons using epifluorescence microscopy. Approximately 70% of all GFP-positive 
neurons were found to accumulate FFN200. Cultures were subsequently immunostained against 
TH to confirm neuronal type since 10-15% of TH-positive neurons do not express GFP in 2 
week-old TH-GFP mouse midbrain cultures. All FFN200-labeled neurons were TH-positive by 
immunostaining. 
In contrast to this, AH180 showed no uptake into cell bodies in neuronal culture. 
Consequently, we did not characterize AH180 any further either in neurons or in tissue slices. 
Experiments in neuronal culture were performed by Dr. Yvonne Schmitz in David Sulzer’s 
laboratory at CUMC and will be discussed in greater detail in our upcoming publication.  
II.4 FFN200 is released from Synaptic Vesicles in Acute Corticostriatal Slices. 
To assess whether FFN200 was released from synaptic boutons in response to activity, 
we started by studying FFN200 release in response to high K+ depolarization. Time lapse 
imaging of FFN200 in corticostriatal slices revealed that FFN200 released into the extracellular 
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space upon perfusion with ACSF containing 40 mM KCl. Stimulation with high K+ buffer 
depolarizes the membrane and causes the fusion of vesicles with the presynaptic membrane. 
However, this method of stimulation generally has a harsh effect on the slice tissue, including xy 
and z shifting and distortion of the field of view. Therefore, with this method of stimulation, it is 
not possible to track and analyze the destaining of individual FFN200 puncta.  
Therefore, in order to obtain a more quantitative understanding of the release kinetics of 
the probe, we monitored the release of FFN200 in response to local electrical stimulation in the 
dorsolateral striatum. This method induces less shifting and distortion of the slice than KCl 
depolarization, thus allowing the monitoring of individual FFN200 puncta destaining. Moreover, 
electrical stimulation is more physiologically relevant as it closely mimics action potential firing 
and the frequency of stimulation can be precisely controlled to match that of endogenous 
frequencies. Local stimulation of striatal terminals at 15 Hz, a frequency within the range of 
dopamine neuron phasic firing14, resulted in the destaining of a subset of FFN200 puncta. These 
release experiments were performed by Dr. Daniela Pereria in David Sulzer’s lab at CUMC. The 
details about the kinetics and quantification of release will also be described in our 
aforementioned upcoming publication.  
II.5 Mechanism of FFN200 Uptake at the Vesicular Membrane  
 In order to understand the mechanism for FFN200 accumulation and retention into 
presynaptic terminals, we investigated whether the plasma membrane transporters or vesicular 
membrane transporters, which are responsible for endogenous dopamine uptake, were involved. 
As explained previously, the dopamine transporter (DAT) is responsible for DA uptake at the 
plasma membrane and the vesicular monoamine transporter 2 (VMAT2) is responsible for DA 
 166 
uptake at the vesicular membrane. The role of both these transporters in the uptake of FFN200 
was explored using a combination of pharmacological and genetic inhibition.  
A brief explanation about the role of the VMAT2 in DA uptake is provided below, 
followed by a discussion about commonly used VMAT2 inhibitors. DAT and its inhibitors are 
discussed in the next section, II.6.     
Role of VMAT2 in Monoamine Uptake  
 There are two vesicular monoamine transporters in mammals – VMAT1, which is 
preferentially expressed by non-neuronal cells such as adrenal chromaffin cells, and VMAT2, 
which is expressed by neurons15. Both isoforms recognize multiple monoamines as substrates. 
VMAT2 has a slightly higher apparent affinity for monoamine substrates16, except for 
histamine17. Consistent with this, VMAT2 is expressed by several populations of monoaminergic 
neurons18.  
 VMATs have a Km in the low micromolar range. In contrast to this, the vesicular 
transporters for acetylcholine, GABA, and glutamate, all show Kms in the low millimolar range. 
Therefore, VMATs have a higher affinity for their substrates as compared to other vesicular 
neurotransmitter transporters, which may contribute to their robust activity as is seen in 
radiotracer flux assays.  
  Uptake of neurotransmitters via VMATs is driven by the electrochemical gradient 
generated by the vacuolar type H+ ATP-ase. This proton electrochemical gradient is a composite 
function of both the pH gradient (ΔpH) and the membrane potential (ΔΨ). The VMATs and 
VAChTs (vesicular acetylcholine transporters) primarily depend on ΔpH for uptake of 
neurotransmitters, as opposed to VGLUTs which are primarily dependent on ΔΨ. Classical 
studies on chromaffin cells have shown that vesicular monoamine transport involves the 
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exchange of two luminal protons for one cytosolic protonated amine and this stoichiometry 
accounts for the greater reliance on ΔpH19.  
Inhibitors for VMAT2  
The most commonly used VMAT2 inhibitors include tetrabenazine (TBZ), 
dihydrotetrabenazine (DHTBZ) and reserpine. In vivo, tetrabenazine (Fig. 9) is rapidly 
metabolized and reduced to dihydrotetrabenazine, which has three stereocenters and eight 
stereoisomers (Fig. 10). There is evidence indicating that the binding of TBZ metabolites to 
VMAT2 is stereospecific20.  Yao et al. synthesized all eight stereoisomers of DHTBZ and 
measured their Ki  by evaluating their binding affinity to VMAT221. These ligand binding 











Fig. 9. Enantiomers of the VMAT2 inhibitor tetrabenazine (TBZ) with their corresponding Ki’s 
shown as mean ± SEM. Ki values as measure by Yao et al. are drastically different for the two 































Ki = 36,400 ± 4560 nM
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Fig. 10. Structures of the dihydrotetrabenazine (DHTBZ) stereoisomers and their respective 
inhibition constants shown as mean ± SEM. Enantiomers (±)2 and (±)3 show a cis configuration 
at C-3 vs. C-11b and enantiomers (±)4 and (±)5 which show a trans configuration at at C-3 vs. 
C-11b. 
 
We chose to investigate the inhibition of FFN200 with the stereoisomer of DHTBZ that 
was known to have the smallest Ki value. Ki, for an inhibitor reflects the strength of the 
interaction between the target (transporter/receptor/enzyme) and the inhibitor. A small Ki value 
reflects high binding affinity of an inhibitor to its target, whereas a large Ki value reflects weak 
binding affinity. Therefore, we used enatiomerically pure (+)2, which has a Ki of 4 nM, for 
inhibition studies.  
First, we investigated the effectiveness of this molecule as a VMAT2 inhibitor in intact 
brain slices. This was accomplished by studying its effect on endogenous dopamine release in 
the mouse brain tissue. We inhibited VMAT2 in the mouse dorsal striatum and then studied the 
release of dopamine by cyclic voltammetry.  As mentioned in Chapter I, cyclic voltammetry is 













































Ki = 3.96 ± 0.4 nM
(2S,3S,11bS)-DHTBZ
(-)-2
Ki = 23,700  ± 2350 nM
(2S,3R,11bR)-DHTBZ
(+)-3
Ki = 13.4  ± 1.36 nM
(2R,3S,11bS)-DHTBZ
(-)-3
Ki = 2460  ± 333 nM
(2R,3S,11bR)-DHTBZ
(+)-4
Ki = 71.1  ± 6.66 nM
(2S,3R,11bS)-DHTBZ
(-)-4
Ki = 4630 350 nM
(2S,3S,11bR)-DHTBZ
(+)-5
Ki = 593  ± 69.7 nM
(2R,3R,11bS)-DHTBZ
(+)-5
Ki = 1253 314 nM
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A solution of 5 µM DHTBZ was constantly perfused over acute mouse striatal slices and 
the slices were stimulated at intervals of 5 minutes in order to evoke neurotransmitter release. A 
gradual decrease in stimulated dopamine release was seen over ~40 minutes, after which no 
dopamine release was detected, consistent with previous studies in the rat striatum22. In contrast, 
the uninhibited, control slice showed no decrease in dopamine release over this time period (Fig. 
11). Assuming that in synaptic vesicles there is a steady state between DA uptake and DA loss 
due to leakage and release, inhibition of DA uptake leads to a depletion of DA content in the 
synaptic vesicles. In uninhibited slices, the DA content in the synaptic vesicles can be 















Fig. 11. Control and 5 µM dihydrotetrabenazine (DHTBZ) inhibited slices were stimulated using 
bipolar stainless steel electrodes and the resulting DA release was measured by CV. Single 
pulses were applied ever 5 minutes. (A) Mean traces ± SEM (SEM represented in gray) of 
dopamine release in control and DHTBZ-treated corticostriatal slices at the given time points. 
Time point zero is the time at which the continuous perfusion was switched to ACSF containing 
5 µM DHTBZ in the inhibited slices. Time point zero represents the first time point at which 
electrical stimulation was started in both control and DHTBZ slices. Control slices showed no 
significant reduction in DA release over 45 minutes.  DHTBZ-treated slices showed no release of 
DA after 35 minutes. Scale bars 500 pA and 2 s. (B) Quantification of dopamine release in 
response to single pulses, normalized for each condition to the average current of 5 pre-pulses 
applied before time point zero. The data shown is representative of 5 independent experiments. 
A. B. 
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Currents generated in response to each pulse were normalized to the average current of the 5 
prepulses and results are expressed as mean normalized current ± SEM.  
 
Next, we studied the uptake of FFN200 in the presence of the (+)-2 DHTBZ inhibitor. 
Acute corticostriatal slices were preincubated with 5 µM DHTBZ. The time period for this 
preincubation was set at 1 hour because we had determined that it took ~ 40 minutes for DHTBZ 
to completely inhibit VMAT2. It is important to note that images were taken at a depth of ~30 
µm below the slice and the carbon fiber microelectrode in the CV experiments was placed at a 
depth of ~ 70 µm below the slice. Therefore, we could be certain that the inhibitor penetrated the 
slice at a depth of 70 µm, well below the imaging depth.   
 After preincubation for 1 hour, 10 µM FFN200 was co-incubated with 5 µM DHTBZ for 
30 minutes. The slice was then washed for 45 minutes (30 minutes in a jar with oxygenated 
ACSF and 15 minutes in an imaging chamber) and imaged using two-photon microscopy. An 
excitation wavelength of 740 nm and emission range of 440 to 490 nm was used. Analysis of 
puncta number as well as puncta intensity was done using the imaging software Volocity and 
statistical analysis was performed using GraphPad Prism. When inhibited by DHTBZ, FFN200, 
showed a statistically significant decrease in both the number and intensity of puncta as 
compared to control slices. A 29% decrease in the puncta number and a 29% decrease in the 
intensity of the puncta were observed (Fig. 12A). A histogram showing the distribution of puncta 
as a function of their intensity indicated that the entire population of puncta in DHTBZ inhibited 
slices lost fluorescence in comparison to the population of puncta in control slices (Fig. 12B). 
This indicates that most FFN200-puncta are affected by DHTBZ, strongly supporting the 




















































Fig. 12. Effect of VMAT2 inhibition with dihydrotetrabenazine (DHTBZ) on the uptake of 
FFN200 in the dorsal striatum. (A) Slices were preincubated with 5 µM DHTBZ for one hour, 
co-incubated with 5 µM DHTBZ and 10 µM FFN 200 for 30 minutes, followed by a 45 minute 
wash. This resulted in a significant decrease in the uptake of FFN200. There was a significant 
difference in mean intensity as well as the number of puncta between the control and DHTBZ-
treated slices. Difference in number and intensity of pucnta and obtained for treated and 
untreated slices were statistically significant based on an unpaired two-tailed t-test with a 95% 
confidence interval (*p<0.05, ***p<0.001). Images are representative of 5 independent 
experiments (n = 5). Data is shown as mean ± SEM. Scale bar 5 µm. (B) A histogram showing 
the distribution of puncta as a function of their intensity. The discrete intervals (bins) on the x-
axis represent the background-subtracted intensity of the puncta. The distribution shows that the 
majority of puncta in DHTBZ inhibited slices had lower intensity values in comparison to 
control slices.  
 
These results were in accordance with the genetic knock down results performed by Dr. 
Daniela Pereria in David Sulzer’s Laboratory at CUMC. In genetic knock down experiments, 
FFN200 loading in VMAT2 hypomorph mice was assessed. These mice express only about 5% 
of wildtype VMAT2 protein levels and contain about 30% of wild type DA in the striatum23. 
There was a significant decrease in FFN200 labeling in the dorsolateral striatum in VMAT2 
hypomorph corticostriatal slices. Both the number and background-subtracted intensity of 
FFN200 puncta were reduced by approximately 30% in these mice. The results of the genetic 
inhibition will be described in further detail in our publication.  
Overall, our data on the disruption of VMAT2 function by genetic and pharmacological 
approaches suggest that FFN200 loading in corticostriatal slices is partially dependent on this 
vesicular transporter.  
We also explored the inhibition of VMAT2 with reserpine (Fig. 13), which has a reported 
Ki of 12 nM for VMAT224. Slices were pre-incubated with 2 µM reserpine for 30 minutes, co-
incuabted with 2 µM reserpine and 10 µM FFN200 for 30 minutes, washed for 45 minutes and 
then imaged, as described previously. Since no qualitative differences between treated and 
untreated slices were observed, we did not perform rigorous quantification on this data.  
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The lack of an obvious effect of reserpine on FFN200 uptake in corticostriatal slices 
could be explained by the physical properties of reserpine. Reserpine can be oxidized to 3,4-di-
dehydroreserpine that exhibits green yellow fluorescence25.  This property of reserpine has 
recently been exploited to visualize catecholaminergic large dense core vesicles (LDCVs) in 
PC12 cells26. In this study, reserpine was excited at 405 nm and visualized in the green region. 
Since these excitation and emission maxima are relatively close to those for FFN200 (370/460 
nm), we cannot completely rule out any contribution by reserpine to the fluorescent signal. In 
order to rigorously test this hypothesis, wild type slices incubated with only reserpine (at the 
same concentration) and lacking FFN200 should be tested. We did not pursue reserpine 
inhibition experiments further since data with DHTBZ as well as VMAT2 hypomorph mice were 























Fig. 13. Effect of the VMAT2 inhibition with 2 µM reserpine on the uptake of FFN200 in the 
dorsal striatum. Inhibited slices were preincubated with 2 µM reserpine for 30 minutes, co-
incubated with 2 µM reserpine and 10 µM FFN200 for 30 minutes, followed by a 45 minute 
wash. Images are representative of two independent experiments. Scale bar 5 µm. 
 
II.6 Mechanism of FFN200 Uptake at the Plasma Membrane 
In order to investigate the uptake of FFN200 at the level of the plasma membrane, we 
investigated the putative role of DAT. This was carried out via both genetic and pharmacological 
inhibition. For pharmacological inhibition, we used the known DAT inhibitor nomifensine and 
for genetic inhibition, we used DAT-Knock Out (KO) mice.  
For pharmacological DAT inhibition, acute corticostriatal slices were pre-incubated with 
the 5 µM nomifensine for 15 minutes, co-incubated with 5 µM nomifensine and 10 µM FFN200 
for 30 minutes, washed for 45 minutes and then imaged. No significant effect on FFN200 
accumulation in the dorsolateral striatum was found between nomifensine-treated and untreated 
slices (Fig. 14).  
This result was in agreement with genetic inhibition data. No significant difference was 
found between the number and intensity of FFN200 puncta in DAT-KO and wildtype 
dorsolateral striatum. It should be noted that this is in contrast with the DAT inhibition of 
FFN102, which shows dramatically reduced loading in the striatum in response to DAT 
inhibition. Our data demonstrates that FFN200, unlike FFN102, does not rely on DAT for 







































Fig. 14. Effect of DAT inhibition on the uptake of FFN200 in the dorsal striatum. A 15 minute 
preincubation with 5 µM of the DAT inhibitor nomifensine followed by a 30 minute co-
incubation with 5 µM nomifensine and 10 µM FFN200, did not significantly decrease the punctal 
accumulation of FFN200. There was no significant difference in mean intensity or number of 
puncta between the control and inhibited slices. Differences obtained for treated and untreated 
slices were not statistically significant based on an unpaired two-tailed t-test with a 95% 
confidence interval. Images are representative of 4 independent experiments. Data is shown as 







CONTROL                              NOMIFENSINE  
 176 
III.  CONCLUSIONS AND FUTURE DIRECTIONS 
We have characterized FFN200 as the first dopamine-selective fluorescent probe that 
allows the labeling of presynapitc synapses and monitoring of exocytosis in and in the brain 
slice. Further, we have also found FFN200 to be the first FFN to selectively label dopamine cell 
bodies in cultured neruons. At the appropriate wash time of 45 minutes, FFN200 showed ~ 85 % 
co-localization with TH-GFP structures in the dorsal striatum in brain slices, confirming its use 
as a selective marker for presynaptic dopamine terminals in this region. FFN200 is, to date, the 
FFN best suited to study monoamine exocytosis because, unlike FFN102, FFN200 fluorescence 
intensity is not pH-dependent, allowing for easier quantification of destaining kinetics.  
Although the mechanism of FFN200 loading into midbrain dopaminergic neurons is not 
fully understood, we determined that its accumulation into synaptic terminals relied partly on 
VMAT2 and was independent of DAT.  This was in contrast to FFN102, whose loading is 
strictly DAT-dependent and does not require a wash period to achieve selectivity towards DA 
terminals. It is currently unknown how FFN200 crosses the plasma membrane. 
Given that FFN200 can initially label non-monoamine structures and needs extended 
washing to achieve selectivity towards dopamine terminals in the slice, it is possible that 
FFN200 may cross the plasma membrane through an unidentified plasma membrane carrier and 
rely on VMAT2 to accumulate in synaptic vesicles. It is also possible that the probe crosses the 
plasma membrane via lipophilic diffusion and the non-specific staining is progressively reduced 
with washing. However, the lack of general non-specific tissue staining by FFN102 which has a 
logD (an estimate of the polarity and lipophilicity of a compound) similar to that of FFN200 (-
1.45 for FFN200 and -1.29 for FFN102) argues against lipophilic uptake of FFN200 and in favor 
of carrier-driven uptake at the level of the plasma membrane.  
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One the advantages of a dopamine-selective probe like FFN200 is the simplicity of the 
loading protocol which consists of easy incubation and washing as opposed to the long and 
complicated loading steps for FM1-43 which consist of pre-stimulation and washing with 
ADVASEP-7. Furthermore, FFN200 is sufficiently bright and photostable for two-photon 
microscopy in the slice and is well suited for time-lapse imaging, as opposed to FM1-43 which 
suffers from photobleaching easily. Moreover, FFN200 does not require the generation of 
transgenic animals or viral infection, which is necessary for the use of SynaptopHluorins. 
Finally, since FFN200 uptake occurs via a transporter, as opposed to via membrane endocytosis 
(as in the case of FM1-43), it labels both presynaptically “silent” and “active” terminals. 
Presynaptically “silent” synapses, those that fail to undergo exocytosis and vesicle fusion in 
response to action potential stimulation and strong calcium influx, have been previously 
described in several types of neurons27,28 and are suggested to play a fundamental role in 
information storage and processing in the brain29. To our knowledge, FFN200 is the first optical 
tool to enable the study of presynaptically silent dopamine synapses in brain tissue. 
  In the future, it will be interesting to use FFN200 to study the density as well as release 
probability of DA terminals in animal models of neurological and psychiatric disorders. FFN200 
could be studied in the mouse 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) model of 
Parkinson’s disease30, a neurodegenerative disease which is characterized by nigrostriatal DA 
damage.  Furthermore, FFN200 could be used to study the modulation of DA terminals in 
response to genetic mutations or deletions. For example, it is known that loss-of-function 
mutations in the parkin gene are the major cause of early-onset familial Parkinson's disease but 
only a few studies have investigated the effects of these mutations on DA regulation and 
release31. Similarly, FFN200 can be used to study the release of DA in response to DA enhancing 
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drugs such as L-DOPA. As such, FFN200 could be used to screen new drugs aimed at 
modulating DA neurotransmission in the brain slice. Additionally, since FFN200 uptake is 
partially VMAT2 driven, it could help identify blockers and enhancers of transport activity and 
could also aid in the detection of pathological transport deficiencies associated with neurological 
and psychiatric disorders.  
Importantly, we have also found that there is a correlation between a compound’s 
VMAT2-dependent uptake in a HEK cell-based system and its selectivity towards presynapitc 
dopamine terminals in tissue slices of the mouse brain. This is an important discovery as it 
indicates that the HEK-VMAT2 cell based system can serve as a model for predicting selectivity 
in the mouse brain slice, atleast for compounds that have a lipophilicity similar to that of 
FFN200. This ensures that future screens in this HEK cell based system will likely yield useful 
hits, rather than hits which work well in cell culture but not in tissue slices.  
During the characterization of FFN200, it was striking to us that the probe was initially 
able to label non-dopaminergic structures. This was an important observation because one of the 
goals of our FFN program was to develop FFNs for synaptic terminals other than dopamine. 
Therefore, a natural extension of this work was to investigate the nature of these non-
dopaminergic terminals as well as characterize other analogs of this probe, in the hopes of 
developing FFNs for other terminals such as glutamatergic and GABAergic terminals. This is the 






IV.  EXPERIMENTAL 
This experimental section pertains only to pharmacological inhibition experiments for FFN200 
performed with DHTBZ, resperine and nomifensine as well as cyclic voltammetry experiments 
with DHBTZ. The colocalization (Section II.2), release (Section II.4) and genetic inhibition 
experiments for FN200 carried out in corticostriatal slices by Dr. Daniela Pereria in David 
Sulzer’s laboratory at CUMC and the labeling experiments carried out in neuronal culture 
(Section  II.3) by Dr. Yvonne Schmitz in David Sulzer’s laboratory at CUMC will be described 
later in our upcoming publication.   
IV.1 Drugs and Reagents  
 The VMAT2 inhibitor DBHTZ was a gift from the National Institute of Mental Health 
(NIMH), a branch of the National Institute of Health (NIH), USA. Catalog number T-802. 
Nomifensine (as its maleate salt) and reserpine were purchased from Sigma Aldrich.  
IV.2 Preparation of 7-Amino Coumarin Stock Solutions 
 FFN200 (GH200) and GH180 were originally synthesized by Dr. Gang Hu in the Sames 
group. FFN200 was later also synthesized by Dr. Adam Henke in the Sames group. AH180 was 
synthesized only by Dr. Adam Henke. FFN200 and AH180 were used as their hydrochloride 
salts. All probes were purified and characterized by mass spectrometry, 1H NMR and 13C NMR. 
Stock solutions of 20 mM of each probe were prepared by dissolving in DMSO. All stock 
solutions were stored at -80OC.  
IV.3 Slice Preparation 
 Unless otherwise noted, all animals used for slice preparation were two to four month old 
male C57BL/6 mice obtained from the Jackson Laboratory (Bar Harbor, ME). All animal 
protocols were approved by the IACUC of Columbia University. Mice were decapitated and 
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acute 250 µm thick coronal slices were cut on a vibratome and allowed to recover for one hour at 
room temperature in oxygenated (95% O2, 5% CO2) artificial cerebrospinal fluid (ACSF in mM): 
125.2 NaCl, 2.5 KCl, 26 NaHCO3, 0.3 KH2PO4, 2.4 CaCl2, 1.3 MgSO4, 10 glucose, 0.8 HEPES; 
pH 7.2-7.4, 292-296 mOsm. Slices were used within 1 to 5 hours after sacrifice of the mouse.  
IV.4 Loading and Imaging of Probes 
 Probes (10 µM) were loaded into striatal slices with a 30-minute incubation period at 
room temperature in oxygenated ACSF. All loading was done in a jar. When the slices were 
ready to image, they were transferred to an imaging chamber (QE-1 Warner instruments) and 
perfused with oxygenated ACSF flowing at 2-2.5 mL/min. The total wash time for all 7-amino 
coumarins was 45 minutes (30 minute wash in jar and 15 minute wash in chamber). All images 
were acquired in the dorsal striatum. The wash time for FFN102 was ~ 15 minutes.  
 Images were acquired on a Leica SP5 confocal/multiphoton microscope with a titanium-
sapphire MaiTai laser (Spectra Physics) equipped with 60X, 0.9 N.A. or 40X 0.8 NA water 
immersion objective objectives. All images were acquired at a depth of ~30 µm below the 
surface of the slice. FFN200 was excited at 740 nm and the emission was visualized between 440 
to 490 nm. Images were collected at a resolution of 512X512 pixels (41 µm X 41 µm). An 
imaging speed of 200Hz was used to collect images.  
IV.5 Colocalization of Probes GH180, AH180 and FFN200 with TH-GFP 
  TH-GFP colocalization experiments were performed mostly as described previously7. 
The initial control colocalization experiment with FFN102 which yielded only ~57% 
colocalization between the FFN and TH-GFP, was performed using a 63X 0.9 NA water 
immersion objective from Leica Microsystems. FFN102 was excited at 740 nm and its 
fluorescence was detected within 440 to 490 nm. GFP was excited at 910 nm and its 
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fluorescence was detected within 510 to 600 nm. FFN102 and GFP were detected by sequential 
imaging of single z-plane 8-bit images (41 x 41 µm field of view; 512 x 512 pixel resolution). 
Lack of crossover between the two channels was confirmed using the exact conditions normally 
used for image acquisition of FFN-GFP image sequences in wildtype slices (no signal in GFP 
channel) and in TH-GFP slices not incubated with FFN (no signal in FFN channel). To avoid 
underestimating GFP-FFN co-localization due to shifts in the z-plane during the acquisition of 
image sequences we acquired FFN-GFP-FFN sequences and discarded any sequences showing 
less than 89% co-localization between the first and second FFN images. Below, the control 
images for FFN102 and TH-GFP are shown, demonstrating a lack of crossover between the two 
fluorophore channels.  
 
Fig. 15. Typical control 
experiments for 
colocalization experiments 
between FFN and TH-GFP 
to confirm lack of cross-talk 
between the two 
fluorophore channels. Wild-
type slices incubated with 
FFN102 were imaged under 
both FFN conditions and 
GFP conditions. TH-GFP 
slices lacking FFN were 
imaged under conditions for 
both FFN and GFP. Control 
experiments looked similar 
for both the 63X 0.9NA 
Leica objective and the 40X 
0.8 NA Olympus objective. 
Images from the 63X 
0.9NA Leica objective are 
shown here. Scale bar 10 
µm.  
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The differences in percentage colocalization of FFN102 with TH-GFP using a 63X 0.9NA Leica 
Objective and a 40X 0.8 NA Olympus objective are shown below.  
 
 
Fig. 16. FFN102-TH-GFP colocalization with TH-GFP in the dorsal striatum using a 63X 0.9NA 
Leica objective (top panel) and a 40X 0.8 NA Olympus objective (bottom panel). The same 
excitation and emission conditions were used for FFN102 and TH-GFP in the case of each 
objective. These conditions were the previously determined excitation and emission conditions in 
the control experiments mentioned above. FFN102 showed 57 ± 1.5% (mean  ± SEM, n = 3) 
colocalization with TH-GFP using a 63X 0.9NA Leica objective and 88% (average of two 
independent experiments having 87% and 89% colocalizaiton) colocalization with TH-GFP 
using a 40X 0.8 NA Olympus objective. Images are representative of three independent 
experiments for the Leica objective and two independent experiments for the Olympus objective. 
Scale bar 10 µm.  
 
Furthermore, since we had begun these experiments using an excitation wavelength of 
740 nm for FFN102, and Rodriguez et al. had originally used an excitation wavelength of 760 































the cause of the poor colocalization seen with the 63X 0.9NA Leica objective. Therefore, we 
took sequential images of FFN102 excited at 740 and 760 nm in order to ensure that the images 
looked the same. This was done with the 40X 0.8 NA Olympus objective (Fig. 17). Our images 
showed identical overlay of FFN102 with 740 and 760 nm excitation. This ruled out that the 
change in excitation wavelength could have caused the low colocalization between FFN102 and 
TH-GFP.  
Fig. 17. FFN102 excited at 740 and 760 nm in the mouse dorsal striatum using a 40X 0.8 NA 
Olympus objective. These images showed identical overlay of FFN102 excited at 740 nm and 
FFN102 excited at 760 nm. Scale bar 10 µm.  
 
The 7-amino coumarins and GFP were detected by sequential imaging of single z-plane 8-bit 
images (38 x 38 µm field of view; 512 x 512 pixel resolution) using the following parameters: 
GFP was imaged using excitation wavelengths of 910-920 nm and its fluorescence was detected 
at 510 to 600 nm. 7-Amino coumarins were excited at 740 nm and their fluorescence was 
detected at 440-490 nm. Lack of cross-talk between the two channels was confirmed as before.  
Shifts in the xy and z plane were accounted for as before. All colocalization experiments for the 
7-amino coumarins were performed using a 40X 0.8 NA water immersion objective from 
Olympus.  
 FFN102 excited at 740 nm!  FFN102 excited at 760 nm! MERGED!
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IV.6 Dopamine Release Recorded in Presence of DHTBZ by Cyclic Voltammetry  
Cyclic voltammetry (CV) recordings of endogenous DA release were performed as 
detailed elsewhere32 with some modifications. Experiments described here were performed in 
collaboration with Dr. Jose Lizardi in David Sulzer’s laboratory at CUMC. Carbon fiber 
electrodes of 5 µm in diameter were placed in the dorsal striatum (close to corpus callosum) ~70 
µm into the slice. A triangular voltage wave (−450 to +800 mV at 294 mV/ms) was applied to 
the electrode every 100 msec and the resulting current was detected with an Axopatch 200B 
amplifier (Axon Instruments, Foster City, CA) using a 10 kHz low-pass Bessel Filter setting and 
a sampling rate of 25 kHz. Data was digitized using the ITC-18 board (Instrutech Corporation, 
Port Washington, NY) and recorded with IGOR Pro 5.03 software (WaveMetrics, Portland, OR), 
using an in-house written acquisition procedure. Striatal slices kept under constant perfusion (2 
mL/min) with oxygenated ACSF were stimulated with a bipolar stainless steel electrode placed 
~150 µm from the recording electrode using an Iso-Flex stimulus isolator triggered by a Master-
8 pulse generator (AMPI, Jerusalem, Israel). Electrodes were calibrated before and after each 
experiment to estimate DA concentration. Upon the onset of recording, five prepulses were 
applied every 2 min to achieve constant DA release and from then onwards slices were 
stimulated with single pulses (1 ms x 40 µA) every 5 min. In DHTBZ-treated slices, the 
perfusion solution was switched to ACSF containing 5 µM DHTBZ, 8 min and 20 s into the 
recording (time point zero in Fig. 5 E-F). Data was analyzed using an in-house written procedure 
in IGOR Pro.  Currents in response to each pulse were normalized to the average current of the 5 
prepulses and results are expressed as mean normalized current ± SEM. All recordings were 
performed at ~30°C.  
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IV.7 Inhibition of FFN200 with DHTBZ 
 Mouse striatal slices were treated with 5 µM DHTBZ for a period of 1 hour. Slices were 
then co-incubated for 30 minutes with 10 µM FFN200 and 5 µM DHTZ in another jar. Slices 
were than transferred to another jar containing oxygenated ACSF free of any probe or drug and 
washed for 30 minutes. Slices were then transferred to an imaging chamber and washed for 15 
more minutes. It is important to note that the total wash time was therefore 45 minutes, the time 
point corresponding to maximal colocalization of FFN200 with TH-GFP. The same procedure 
was followed for control slices, except that an equivalent amount of DMSO free of inhibitor was 
used in the preincubation periods. A total of 5 independent experiments (n = 5), each using 2 
slices (control and inhibited), were carried out. In order to account for the effect that the age of 
the slice may have on the uptake of FFN200 the order in which the slices were imaged were 
reversed as follows:  For two experiments, the control slice was imaged first, followed by the 
inhibited slice. For three experiments, the inhibited slice was imaged first, followed by the 
control slice.   
IV.8 Inhibition of FFN200 with Reserpine 
 Mouse striatal slices were incubated with reserpine (2 µM) for 30 minutes. They were 
then transferred to a jar containing FFN200 (10 µM) and reserpine (2 µM) and incubated for 30 
minutes. Slices were washed for 45 minutes (30 minutes in a jar and 15 minutes in the imaging 
chamber) as mentioned previously. In order to account for the effect that the age of the slice may 
have on the uptake of FFN200, the order in which the control and inhibited slices were imaged 
was switched for each independent N, as mentioned earlier.  
IV.9 Inhibition of FFN200 with Nomifensine 
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 Mouse striatal slices were pre-incubated with nomifensine (5 µM) for 15 minutes and 
then co-incubated with nomifensine (5 µM) and FFN200 (10 µM) for 30 minutes. Slices were 
washed for 45 minutes (30 minutes in jar and 15 minutes in imaging chamber) and then imaged, 
as described previously. 4 independent experiments were performed, each with 2 slices. As 
previously mentioned, the order in which control and inhibition slices were imaged was 
alternated. For 2 experiments, the control slice was imaged first and for the next two 
experiments, the inhibited slice was imaged first.  
IV.10 Image Analysis  
 All images were quantified using Volocity version 4.4 software by Improvision. Raw 
images were imported into Volocity as “.liff” format (from the Leica LASAF software). The 
pixel size was adjusted to 0.080 µm/pixel after images were imported into Volocity. Presynaptic 
terminals were identified as objects in each of the images using a number of parameters from the 
Measurement Protocol Tasks in Volocity. The tasks applied for object identification included: 
Find Objects by Standard Deviation of Intensity, Object Size Guide, and Exclude Objects 
by Size. Each of these parameters is explained below.  
1) Find Objects by Standard Deviation (SD) of Intensity: This parameter uses a certain 
number of SDs of intensity above the mean intensity to pick objects, instead of using absolute 
intensity. This method of picking objects therefore standardizes the intensity threshold at which 
objects are picked within images. The absolute intensity of images may vary from day to day 
based on the slices, laser power, particular batch of fluorophore etc. Therefore, the absolute 
intensity value used to analyze one slice may not provide an accurate threshold for another slice. 
In this task, Volocity calculates the mean intensity of the image, and represents intensities within 
the image as a range of SDs above or below the mean intensity. The mean intensity is set at zero 
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standard deviations. A threshold of certain number of SDs above the mean intensity is chosen in 
order to pick fluorescent objects. This threshold is chosen so that the majority of fluorescent 
objects, as based on visual inspection, get selected. Objects that fall within the chosen threshold 
and the upper limit of 100 are considered regions of interest and objects below this threshold are 
considered as background.  
2) Object Size Guide: This task finds objects based on the size guide that it is instructed to 
follow. This size guide (in µm2) is chosen based on the known structures that are being studied 
(cell bodies, presynaptic terminals, intracellular organelles etc.) This task is able to separate the 
objects based on the given size guide. Therefore, if two objects are touching each other, instead 
of recognizing them as one large object, this task is able to separate them as two independent 
objects.    
3) Exclude objects by Size: This task sets a minimum and maximum value for the object area 
(µm2) to be excluded. Usually, objects above and below the average size of the region of interest 
are excluded.  
Selection of Puncta  
For selecting puncta, the parameters for the above mentioned three tasks were optimized 
based on the known size of dopaminergic presynaptic terminals. The average size of a 
presynaptic dopaminergic terminal is 0.25 µm33. Therefore, the parameters chosen for analysis of 
three probes were as follows: 
1) SD of Intensity: The threshold was set between 0.05 to 0.5 SDs of intensity above the 
mean, depending on visual inspection.   
2) Object Size Guide: The average object size was set at 0.3 µm  
3) Exclude Objects by Size: Objects below 0.2 µm and above 3 µm were excluded.  
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Once these parameters were set, a measurement table was generated by Volocity that 
provided the number of fluorescent punctum. This table also provided information about each 
puncta such as the mean fluorescence intensity of each puncta as well as the area of each puncta. 
Even though Volocity did a good job of picking puncta, it had some flaws that could be easily 
seen upon visual inspection. For example, sometimes puncta were selected within larger 
fluorescent objects that represented structures other than terminals (blood vessels, cell bodies 
etc). Furthermore, sometimes large groups of puncta were selected where there was a diffused 
background staining. Additionally, some puncta that were picked, even though they fit the size 
guide, were not the appropriate shape. i.e they were not rounded enough to appropriately 
represent a presynaptic terminal (they were elongated or linear). Therefore, in order to ensure 
maximally accurate picking of fluorescent objects, each selected object was inspected manually 
to confirm its validity as a terminal. If it did not fit the appropriate size and rounded shape for a 
terminal, it was discarded. An example of the difference between the objects selected before and 
after manual inspection of the puncta is shown below.   
 
Fig. 18 A representative example of manual puncta selection. The raw image (left) of FFN200 
shows presynaptic terminals as small (~ 1 µm) bright spherical regions. The arrow shows a large 
diffused fluorescent area on the upper right side that was picked by Volocity as a large cluster of 
individual puncta (middle image). These puncta were deleted in the manual filtering process 
(right) since it was clearly seen that they did not represent individual presynaptic terminals. Scale 
bar 10 µm.  
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For each experiment, once the optimal SD of intensity for images was picked, it was applied 
consistently to all images in that experiment. Therefore, within each experiment, the control and 
experimental slices were analyzed using the same parameters.  
Quantification of Colocalization of Probes AH180 and GH180 with TH-GFP  
Fluorescence colocalization is described as the detection of signal of the same pixel 
location in two channels, each channel corresponding to images of different fluorophores taken 
from the same region of interest. To determine the number of AH180 and GH180 labeled objects 
that colocalized with TH-GFP structures, sequential images of Probe-GFP-Probe were imported 
into Volocity as three channels. To correct for shifts in the x and y plane that occur during 
sequential imaging, the Registration Correction function of Volocity was applied. This function 
anchors one image while shifting the second image in the xy plane until maximum registration is 
achieved between the two images. This function can either be carried out manually, by 
specifying the number of pixels in the x or y plane that the image needs to be moved by, or it can 
be carried out using an Auto Registration Correction function. In all cases, the probe channel was 






















Presynaptic terminals in the FFN channel were identified as objects using the aforementioned 
parameters that were set for the three tasks - Find Objects by SD Intensity, Object Size Guide 
and Exclude Objects by Size. The parameters used for detecting objects in the GFP channel were 
as follows: 
1) SD of Intensity: The threshold was set between 0.1 to 0.6 SDs of intensity above the 
mean, depending on visual inspection.   
2) Object Size Guide: The average object size was set at 0.3 µm  
3) Exclude Objects by Size: Objects below 0.2 µm and above 3 µm were excluded.  
The Calculate Object Colocalization task was then used to determine the level of colocalization 
between GH180/AH180 labeled objects and GFP labeled objects. This task calculates the 
Fig. 19. Using AH180 as a representative example, a 
FFN-GFP-FFN sequential sequence is shown (top 
panel). After applying the Auto Registration 
Correction function, which corrects for shifts in the xy 
plane, 91% colocalization is seen between the first 
AH180 and second AH180 image. This is 
demonstrated by the yellow puncta seen in the AH180-
AH180 merged image (bottom panel). Scale bar 10 
µm.  
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colocalization coefficient for each object selected, by comparing the signal of each pixel within 
the selected objects in the FFN and GFP channel. For the program to determine the 
colocalization coefficients between the two channels of interest, a threshold of the absolute 
intensity for each of the channels must be selected. Since the objects were initially selected based 
on SD of Intensity, a rough conversion had to be applied to make sure that the threshold chosen 
for colocalization was similar to that of the SD intensity chosen for puncta selection. Thus, we 
made sure that the number of Volocity-picked puncta by both selection methods (absolute 
intensity and SD intensity) was the same.  
Once all of the above parameters were defined, Volocity provided colocalization 
coefficients for each of the selected objects. As mentioned previously, to ensure the most 
accurate image analysis, after the program selected the objects, a manual inspection was 
performed where each object was visually inspected in order to confirm its validity as a terminal. 
Objects selected by the program, that did not conform to terminal properties were discarded. 
Colocalization coefficient values can have a value between 0 and 1, where 0 indicates that none 
of the signal within that selected object in that particular channel colocalizes with the other 
channel. A value of 1 indicates that all signal within the selected object in that particular channel 
colocalizes with the other channel. In our studies, a colocalization coefficient higher than 0.5 was 
considered to be acceptable to count a puncta as a positive “hit” for colocalization. Visual 
inspection was performed to account for false positives and false negatives. Percent 
colocalization ± SEM were calculated from atleast two independent experiments (n = 2) and two 




Quantification of Mean Fluorescence Intensity of Selected Puncta  
After manual inspection and discarding of puncta, the average number of puncta for each 
image was calculated. In order to analyze the mean fluorescence intensity of each slice, the 
following calculation was carried out: First, the mean background intensity was calculated. This 
was done by using the Find Objects by SD Intensity task and selecting the upper threshold of 
SD intensity to be the same as the lower threshold of SD intensity that was used for picking 
object. This way, everything below the lowest threshold for object selection could be considered 
background. The mean intensity of the background was calculated by averaging the intensity of 
all areas selected as background. This mean background intensity was subtracted from the 
absolute intensity of each puncta. Then, background-subtracted absolute intensity of all puncta 
was averaged to obtain the mean fluorescence intensity of each slice. 
 Two or four slices were imaged for each experiment. Two images were analyzed per 
slice.  
IV.11 Statistical Analysis of Data  
 Differences in puncta number and mean fluorescence intensity between inhibited and 
uninhibited slices were calculated using GraphPad Prism software. Two tailed unpaired t-tests 
with 95% confidence intervals were used to analyze whether differences between treated and 
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 CHAPTER IV 
FFN7122: DEVELOPMENT AND CHARACTERIZATION OF A 
“GLOBAL” FFN FOR IMAGING SYNAPTIC ACTIVITY IN THE MOUSE 
BRAIN  
 
I.  INTRODUCTION 
As part of a broad program aimed at imaging neurotransmission, we have developed 
fluorescent false neurotransmitters (FFNs) for specifically studying dopamine (DA) 
neurotransmission. The successful development of two DA-selective FFNs, FFN102 and 
FFN200, validated our approach of using small molecules to visualize neurotransmitter (NT) 
release. Therefore, in an effort to extend this approach, our next goal was to develop an FFN that 
could visualize NT release from a variety of presynaptic terminals, not just dopaminergic ones.  
As elaborated upon in Chapter II, the fluorescent styryl dye FM1-43 and the genetically 
encoded pH-sensitive fluorescent membrane protein SynaptopHluorin have been previously used 
to uncover a wealth of information regarding synaptic activity at several types of terminals. In 
this regard, they have been extensively used to study synaptic activity at glutamatergic 
terminals1, which occur widely throughout the brain. Even though these techniques have been 
immensely valuable for neuroimaging, they measure vesicle membrane fusion and do not enable 
the study of vesicle content release. Furthermore, FM1-43 requires long and complicated 
stimulation procedures for dye loading and can only load certain presynaptically “active” 
terminals that undergo vesicle fusion in response to stimulation. Presynaptically “silent” 
synapses which fail to undergo vesicle fusion in response to action potential stimulation2 cannot 
be labeled using FM1-43. Therefore, presynaptically “silent” glutamatergic synapses3, which 
play an important role in synaptic plasticity4, cannot be studied with FM1-43. Moreover, FM1-43 
suffers from issues of photobleaching and phototoxicity.  
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SynaptopHluorin was one of the first widely used fusion proteins in the study of activity 
at presynaptic terminals. Since its development, new fusion proteins that serve as optical sensors 
of NT release have been developed. In this new approach, a NT receptor is fused with a 
fluorescent protein (or a small molecule fluorescent dye). NT release is detected by fluorescence 
changes that occur due to protein conformational changes elicited by NT binding. So far, this 
approach has been applied towards the study of glutamate release, as it is the major excitatory 
NT in the central nervous system and one of the most important signaling molecules of life. In 
this regard, three major classes of glutamate binding fusion proteins have been developed. These 
include the glutamate (E) optical sensor (EOS)5, two FRET (Förster resonance energy transfer) 
based sensors called glutamate-sensing fluorescent reporter (GluSnFR)6 and fluorescent indicator 
protein for glutamate (FLIPE)7, and lastly, an intensity-based glutamate-sensing fluorescent 
reporter (iGluSnFR)8.  
The fusion protein EOS consists of a glutamate binding protein and a small molecule 
fluorescent dye (Fig. 1A). The ligand-binding domain of the glutamate receptor GluR2 serves as 
the glutamate binding protein and Oregon green serves as the small molecule dye. Upon binding 
to glutamate, EOS shows a 40% increase in ΔF/F at the emission peak of 520 nm (Fig. 1B). EOS 
has been immobilized on the cell surface of neurons (by chemical alkylation of the tissue to 
enable biotin-streptavidin linkages) in hippocampal neuronal culture in order to study the release 















Fig. 1. Design and fluorescent properties of glutamate (E) optical sensor (EOS). A) A schematic 
of EOS structure overlaid on the original GluR2 receptor. The original GluR2 protein is consists 
of the amino-terminal domain (ATD), the S1S2 domain and the transmembrane domains M1, 
M2 and M3. The EOS protein consists of a recombinant S1S2 domain which incorporates a 
fluorescent dye indicated by the asterisk. The glutamate binding pocket is indicated by the 
location of ‘Glu’. B) The emission spectra of EOS in the absence (dotted) and presence (solid) of 
100 µm glutamate indicate a 37% increase in fluorescence intensity upon glutamate binding. Fig. 
is adapted from Namiki et al. (2007) The European Journal of Neuroscience 25, 2249–59. 
 
The second class of glutamate sensors consists of the FRET-based reporters FLIPE and 
GluSnFR. These were constructed by fusing a donor and acceptor fluorescent protein to the two 
termini of the glutamate binding periplasmic protein Escherichia coli GltI (also known as ybeJ). 
In these sensors, the hinge bending motion of the GltI protein, which occurs upon binding to 
glutamate (Fig. 2A), is translated into a reduction in the amount of FRET between the two 
fluorophores. In the case of FLIPE, the donor fluorophore is enhanced cyan fluorescent protein 
(ECFP, λex/λex = 425/485 nm) and the acceptor fluorophore is Venus (λex/λex = 515/528 nm), a 
variant of yellow fluorescent protein. The ECFP/Venus ΔF/F ratio increases upon addition of 
glutamate to the sensor (Fig. 2B). FLIPE sensors have been expressed on the surface of rat 
A.! B.!
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hippocampal neurons and PC12 cells where they respond to extracellular glutamate with a 
reversible concentration-dependent decrease in FRET efficiency7.  
In the case of GluSnFR, the two fluorescent proteins are ECFP and citrine, a variant of 
yellow fluorescent protein (Fig. 3A). The original GluSnFR was designated GluSnFR0N0C, where 
the subscript indicates the amino acids truncated from the N and C termini of mature GltI before 
fusion to the fluorescent proteins. The response of GluSnFR0N0C to glutamate binding was 
studied by measuring the ECFP/YFP fluorescence ratio in the absence and presence of 
glutamate. In the presence of glutamate, this ratio increased by only 7% (Fig. 3B). In order to 
maximize the response of GluSnFR0N0C to glutamate, a library of GluSnFRs with varying linker 
lengths were developed. GluSnFRs with varying N and C terminal truncations of GltI were 
screened on the surface of HEK293 cells. This resulted in the identification of SuperGluSnFR 
which showed a 44% increase in the ECFP/YFP ratio upon binding to glutamate, representing a 
6.2 fold increase over the original construct.  SuperGluSnFR has been used to study the time 






Fig. 2. Conformational changes and fluorescence intensity of FLIPE. A) A conformational 
change is induced in E. Coli GltI protein upon binding to glutamate. The two domains of the 
protein are shown in green and blue. B) The emission spectrum of a FLIPE sensor, in particular 
FLIPE-600n, in the absence (black) and presence (blue) of glutamate. The red curve represents 
the emission spectrum when the sensor is saturated with glutamate. The ECFP/Venus ΔF/F ratio 
increases in response to glutamate addition. Fig. is adapted from Okumoto et al. (2005) 












Fig. 3. A) Schematic of GluSnFr attached to the surface of the cell membrane. B) In vitro ΔF/F 
emission spectra changes of GluSnFR0N0C in the presence and absence of 1 mM glutamate in Tris 
buffer or HBSS buffer. Fig. is adapted from Hires et al. (2008) Proceedings of the National 
Academy of Sciences 105, 4411–6. 
 
The aforementioned FRET sensors have several advantages and drawbacks as compared 
to single wavelength imaging. For instance, FRET sensors enable ratiometric imaging which can 
be used for concentration determination, but often lack sensitivity due to low changes in signal. 
Furthermore, since they occupy a large spectral bandwidth, they are not well suited for multiplex 
imaging. In order to address these limitations, a single wavelength glutamate senor, iGluSnFR 
has been developed using circularly permuted green fluorescent protein (cpGFP).  
  Like FLIPE and GluSnFR, iGluSnFR also uses E. coli GltI as the glutamate binding 
protein. However, in contrast to FLIPE and GluSnFR, iGluSnFR uses the single wavelength 
cpGFP as its fluorophore. In cpGFP, GFP is circularized by linking the N and C terminal ends 
via a short linker peptide. The circular protein is subsequently cleaved at another position in the 
sequence, generating new termini. Remarkably, when GFP is circularly permuted in this way, it 
still remains fluorescent9. In order to generate iGluSnFR, cpGFP was inserted close to the 
interdomain hinge region of the GltI protein (Fig. 4). Expression of iGluSnFR in layer V 
pyramidal neurons of the mouse forelimb motor cortex has enabled the study of glutamate 
activity during running9.  
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Fig. 4. Schematic for the insertion of cpGFP into the GltI 
protein. After residue GltI253, the protein chain passes 
through cpGFP which then regions the remainder of GltI. 
The ligand-free state of the sensor is dim, likely due to the 
distortion of cpGFP indicated by the tilted triangles. The 
binding of glutamate causes a conformational change, 
allowing the cpGFP to fluoresce more brightly.  Fig. is 
adapted from Marvin et al. (2013) An optimized fluorescent 
probe for visualizing glutamate neurotransmission, Nature 
Methods 10, 162–67. 
 
Even though these optical techniques for sensing 
glutamate release have opened several new avenues for the 
study of glutamate release, they require the generation of transgenic animals or delivery of a 
genetically encoded sensor by viral infection. Furthermore, the fluorescence signal relies on 
confounding factors such as the affinity of the sensor for glutamate as well as the efficiency of 
energy transfer between the two chromophores, in the case of the FRET-based sensors. Thus, 
despite the widespread distribution and importance of glutamate, no small molecules exist to 
directly measure its release from the synapse. NADH, a small fluorescent molecule coupled to 
glutamate neurotransmission, has been used to study glutamate release10. However, NADH is 
only weakly fluorescent and requires excitation by UV light which can be toxic to biological 
samples. Furthermore, this approach only provides only an indirect, secondary readout of 
glutamate concentration (Fig. 5).  
                                                         Fig. 5. Schematic of monitoring glutamate with NADH 
fluorescence. Glutamate is converted to α-ketoglutarate by 
glutamate dehydrogenase (GDH), with simultaneous 
production of NADH. α-Ketoglutarate is converted to 
glutamate by glutamate-pyruvate transaminase (GPT), driven 
by excess of supplied alanine. This reaction cycling increases 
production of NADH, the fluorescence of which is monitored 
by UV to determine the release of glutamate. Fig. is adapted 




In order to address these limitations, we set out to develop a “global” FFN that could be 
used to study NT release from a variety of synapses. We reasoned that such an FFN would be 
particularly useful for the study of glutamatergic synapses because these synapses heavily 
innervate several areas of the brain and form the majority of synapses in crucial brain regions 
such as the dorsal striatum11, hippocampus12 and cortex13. 
Our Approach Towards a “Global” FFN 
In order to develop a “global” FFN, we took inspiration from our work with the three 
aforementioned 7-amino coumarin vesicular monoamine transporter 2 (VMAT2) substrates that 
were discussed in Chapter III, namely FFN200, AH180 and GH180. From our colocalization 
experiments with these molecules, we knew that these three compounds, could initially (before 
the 45 min time point in the wash period, see Chapter III, Section II.2) label non-dopaminergic 
structures in the mouse dorsal striatum. It was unclear to us whether the uptake of these 
particular 7-amino coumarin compounds into non-dopaminergic structures was due to the 
activity of a transporter other than VMAT2, or due to lipophilic diffusion across the plasma 
membrane. Therefore, in order to explore the role of lipophilicity in the labeling of non-
dopaminergic structures, we decided to test lipophilic analogs of FFN200 in the mouse dorsal 
striatum. We hoped that this approach would enable us to find an FFN that could label a variety 
of synapses, not just dopaminergic ones.   
 Consequently, three lipophilic analogs of FFN200 were designed and synthesized. The 
structures of these compounds are shown in Fig. 6. The lipophilicity of each analog was 
estimated by measuring its logD value. The logD of a compound measures its tendency to 
partition between an organic phase and a a buffered aqueous phase. In this case, logD was 
measured as a ratio of the compound’s concentration in each phase of a two-phase system of 
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octanol and PBS at pH 7.4. The equation to calculate logD is given by logD = log10 [in 
octanol]/[in water]. As such, a compound with a positive logD value has a greater affinity for 
lipophilic environments than a compound with a negative logD value. Accordingly, the three 
compounds that were studied in our effort to develop a “global” FFN, had logD values that were 
more positive than that of FFN200 (logD -1.29). Their logD values ranged from -0.5 to 0, 
calculated at pH 7.4. For a comparison, dopamine has a logD value of -2.21 and amphetamine 
has a logD value of -0.65 at a pH of 7.4 (values are taken from ChEMBL, chemical database of 
the European Bioinformatics Institute). GH206 had excitation and emission peaks similar to that 
of FFN200 and occurred at 369 and 464 nm respectively. The excitation and emission peaks of 
PV139 and PV7122 were slightly red shifted in comparison to FFN200. The λex/em for PV139 
were 374/482 nm and the λex/em for  PV7122 were 379/474 nm. Dr. Gang Hu in the Sames group 
synthesized GH206 and Dr. Paul Vadola in the Sames group synthesized PV139 and PV7122.  
 
Fig. 6. The structures of FFN200 and its 
lipophilic analogs are shown. We synthesized 
three lipophilic analogs of FFN200 - GH206, 
PV139 and FFN7122. The FFN200 core is 
preserved in all three derivatives. The groups 
added to increase lipophilicity of FFN200 are 
highlighted in blue. GH206 incorporated a 
methyl group at the 7-amino group on FFN200 
and PV139 and PV7122 incorporated six-
membered rings into the structure of FFN200 
which linked the 7-amino group to the 8-position 
and 6-position of the coumarin ring respectively 
(for assignment of coumarin ring positions see 
Chapter II Section II.1). The logD values of all 
three lipophilic analogs were more positive than 
that of FFN200. These values are noted below 
























This chapter describes the investigation of these three compounds in the mouse brain 
tissue. We compared the labeling patterns of these compounds in the mouse dorsal striatum with 
that of FFN200 and further investigated the nature of the structures which they labeled. At the 45 
minute wash time point, all three compounds showed a punctate staining pattern which was 
denser than that of FFN200 in the mouse dorsal striatum. The fluorescent puncta had size (~1 
µm) and shape (round) consistent with presynaptic terminals, indicating that these compounds 
could potentially be developed as “global” FFNs.  
Since both PV139 and PV7122 had a good signal to noise ratio when loaded into brain 
slices and were sufficiently photostable for two-photon microscopy, they were used for further 
studies. Their specificity towards presynaptic terminals was investigated by colocalization 
experiments with genetic markers for dopaminergic and glutamatergic presynaptic terminals, as 
they constitute the majority of synapses in the dorsal striatum12. Through a systematic study of 
colocalization patterns of these probes, PV7122 emerged as a potential general synaptic marker 
in the mouse dorsal striatum, hippocampus and motor cortex. PV7122 was released in a calcium 
dependent manner from presynaptic terminals in the dorsal striatum and CA1 region of the 
hippocampus. Further, we investigated the mechanism of uptake of PV7122 in the mouse brain 
tissue and propose two hypotheses for this mechanism based on our observations. Since PV7122 
displayed properties of a fluorescent false neurotransmitter (terminal labeling and calcium 
dependent release from presynaptic terminals), it is referred to as FFN7122 from here onwards.     
 It is interesting to note that when we tested these three lipophilic analogs of FFN200 in 
HEK293 cells transfected with VMAT2, we discovered that GH206 and PV139 still retained 
activity for VMAT2. GH206 and PV139 both emerged as good VMAT2 substrates and FFN7122 
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emerged as a non-VMAT2 substrate in cell culture. The implications of these results are also 























II. RESULTS AND DISCUSSION 
 All imaging experiments described here were carried out in the mouse brain tissue using 
two-photon microscopy. Coronal or horizontal slices of the specified region of the mouse brain 
were prepared and kept alive in their required oxygenated buffers for 4-5 hours. Buffers used for 
the preparation of acute corticostriatal slices were the same as those described in Chapter III, 
Section IV (experimental).  Buffers used for preparation of hippocampal slices differed from 
those used for preparation of corticostriatal slices. Their composition is given in the experimental 
section of this chapter. The imaging set up used here is similar to that described in Chapter III, 
Section II.1.  
II.1 Labeling Patterns of FFN200, GH206, PV139 and FFN7122 in the Mouse Dorsal 
Striatum 
 
In order to get a first clue about the behavior of the lipophilic analogs of FFN200, we 
looked at their labeling patterns in the mouse dorsal striatum and compared then with that of 
FFN200 (Fig. 7). In order to get an accurate comparison of the labeling patterns, we used a wash 
period of 45 minutes for all probes, as this was determined to be the optimal time point at which 
FFN200 achieved selectivity towards dopamine terminals in the mouse dorsal striatum. Acute 
coronal slices of the dorsal striatum were prepared and probes were loaded and imaged in this 
region as described previously in Chapter III, Section II.1. Tissue slices were incubated for 30 
minutes with the probe and washed for 45 minutes before imaging. Even though the incubation 
and wash period for each probe was the same, some imaging conditions differed due to the 
inherent differences in photophysical properties of the probes. Excitation and emission 
wavelengths as well as concentration were optimized for each probe. FFN200 and GH206 were 
excited at 740 nm and imaged within the range of 440 to 490 nm. PV139 and FFN7122 were 
excited at 760 nm and imaged within the range of 450 to 500 nm. Since PV139 and FFN7122 
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were found to be brighter than FFN200 and GH206 in the tissue slice, they were used at half the 
concentration (5 µM) of the latter two compounds (10 µM). Furthermore, due to the short life 
span of slices (4-5 hours) it was not feasible to image all four probes in the same animal on the 
same day. Since there were minor variations in the imaging conditions between probes, we used 
the labeling pattern of the probes simply as a qualitative guide rather than as a rigorous 
quantitative method for understanding their staining properties.  
 GH206, PV139 and FFN7122 all showed a denser labeling pattern in the dorsal striatum 
as compared to FFN200. This indicated to us that they could potentially be used to label 
structures that were not labeled by FFN200. Moreover, it was important to note that the 
structures labeled by these three probes appeared to have the right size (~ 1 µm) as well as shape 
(round), indicating that they may represent synaptic terminals. PV139 and FFN7122 both had a 
Fig. 7. Labeling patterns of FFN200 (10 µM), GH206 (10 
µM), PV139 (5 µM) and FFFN7122 (5 µM) in the mouse 
dorsal striatum. Probes were incubated in slices for 30 
minutes, washed for 45 minutes and imaged at their respective 
optimized excitation and emission wavelengths and laser 
powers. For FFN200 and GH206, λex = 740 nm and λem = 440 
to 490 nm. For PV139 and FFFN7122, λex = 760 nm and λem = 
450 to 500 nm. The lipophilic analogs had a denser labeling 
pattern than FFN200. PV139 and FFN7122 had a better signal 
to noise ratio than GH206. Images are representative of atleast 




better signal to noise ratio and a more distinct punctate staining pattern as compared to GH206. 
Consequently, they were chosen for further studies.  
Next, we sought to investigate the structures being labeled by PV139 and FFN7122. We 
used the percentages of the types of terminals present in the dorsal striatum (Fig. 8) as a guide to 
establish a starting point for this investigation. Since it is well established by immunohistological 
analysis that glutamatergic and dopaminergic terminals form the majority of synapses in the 
dorsal striatum14, we began by performing colocalization experiments between the two probes 









Fig. 8. The proportion of each synapse type, expressed as a percentage of the total number of 
synapses in the rat striatum. The data is based on immunohistological analyses performed by 
Gaugler et al15. gamma-Aminobutyric acid is represented as GABA.  
 
II.2 Colocalization of PV139 and FFN7122 with TH-GFP in the Dorsal Striatum 
 As mentioned in Chapter III, Section II.2, TH-GFP is a commonly used marker for 
dopaminergic terminals in the mouse dorsal striatum15. In thse mice, GFP is expressed under the 










PV139 and FFN7122 were dopaminergic terminals, we performed colocalization experiments 
with the probes and TH-GFP in the dorsal striatum.  
 Striatal slices were prepared by coronal sections of the mouse brain as described in 
Chapter III. The slices were incubated with 5 µM probe for 30 minutes, washed for 25-30 
minutes and imaged. It is important to note that 25-30 minutes was chosen as the wash period, as 
opposed to the previously used washed period of 45 minutes for FFN200. This is because after 
the initial 15 minutes of washing, the number of puncta being labeled appeared to remain stable 
and independent of wash time (until 55 minutes, after which the punctate signal started becoming 
too dim to obtain a good signal over background).  
The colocalization experiments were performed similarly to those described in Chapter 
III, Section II.2.  First, we performed control experiments in order to ensure that there was no 
crossover of signal between the two fluorophore channels. Since the two-photon excitation and 
emission wavelengths of PV139 and FFN7122 are shorter than that of GFP, their excitation and 
emission spectra could be resolved from GFP. A wavelength of 760 nm was used to excite the 
coumarins and their fluorescence was detected in the range of 450 to 500 nm. A wavelength of 
910 nm was used to excite GFP and its fluorescence was detected in the range of 510 to 600 nm.  
A lack of crossover of PV139 and FFN7122 into the GFP channel was confirmed by 
imaging wild-type (WT) slices incubated with the probe under conditions used for GFP. No 
signal was seen in the GFP channel. Similarly, a lack of crossover of GFP into the FFN channel 
was confirmed by imaging GFP slices lacking probe under the conditions used for the FFN. No 
signal was seen in the FFN channel.  
As explained previously, in order to account for shifts in the xy and z planes, a second 
FFN image was taken after the GFP image. Thus, images were taken in the order FFN-GFP-
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FFN. Only images in which the colocalization between the first and second FFN images was 
greater than 90% were analyzed.  
Both PV139 and FFN7122 showed a denser labeling pattern than that of TH-GFP in the 
dorsal striatum. We analyzed the fraction of PV139/FFN7122 terminals that also contained GFP 
signal. We found that ~ 44% of terminals labeled by PV139 were also labeled by TH-GFP and ~ 
30% of terminals labeled by FFN7122 were also labeled by TH-GFP (Fig. 9). Furthermore, ~ 60 
% of TH-GFP terminals also contained FFN7122. Thus, even though neither probe showed 
exclusive labeling of dopaminergic terminals, PV139 had a greater preference for dopamine 
terminals as compared to FFN7122. This could possibly be due to the fact that PV139 proved to 
be a VMAT2 substrate in HEK–VMAT2 cells where as FFN7122 was a non-VMAT2 substrate. 
Furthermore, it is important to note that even though PV139 was a VMAT2 substrate in cell 
culture, it failed to show a high (above 80%) colocalization with dopaminergic terminals. This 
could be a facet of its increased lipophilicity in comparison to other strong VMAT2 substrates, 
FFN200 and AH180 (see Chapter III, Section I), which both showed ~ 85% colocalization with 
TH-GFP.  This is discussed further in the Discussion section of this Chapter.  
Since both probes showed labeling of non-dopaminergic structures, we could have 
chosen either of them for development as a “global” FFN. However, since FFN7122 showed a 














Fig. 9. Colocalization of PV139 (5 µM) with TH-GFP (top panel) and FFN7122 (5 µM) with 
TH-GFP (bottom panel) in the mouse dorsal striatum. A wavelength of 760 nm was used to 
excite PV139 and FFN7122 and their fluorescence was detected in the range of 450 to 500 nm. A 
wavelength of 910 nm was used to excite GFP and its fluorescence was detected in the range of 
510 to 600 nm. 44% (average of two independent experiments showing 40% and 48%) of 
terminals labeled by PV139 were also labeled by TH-GFP and 30% (average of two indepedent 
experiments showing 32% and 28%) of terminals labeled by FFN7122 were also labeled by TH-
GFP. Furthermore, 59% (one experiment, two slices) of TH-GFP puncta were also labeled by 
FFN7122. Images are representative of two independent experiments for FFN-TH-GFP 
colocalization and one independent experiment for TH-GFP-FFN7122 colocalization. Scale bar 
10 µm.  
  
II.3 Colocalization of FFN7122 with VGLUT1Venus in the Dorsal Striatum 
Since glutamatergic terminals form the majority of synapses in dorsal striatum, we 
surmised that they could represent the non-dopaminergic structures being labeled for the FFN200 
analogs. Accordingly, we carried out colocalization experiments between our most promising 






Knock-In mice16 in order to selectively study and image 
glutamate terminals. These mice were developed using a knock-in (KI) mutagenesis strategy to 
cause expression of VGLUT1Venus. Venus is a rapidly maturing and brightly fluorescing variant 
of yellow fluorescent protein17 which has used been widely to image neuronal cells in many 
organisms18. The strategy used for expression of fluorescent protein (FP) in this case thus 
differed from that used in our previously studied TH-GFP mice. In the VGLUT1Venus
 
KI mice, 
the FP was directly fused with VGLUT1 whereas in the TH-GFP animals, GFP was expressed 
under the control of the TH gene promoter.  
As mentioned in Chapter I, the Vesicular Glutamate Transporter 1 (VGLUT1) is the main 
synaptic vesicle (SV) membrane transporter that is responsible for the uptake of glutamate into 
presynaptic terminals. In the VGLUT1Venus
 
KI mice, VGLUT1 was used as the SV protein 
because it is marker of glutamatergic SVs19 and its expression levels are tightly correlated with 
changes in quantal size and modulations of synaptic plasticity20. The global patterns of Venus 
expression in different regions of the VGLUT1Venus
 
























Fig. 10. The localization of VGLUT1Venus in various regions of the mouse brain. The scale bar in 
image I applies to all images A-I, but represents different scales. The scale for each image is 
specified below. (A) and (B) Overview of VGLUT1Venus fluorescence in paraformaldehyde-fixed 
wild-type (WT) and Venus whole mouse brains and sagittal sections . Scale bar 2 mm. (C), (D) 
and (E) Higher resolution images of the Venus sagittal section shown in (B) depicting 
hippocampus (Hipp), cortex (Cx), and cerebellum (Cb). Fine fluorescent puncta as a granular 
pattern can be seen. This is very similar to structures and patterns that are typically stained by 
conventional anti-VGLUT1 immunohistochemistry. Scale bar 500 µm. (F) High-resolution 
image of a Venus retina (Ret) section. Bright VGLUT1Venus positive varicosities are found in the 
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outer and inner plexiform layers (OPL, IPL), which contain glutamatergic synapses. ONL, Outer 
nuclear layer; INL, inner nuclear layer. Scale bar 20 µm.  (G) and (H) Newborn Venus brain (P0) 
at dorsal view (G) and ventral view (H). There is a lack of fluorescence in the striatum (Str) in 
the newborn mice. Scale bar, 500 µm. (I) Coronal section of a Venus brain at postnatal day 5 
(P5) showing the striatum. VGLUT1Venus corticostriatal fibers enter the striatum at around P5. 
Scale bar, 700 µm. Fig. is adapted from Herzog at al. (2011) The Journal of Neuroscience 31, 
15544–59. 
 
 As is seen from Fig. 10, VGLUT1Venus is expressed is the striatum, hippocampus, cortex 
and cerebellum. In order to study whether FFN7122 could label glutamatergic presynaptic 
terminals in the dorsal striatum, we performed colocalization experiments between FFN7122 and 
VGLUT1Venus. The technique used was similar to that for colocalization experiments with TH-
GFP. FFN7122 and VGLUT1Venus could be spectrally resolved because FFN7122 has a shorter 
excitation and emission wavelength as compared to VGLUT1Venus.  
 We found that ~ 73% percent of terminals labeled by FFN7122 in the dorsal striatum 
were also labeled by VGLUT1Venus (Fig. 11). Further, a majority of VGLUT1Venus terminals, 
~80%, were also labeled by FFN7122. Thus, the, combined results from colocalization 
experiments with VGLUT1Venus and TH-GFP (30% of FFN7122 terminals also have TH-GFP) 
indicate that it primarily labels glutamatergic and dopaminergic terminals in the dorsal striatum.   
Fig. 11. Colocalization of FFN7122 (5 µM) and VGLUT1Venus in the mouse dorsal striatum. A 
wavelength of 760 nm was used to excite FFN7122 and its fluorescence was detected in the 
range of 450 to 500 nm. A wavelength of 910 nm was used to excite VGLUT1Venus and its 
FFN7122! VGLUT1Venus! MERGED!
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fluorescence was detected in the range of 510 to 600 nm. 73% (average of two independent 
experiments showing 72% and 74%) of terminals labeled by FFN7122 were also labeled by 
VGLUT1Venus. 79% (average of two independent experiments showing 75% and 83%) terminals 
labeled by VGLUT1Venus were also labeled by FFN7122. Images are representative of two 
independent experiments. Scale bar 10 µm.  
  
II.4 Colocalization of FFN7122 with VGLUT1Venus in Layer V and VI of the Motor 
Cortex 
  
 Next, we investigated the colocalization of FFN7122 with VGLUT1Venus  in the motor 
cortex of the mouse brain, another region which is heavily innervated with glutamatergic 
terminals. The motor cortex is the region of the cerebral cortex that plays a central role in 
controlling movement execution through both short range and long-range projections. It is well 
established that activity in the motor cortex correlates with actual movement trajectories21.  
 The motor cortex (M1) consists of five different layers that are designated based on 
variations in the packing density and the shapes and sizes of the neurons. These include layers I, 
II/III and V and VI. The conventional fourth layer, which is seen in other areas of the cortex, is 
missing (Fig. 12)22.  
 The motor cortex is innervated by axons from the thalamus and from the frontal and 
parietal cortex. For example, somatosensory information reaches M1 via inputs from the primary 
somatosensory (barrel) cortex23 as well as from higher-order sensory thalamic structures such as 
the posterior nucleus24. Different layers and cell types are engaged by these different 
corticocortical and thalamocortical inputs. 
  The motor cortex makes direct projections to the spinal cord as well as projections to the 
thalamus and brain stem motor centers25 and collaterals from these projections innervate the 
striatum26. Furthermore, it also makes short and long-range corticocortical projections to other 
cortical regions in the same as well as opposite hemisphere27. Neurons projecting to all these 
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targets are found in layer V of M1. As such, studying the excitatory inputs into pyramidal 
neurons of layer V is of particular interest.  
 Through colocalization studies of FFN7122 with VGLUT1Venus  in layer V and VI of the 
motor cortex, we found that ~ 75% of the punctate structures labeled by FFN7122 were also 
labeled by VGLUT1Venus (Fig. 13). Further, ~ 79% of terminals labeled by VGLUT1Venus were 
also labeled by FFN7122. The residual labeling of FFN7122 in this region could represent a 
combination of terminals arising from GABAergic neurons and glutamatergic neurons 
expressing VGLUT2, both of which are found in the motor cortex. GABAergic neurons have 
been found to make synapses with pyramidal cells in the motor cortex in order to inhibit motor 
activity28. VGLUT2 expression in the motor cortex has been identified using VGLUT2 
immunohistochemistry29. The level of VGLUT2 expression varies throughout the layers of the 
motor cortex, with higher expression in layer II/III and layer VA (upper end of layer V) and 
lower expression in layer VB (lower end of layer V). Layer VI was found to have very low levels 
of VGLUT2 which were not readily detectable by the immunohistochemistry method used by 
Oswald et al. (Fig. 12B).  
 Coronal corticostriatal slices were prepared as described previously. Since the dorsal 
striatum and motor cortex can be accessed in the same slice (Fig. 12A), images were taken 








































Fig. 13. Colocalization of FFN7122 (5 µM) and VGLUT1Venus in the mouse motor cortex. A 
wavelength of 760 nm was used to excite FFN7122 and its fluorescence was detected in the 
range of 450 to 500 nm. A wavelength of 910 nm was used to excite VGLUT1Venus and its 
fluorescence was detected in the range of 510 to 600 nm. 75% (average of two independent 
experiments showing 73% and 77%) of terminals labeled by FFN7122 were also labeled by 
Fig. 12. Coronal sections of corticostriatal slices. (A) Corticostriatal 
slice showing the location of the motorcortex (MCTX) and corpus 
callosum (CC) in relation to the dorsal striatum (DSTR). Both 
regions could be imaged from the same slice due to their adjacent 
locations. A higher resolution image of the MCTX shows the 
disparate layers I,II,III,V and VI. Layer IV is missing in this cortical 
region. Fig. 12.A is adapted from the Allen Brain Atlas @ 
http://mouse.brain-map.org (B) Profile of VGLUT2 immunoreactive 
terminals across the various layers of MCTX. High VGLUT2 
expression is seen in layer 2/3 and 5B. Low VGLUT2 expression in 
is seen in layer 5A and very minimal expression in layer 6. Fig. 12.B 
is adapted from Oswald et al. (2013) Frontiers in Cellular 




VGLUT1Venus. 79% (one experiment, two slices) of terminals labeled by VGLUT1Venus were also 
labeled by FFN7122. Images are representative of two independent experiments. Scale bar 10 
µm. 
 
II.5 Colocalization of FFN7122 with VGLUT1Venus in CA1 of the Hippocampus 
 The hippocampus is amongst the most extensively studied glutamatergic regions in the 
brain and its proper functioning is widely accepted to play a crucial role in learning and 
memory30. Damage to the hippocampus is associated with several neuropsychiatric disorders 
such as Schizophrenia and Alzheimer’s Disease (AD)31.  
 Furthermore, one of the most important forms of neural plasticity known as long-term 
potentiation (LTP) was first observed in the hippocampus32 and has extensively been studied in 
this structure. Long-term potentiation is defined as a stable, relatively long lasting (hours to days) 
increase in synaptic efficacy following a brief tetanic (high frequency) stimulation. Thus, 
following LTP induction, a fixed amount of presynaptic stimulation induces a “potentiated” 
postsynaptic response. For example, this response could be an increase in EPSPs (excitatory 
post-synaptic potentials) via recruitment of AMPA or NMDAR receptors to the postsynaptic 
membrane. LTP occurring in the hippocampus is widely believed to be one of the main neural 
mechanisms by which information is stored in the brain33.  
 Besides its crucial role in memory, the hippocampus anatomy also makes it an attractive 
area to study. The hippocampus has neuronal cells and their axons that are neatly organized into 
distinct layers which makes it a model system for studying neurophysiology. The three distinct 
cell layers of the hippocampus are the Dentate Gyrus (DG), CA3 and CA1, which form a 
characteristic tri-synaptic loop. Remarkably, these cell layers can easily be identified under 
bright field microscopy without the need for a neuronal stain or dye.  
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 Cell bodies in the DG are granular in shape whereas cell bodies in the CA3 and CA1 
region are pyramidal in shape. The hippocampus forms a unidirectional network with inputs 
arising from the entorhinal cortex. These inputs form synaptic connections with the DG via the 
perforant path (PP). Axons from the granular cells in the DG project to the CA3 pyramidal 
neurons via the mossy fibers (MF) pathway. Axons from CA3 in turn project to CA1 pyramidal 
neurons via the Schaffer collateral (SC) pathway. These CA1 neurons then send the main output 
back to the entorhinal cortex. CA3 and CA1 neurons can also receive input directly from the 
perforant path. The SC pathway from the CA3 to the CA1 has been extensively studied. In 
electrophysiology experiments pertaining to this region, the SC axons are electrically stimulated 
and their response is recorded in the CA1 region (Fig. 14).  
 Further, it should also be noted that cell bodies in the DG, CA3 and CA1 are 
glutamatergic in nature and over 95% of synapses in the hippocampus are excitatory. 
GABAergic interneurons are present in the hippocampus however GABAergic terminals account 
for only 2.5% of the synapses in the hippocampus34.  
 Thus, given that the hippocampus is such an important and widely studied glutamatergic 
region of the brain, we decided to explore FFN7122 as a marker for glutamate terminals in this 
region. We investigated the loading of FFN7122 in the stratum radiatum layer of the CA1, where 
the SC axons form numerous synapses with the dendrites of CA1 cell bodies. We performed 
colocalization studies using with FFN7122 and VGLUT1Venus. We found ~ 88% of structures 
labeled by FFN7122 in the stratum radiatum of CA1 were also labeled by VGLUT1Venus (Fig. 
16). Further, ~ 86% of terminals labeled by VGLUT1Venus were also labeled by FFN7122. Thus 
FFN7122 emerged as an excellent presynaptic marker for glutamate terminals in the 
hippocampus.  
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 While preparing hippocampal slices, we cut the brain in a horizontal plane (Fig. 15) 
rather than a coronal plane, as was done for preparation of corticostriatal slices. This was done in 
order to preserve anatomical similarities between dorsal and ventral slices. In coronal sections of 
the hippocampus, the distance between the CA3 and CA1 increases dramatically when moving 
from frontal to caudal slices. Furthermore, the slicing protocol for this region was changed. A 
cutting solution which was low in calcium (0.5 mM) had to be used in order to prevent 
excitotoxicity to the hippocampus during slicing. Excitotoxicity is commonly observed in the 
hippocampus due the extensive presence of glutamatergic cell bodies and synapses in this region. 
Reduction in external calcium concentration is well known to reduce excitotoxicity in 
glutamatergic neurons35.   
  
 
Fig. 14. The tri-synaptic hippocampal network. The hippocampus receives inputs from the 
entorhinal cortex which form synaptic connections with the dentate gyrus (DG) via the perforant 
path (PP). Cells from the DG project their axons to CA3 neurons via the mossy fibers (MF) 
pathway which in turn project to CA1 pyramidal neurons via the Schaffer collateral (SC) 
pathway. The SC pathway from the CA3 to the CA1 has been extensively studied. The position 
of the stimulating and recording electrodes typically used to study the CA3-CA1 pathway are 
shown. Fig. is adapted from Ho et al. (2011) Trends In Molecular Medicine 17, 617–24. 
 





Fig. 15. (A) Whole mouse brain cut in a horizontal plane. (B) A horizontal slice of the mouse 
brain showing the two hemispheres. Hippocampi in each hemisphere are highlighted in the 
boxed region. Fig. is adapted from the Allen Brain Atlas @ http://mouse.brain-map.org (C) A 
high-resolution image of the hippocampus showing the s-shaped circuit of the cell body layers. 
The three cell body layers dentate gyrus (DG), CA3 and CA1 appear dark.  
 
 
Fig. 16. Colocalization of FFN7122 (5 µM) and VGLUT1Venus in the CA1 region of the 
hippocampus. A wavelength of 760 nm was used to excite FFN7122 and its fluorescence was 
detected in the range of 450 to 500 nm. A wavelength of 910 nm was used to excite 
VGLUT1Venus and its fluorescence was detected in the range of 510 to 600 nm. 88 ± 1.2% (mean 
± SEM, n = 5) of terminals labeled by FFN7122 were also labeled by VGLUT1Venus. 86% (two 
independent experiments showing 83% and 89%) of terminals labeled by VGLUT1Venus were 











II.6 Colocalization of FFN7122 with GAD65-GFP in CA1 of the Hippocampus 
 Once we established FFN7122 was a marker for presynaptic terminals in various brain 
regions, we investigated whether FFN7122 also labels dendrites. In order to do so, we performed 
colocalization experiments with FFN7122 and a genetic marker for GABAergic dendrites, 
GAD65-GFP. Since GABAergic interneurons are found throughout the hippocampus36 and 
FFN7122 had already been characterized in this area, it was an appropriate region to carry out 
these colocalization experiments.  
 GAD65 (glutamamic acid decarboxylase 65) is an enzyme that converts glutamate to 
GABA. GAD65-GFP mice, in which GFP is expressed under the control of the GAD65 
promoter, have been extensively used to study GABAergic neurotransmission37.  Since GFP is 
expressed under the control of a promoter, as opposed to fused to a specific protein, it fills the 
entire GABAergic neuron. As such, structures visualized by GFP fluorescence in these mice are 
expected to include cell bodies, terminals and dendrites. Because the GABAergic interneurons in 
the hippocampus are not organized into distinct layers (like the GABAergic Purkinje cells that 
are in the cerebellar cortex), both their dendrites and terminals are dispersed all throughout the 
hippocampus, making it difficult to distinguish them from each other. Therefore, it was unclear 
whether the GFP puncta visualized in the hippocampus of these mice were dendrites, terminals 
or both. However, based on correspondence with Professor Adam C. Puche at the University of 
Maryland, Baltimore, who has used these mice to study GABAergic interneurons in the olfactory 
bulb38, we learned that the GFP expression in the synaptic terminals of these mice is typically too 
weak to enable their visualization. Thus, most GFP puncta in these mice are likely to represent 
GABAergic dendrites. This is consistent with the size and shape of many of the GFP puncta we 
visualized, since they appeared to be bigger (2-3 µm) than the average size of a presynaptic 
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terminal. However, in the absence of a rigorous characterization of the GFP expression levels in 
the terminals, we cannot rule out that some of these puncta were presynaptic terminals.  
 Colocalization between FFN7122 and GAD65-GFP in the stratum radiatum of CA1 (Fig. 
17) showed distinctly different patterns of staining of FFN7122 puncta and the putative 
GABAergic dendrites. Extensive quantification was not performed on these images due to 
uncertainty about the identity the lack of the GFP stained puncta. One method to rigorously 
characterize the nature of these puncta would be to perform colocalization experiments with 
FM1-43. Since FM1-43 only labels presynaptic terminals, this experiment could give us an idea 
about the fraction of GFP puncta that are terminals versus dendrites. Alternatively, double 
labeling immunohistochemistry experiments with antibodies against GFP and GAT1 (the GABA 
plasma membrane transporter located at presynaptic terminals) would also shed light on the 
nature of the GFP puncta in the GAD65-GFP mice.   
 
Fig. 17. Colocalization of FFN7122 (5 µM) and GAD65-GFP in the CA1 region of the 
hippocampus. A wavelength of 760 nm was used to excite FFN7122 and its fluorescence was 
detected in the range of 450 to 500 nm. A wavelength of 910 nm was used to excite 
VGLUT1Venus and its fluorescence was detected in the range of 510 to 600 nm. Images are 





II.7 Evoked Release of FFN7122 in Response to Depolarization with 40 mM KCl  
 In order to confirm whether FFN7122 was localized within synaptic vesicles, we 
investigated whether it could be released in response to stimulation with 40 mM KCl. A high 
external K+ concentration causes opening of voltage gated calcium ion channels and is thus 
associated with an increase in intracellular calcium concentrations. The rise in intracellular 
calcium concentration, in turn, causes exocytic fusion of the presynaptic vesicles with the 
presynaptic membrane.  
The KCl release experiments as well as their corresponding controls were performed on a 
Prairie Ultima Multiphoton Microscopy System which had more sensitive fluorescence detectors 
in comparison to the Leica SP5 microscope which was used for colocalization experiments. 
Thus, a lower concentration of 2 µM was better suited for the KCl destaining experiments and 
their controls.  
 Slices were incubated with FFN7122 (2 µM) for 30 minutes and then washed for 10 
minutes in a jar and transferred to an imaging chamber. A typical set up for KCl destaining 
experiments involved a perfusion system that allowed for buffer switching. Slices were washed 
with a standard solution of artificial cerebrospinal fluid (ACSF) first, and then buffer was 
switched to high K+ to induce exocytosis. In the perfusion system used, it took 1-1.5 minutes for 
KCl to travel through the perfusion system and reach the slice. When it reached the slice, KCl 
produced a movement in the xy and z planes of the slice. The time point at which a movement 
was detected in the slice was considered to be the time point at which KCl reached the slice.  
 In order to account for the movements in the z plane, z stacks were accquired over the 
time course of KCl destaining. A time-lapse experiment was conducted in which z stacks were 
taken continuously for a total time of 9 minutes. During the first 5 minutes, slices were perfused 
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with a standard solution of ACSF (for concentration of salts see Experimental section of this 
chapter) and baseline images without stimulation were collected. At the five-minute time point 
the perfusion was switched to ACSF containing 40 mM KCl (prepared by isotonic replacement 
of NaCl) in order to induce destaining. 
 KCl destaining experiments were performed in the stratum radiatum of CA1 in the 
hippocampus. A drastic change in the punctate staining pattern was seen within 1-2 minutes after 
the 40 mM KCl solution reached the slice. A 50 ± 2.1% (mean ± SEM, n = 3) decrease in the 
number of puncta was seen after 2 minutes of stimulation with 40 mM KCl. This time point 
indicating “2 minutes after stimulation” respresnts two minutes after the twitching of the slice 
and ~ 3 to 3.5 minutes after switching the perfusion to 40 mM KCl.This difference in the number 
of puncta was found to be statistically significant (p<0.0001) using an unpaired two-tailed t-test 
with a 95% confidence interval. Since KCl produces minor distortions in the slice, we cannot 
entirely rule out the disappearance of some puncta due to changes in the morphology of the slice. 
However, this minor effect is not likely to cause a large and consistent loss in the number of 
puncta that was seen here (Fig. 18A).    
 In order to confirm that the release of FFN7122 was calcium-dependent, calcium ion 
channels were blocked with 200 µM Cd2+ prior to stimulation with 40 mM KCl. In this 
experiment, no drastic change in the punctate staining pattern was observed after the perfusion 
was switched to ACSF containing 40 mM KCl. Additionally, no significant change in the 
number of puncta was observed after stimulation (Fig. 18B). Since the influx of calcium ions is 
necessary for vesicle fusion, this experiment demonstrated that the releasable proportion of 
FFN7122 must likely be contained within presynaptic vesicles.  
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 Further, as a control, we washed the slice with ACSF containing the standard 
concentration of salts, (K+ is 2.5 mM) and imaged over the same time course as the stimulated 
slices. No dramatic change in the punctate staining pattern was observed over the time course of 
the washing period in the control slices. Additionally, no significant change in the number of 




Fig. 18. High K+ (40 mM) induced destaining of 2 µM FFN7122 in the stratum radiatum of CA1 
in the hippocampus along with corresponding control experiments. Images on the left labeled as 
“before” represent the time point immediately before the perfusion was switched to the indicated 
buffer. The two-minute time point here corresponds to two minutes after the effect of KCl was 
first visualized. (A) The punctate staining pattern of FFN7122 before and 2 minutes after KCl 
reaches the slice. A 50 ± 2.1% (mean ± SEM, n = 3) decrease in the number of puncta was 
observed after stimulation with KCl. This was found to be a significant difference 
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(****p<0.0001) using an unpaired two-tailed t-test with a 95% confidence interval. (B) Blocking 
Ca2+ ion channels with 200 µM Cd2+ and then stimulation with 40 mM KCl + 200 µM Cd2+ 
produced no drastic change in the punctate staining pattern and no significant change in the 
number of FFN7122 puntca. (C) Control experiment where FFN7122 was loaded into the slice 
and washed with ACSF containing the standard concentration of KCl over the same time course 
as the stimulated slices. No drastic change in the punctate staining pattern and no significant 
change in the number of puncta was seen over the time course of washing. Large bright objects 
seen here (~ 5-10 µm) are likely blood vessels which were seen in several instances to be labeled 
by FFN7122. Images are representative of atleast three independent experiments and 1-2 slices 
per experiment. Scale bar 10 µm.  
 
 Further, we also studied the response of FFN7122 to KCl stimulation in the dorsal 
striatum (Fig. 19). Stimulation and control experiments were performed as described before. As 
expected, a drastic loss of punctate staining pattern was seen in stimulated slices but not in 
control slices.  
Fig. 19. High K+ (40 mM) induced 
destaining of 2 µM FFN7122 in the 
dorsal striatum with its corresponding 
control experiment. The two-minute 
time point here corresponds to two 
minutes after the KCl reaches the slice. 
Large bright objects seen here (~5-10 
µm) are likely blood vessels which 
seen in several instances to be labeled 
by FFN7122. (A) The punctate staining 
pattern before and 2 minutes after KCl 
reaches the slice. (B) Control 
experiment showing the punctate 
staining pattern of FFN7122 in which 
slices were washed with ACSF 
containing the standard concentration 
of KCl over the same time course as 
the stimulated slices. Images are 
representative of two independent 
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II.8 Reduced Uptake of FFN7122 in VGLUT1-Knock Out Mice 
 In order to investigate the mechanism of FFN7122 uptake in the mouse brain tissue, we 
studied the putative role of VGLUT1 in the accumulation of this probe. First, we searched the 
literature for a VGLUT1 inhibitor for use in the brain tissue. We found that even though several 
small molecules have been used as potent inhibitors of VGLUT1, to the best of our knowledge, 
they have only been used in biological systems that are simpler than the mouse brain tissue such 
as purified synaptosomes or transfected HEK cells. For example, the fluorescein derivative Rose 
Bengal is a potent inhibitor of VGLUT1 with a Ki of 19 nM. Treatment of synaptosomes with 
this compound successfully inhibits glutamate uptake in synaptosomes39. However, due to its 
polarity, Rose Bengal cannot cross the plasma membrane efficiently. Consequently it needs to be 
used in conjunction with digitonin, which permeabilizes the cell membrane, allowing Rose 
Bengal to reach VGLUT1. Such a membrane permeabilization approach would be unfeasible in 
the brain tissue which consists of several lipophilic membrane structures that help maintain its 
structural integrity. Further, the azo dye Trypan Blue is also a potent VGLUT1 inhibitor with a 
Ki of 50 nM39. However, this is also commonly used as a dye to label dead cells in which the cell 
membrane is compromised. It does not label live cells, indicating that it too cannot readily cross 
an intact cell membrane.    
 Thus, in the absence of any established pharmacological membrane permeant VGLUT1 
inhibitors for use in the brain tissue, we chose to pursue a genetic approach. We used VGLUT1 
Knock Out (KO) mice developed by Fremeau et al40. Homozygous VGLUT1 KO mice displayed 
no obvious phenotypic abnormalities for about 2 weeks after birth during which period they were 
indistinguishable from the WT. However, homozygous VGLUT1 KO animals older than 2 to 3 
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weeks fed poorly and did not survive unless maintained separately from their littermates. 
Therefore, we performed experiments on KO mice between postnatal day 10 and 17.   
 Horizontal hippocampal slices from homozygous VGLUT1 KO mice were compared 
with slices from their WT littermates as a control. Slices were allowed to recover for 1 hour in 
each case before use. The WT littermate was sacrificed and imaged first, followed by the KO 
mouse. FFN7122 labeling procedures were the same as described previously. Two to three slices 
per animal were imaged and two independent experiments were performed. Images were 
accquired in the stratum radiatum layer of the CA1 region of the hippocampus. We found that 
the VGLUT1 KO mice showed a 42% (average of two indepednet experimetns showing 40% 
and 44%) decrease in the number of puncta as compared to their WT littermates. This difference 
was statistically significant (p<0.01) using an unpaired two-tailed t-test with a 95% confidence 
interval. However, there was no significant difference in the intensity of puncta between the KO 




Fig. 20. FFN7122 (5 µM) uptake in the stratum radiatum of CA1 in VGLUT1 KO mice and their 
WT littermates. (A) FFN7122 staining in VGLUT1 KO mice between p10 to p17 and their WT 
littermates. Slices were incubated for 30 minutes in FFN7122, washed for 20-30 minutes and 
then imaged. Images shown are representative of two independent experiments. Scale bar 10 µm. 
(B) The VGLUT1 KO mice showed a 42% (average of two indepednet experimetns showing 
40% and 44%) decrease in the number of FFN7122 puncta which was statistically significant 
(**p<0.01) using an unpaired two-tailed t-test with a 95% confidence interval. No significant 
difference in the intensity of puncta was found between the VGLUT1 KO mice and their WT 
littermates.  
 
 In order to interpret these results, it is important to take note of a few experiments 
performed by Fremeau et al. during their characterization of the VGLUT1 KO mice. In 
particular, we will consider the experiments they performed in regard to the characterization of 




WT and VGLUT1 KO mice, they found that the expression of the two other isoforms of 
VGLUT, VGLUT2 and VGLUT3, was not up-regulated in the VGLUT1 KO mice at three weeks 
of age. Therefore, there was no global compensatory effect of VGLUT2 and VGLUT3 in the 
VGLUT1-KO mice. This result was in accordance with observations by Wojcik et al41 in 
VGLUT1 KO mice. Since whole brain extracts do not reveal information about specific 
localization of proteins, Fremeau et al. performed in situ hydridization experiments in 
hippocampal tissue slices of developing WT mice (from 4 days to adulthood) in order to know 
which regions express VGLUT2.  They found that VGLUT2 is expressed along with VGLUT1 
in the hippocampus until two weeks of age, after which its expression drastically declines (Fig. 
21). Since similar levels of VGLUT2 were expressed in WT and VGLUT1-KO mice (at least 
until three weeks of age) and WT mice display VGLUT2 expression in the hippocampus in early 
postnatal development, it is likely that VGLUT1 KO mice also express VGLUT2 in the 
hippocampus during early postnatal development. Indeed, this would be in accordance with 
Herzog et al. who detected a low level of VGLUT2 expression in synapses of hippocampal 
neurons cultured from VGLUT1 KO mice42.  
 
Fig. 21. In situ hybridization from the WT 
developing mouse brain with 35S-labeled 
VGLUT1 and two antisense RNA probes is 
shown in the top panel (1). VGLUT1 
expression increases from 4 days (4d) to 
adulthood (Ad). In contrast, VGLUT2 
expression shown in the bottom panel (2) 
does not change in the thalamus but reaches 
a peak at 1 week (1 wk) in the 
hippocampus, followed by a rapid decline and disappearance by adulthood. Hippocampus is 
abbreviated as Hc and Thalamus abbreviated as Th. Fig. is adapted from Fremeau et al. (2004) 
Science 304, 1815–19. 
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 Taking these data into consideration, we hypothesize that the decrease in uptake of 
FFN7122 in the stratum radiatum of CA1 in VGLUT1-KO mice is due to its ability to act as a 
VGLUT1 substrate and its residual uptake is due to the presence of VGLUT2 in the 
hippocampus during early postnatal development (Hypothesis 1). In order to fully address this 
hypothesis, we propose that experiments could be done with mature VGLUT1-KO mice at the 
age of 6 to 8 weeks. At this age, when the expression of VGLUT2 in the stratum radiatum of 
CA1 is likely to be negligible, as it is well known that the adult hippocampus is primarily a 
VGLUT1 expressing region43.  
 Another important experiment performed by Fremeau et al. characterized the changes in 
number of terminals as well as the number of vesicles per terminal in WT and KO mice (Fig. 
22). Using electron microscopy (EM), they found that there was no change in the number of 
terminals in the WT and KO mice in the stratum radiatum of CA1. However, they did find that 
there was a 50% decrease in the number of vesicles per terminal. As such, there could be an 
alternative explanation for the finding that FFN7122 puncta were half as numerous in the KO 
mice as compared to the WT mice. It is possible that FFN7122 crosses the cell membrane via 
passive diffusion and enters acidic presynaptic vesicles where it gets protonated and sequestered. 
The protonated species of FFN7122 would carry two cationic charges within the vesicles, one on 
each amine, rendering it too polar to exit the vesicles via passive diffusion. Given that FFN7122 
has a logD value close to zero at pH 7.4, it has a similar affinity for lipophilic and aqueous 
environments. Therefore, it would not be an unlikely scenario for this probe to cross the cell 
membrane and synaptic vesicle membrane via passive diffusion. Thus, our second hypothesis 
proposes that FFN7122 behaves as a lipophilic weak base that labels acidic compartments such 
as synaptic vesicles in the mouse brain tissue (Hypothesis 2). As such, the 41.8% decrease in the 
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number of FFN7122 puncta in VGLUT1 KO mice could be a result of a decrease in acidic 

















Fig. 22. (A) Quantification of excitatory 
terminal density in hippocampus (Hc) and 
cerebellum (Cb) showed no significant 
difference between WT (+/+) and VGLUT1 
KO (–/–) mice at 3 weeks or as adults (7 
weeks). (B) A significant reduction in the 
number of synaptic vesicles was seen in 
both the hippocampus and the cerebellum 
of KO mice. Fig. is adapted from Fremeau 
et al. (2004) Science 304, 1815–19. 
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II.9 Comparison of FFN7122 labeling with Lipophilic Weak Base Acridine Orange 
 In order to address the lipophilic weak base hypothesis, we compared the labeling pattern 
of FFN7122 with acridine orange (AO), which is well established as a membrane permeant weak 
base that interacts with DNA and RNA and also labels acidic organelles such as endosomes and 
lysosomes in cells44. When AO enters acidic compartments in cells, it becomes protonated and is 
sequestered within these compartments. As such, AO has been used for studying pH gradients 
across vesicular as well as lysosomal and endosomal membranes45.  
 AO stains living and fixed tissues with variable hues of fluorescence. Dilute AO solutions 
or AO molecules bound to deoxyribonucleic acid (DNA) emit green orthochromic fluorescence 
(λex/em = 502/525 nm). Concentrated solutions or aggregates of AO (as in acidic compartments of 
cells) exhibit red metachromatic fluorescence (λex/em = 460/650 nm)46. Metachromasy is defined 
as the change in absorption and emission wavelengths of a dye that is caused due to changes in 
conditions such as dye concentration, pH, temperature and substrate binding. More specifically, 
metachromasy involves changes in absorption of a dye to shorter wavelengths that is 
accompanied by an increase in the fluorescence emission wavelength and a decrease in the 
intensity of emitted fluorescence47.  
 First, we compared the labeling of both fluorophores in the hippocampus. Horizontal 
hippocampal slices were incubated in 2 µM (FFN7122) or 4 µM (AO) fluorophore followed by a 
20-30 minute wash period. In order to account for the metachromasy of AO, the optimal 
wavelengths for the excitation and emission of the fluorophore needed to be determined.  We 
performed an excitation wavelength scan from 850 to 980 nm while capturing fluorescence from 
510 to 700 nm. A strong fluorescent signal was detected at excitation wavelengths ranging from 
850 to 950 nm and a very dim fluorescent signal was detected for excitation wavelengths ranging 
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from 950 to 980 nm.  No difference in the fluorescent patterns was detected while exciting from 
850 to 950 nm. Within this range, excitation at 910 nm was found to have the brightest 
fluorescence signal and hence this was used as the excitation wavelength for further experiments 
with AO.  Furthermore, when the emission range was changed from 510-700 nm to 510-600 nm, 
no change in the fluorescence intensity or pattern was seen, indicating a minimal contribution of 
fluorescence from 600-700 nm. This observation was in accordance with the two-photon induced 
emission of AO, which has a broad emission peak from 500-600 nm48.   
 A low-resolution (10X) image of the hippocampal staining of each fluorophore is shown 
in Fig. 23. These low-resolution images were taken in superficial layers of the slice (15-20 µm 
below the surface) as opposed to deeper layers at ~30 µm below the surface which was the 
typical imaging depth used for other FFN experiments. This was because 10X objectives (as the 
one used in this experiment) have a smaller depth of focus as compared to higher magnification 
objectives such as the 63X objectives that were typically used for other FFN experiments. This 
phenomenon is related to the numerical aperture and magnification of the objective, and under 
some conditions, high numerical aperture systems (usually with higher magnification power) 
have deeper focus depths than do those systems of low numerical aperture49. 
FFN7122 densely stained the stratum radiatum (SR) layer of the CA1 in the 
hippocampus, which is abundantly innervated by glutamatergic synapses. In contrast to this, AO 
showed almost no staining in this layer. Furthermore, in the low-resolution images, FFN7122 
showed no labeling in the stratum pyramidal (SP) layer, which contains the pyramidal cell bodies 
of the CA1. In contrast to this, AO densely labeled cell bodies in this layer (Fig. 23). Similar 
differences in staining patterns of both probes were also observed in the DG at 10X resolution.   
 Next, in order to get a more comprehensive understanding of the differences in the two 
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fluorophores, we took higher magnification images (63X) of the hippocampus labeled with 
FFN7122 and AO (Fig. 24). We discovered that when imaging at 63X magnification and depths 
of greater than 35 µm in the slice, FFN7122 did indeed label cell bodies in both the SP and 
granular layer of the DG. While AO labeled cell bodies in both superficial (10-30 µm) and deep 
(> 35 µm) layers, FFN7122 labeled cell bodies only in the deeper layers of the slice.  
 The lack of FFN7122 cell body labeling on in the superficial layers of the slice can likely 
be explained by the presence of unhealthy and/or dead cells in layers closer to the surface. It is 
well known that excessive excitotoxicity of glutamatergic neurons causes cell bodies in 
hippocampal slice preparations to be susceptible to cell death, particularly on the surface of the 
slice50.  Consistent with this, we observed dead cell bodies as large (15-20 µm) and rounded 
(versus healthy granular or pyramidal) structures on the surface of the slice in bright-field 
images. Considering this aspect of hippocampal slices, it became apparent that FFN7122 
primarily labeled healthy cell bodies (dead cell bodies were seen as rounded black structures) 
and AO labeled both healthy and dead cell bodies. This phenomenon of AO-cell body labeling of 
both dead and living cells is in accordance with observations by Wolf et al51.   
 Furthermore, the staining pattern in FFN7122-labeled bodies differed from that seen in 
AO-labeled bodies. While FFN7122 showed a more homogenous and diffuse labeling pattern in 
cell bodies of the CA1, AO showed a punctate staining pattern. The visualization of two 
prominent large and bright puncta in several AO-labeled cell bodies was in accordance with AO 
staining of DNA in the nucleus and nucleolus of the cell body51.   
 More strikingly, AO did not demonstrate a punctate labeling pattern in the SR of the CA1 
outside of the cell bodies, indicating that it could not be used to visualize a majority of 
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presynaptic terminals in this region. This is in stark contrast to the FFN7122 punctate pattern 
seen outside of the cell bodies.  
 The lack of AO fluorescence in presynaptic terminals could be explained either by a lack 
of AO loading into presynaptic vesicles, or an alteration in the photophysical properties of the 
fluorophore in response to the acidic pH of the vesicles. Regardless, our data indicate that AO is 
not well suited as a marker for presynaptic terminals in tissue slices of the mouse brain. The 
distinctly different labeling patterns of AO and FFN7122 in mouse brain tissue slices could point 
to either disparate mechanisms of uptake, partitioning of the probes into different compartments,  


















Fig. 23. FFN7122 (2 µM) and Acridine Orange (4 µM) labeling in the hippocampus. Slices were 
incubated for 30 minutes and washed for 20-30 minutes before imaging. FFN7122 was excited at 
770 nm and emission visualized between 440 to 500 nm. AO was excited at 910 nm and 
emission visualized at 530 to 600 nm. FFN7122 densely labels the stratum radiatum (SR) of the 
CA1 as opposed to AO, which sparsely labels this layer. Almost no FFN7122-labeleing is seen 
in the stratum pyramidal (SP) of the CA1 under the 10X objective, where as dense AO-labeling 
labeling is seen in this layer. Images were taken at depths of 15-20 µm below the surface of the 


































Fig. 24. FFN7122 (2 µM) and Acridine Orange (4 µM) display distinctly different labeling 
patterns both within cell bodies and outside the cell bodies. Cell bodies can be seen as rounded or 
pyramidal structures of 10-15 µm in size. Imaging conditions used were the same as specified in 
Fig. 23 above. FFN7122 has a diffuse and homogenous labeling inside cell bodies (rounded 
structures of ~ 10 to 15 µm) as opposed to the punctate pattern seen with AO. FFN7122 densely 
labels synapses (spherical structures of ~1 µm) outside the cell body in contrast to AO, which 
fails to load into synapses. Images are representative of two independent experiments for 
FFN7122 and three independent experiments for AO. Images were taken at depths of 35-45 µm 













III. CONCLUSIONS AND FUTURE DIRECTIONS 
 In order to develop a “global” FFN that could be used as a general synaptic marker, we 
investigated the nature of synaptic labeling of three lipophilic analogs of FFN200 - GH206, 
PV130 and FFN7122.  We found that even though GH206 and PV139 were strong VMAT2 
substrates in HEK cells, they showed poor colocalization with dopaminergic terminals in the 
dorsal striatum of the mouse brain (less than 45%, GH206 colocalization data is an unpublished 
observation by Dr. Shu Li in the Sames laboratory). This is in stark contrast to the more polar 
VMAT2 substrates, FFN200 and AH180, which showed ~ 85% colocalization with 
dopaminergic terminals in the dorsal striatum of the mouse brain. This indicates that compounds 
can be good VMAT2 substrates in cell culture, however, other competitive uptake processes 
(such as lipophilic diffusion) can cause them to have to poor selectivity for VMAT2-containing 
synapses in the more complex system of the mouse brain. This finding will help inform the 
design and structure of new FFNs which are targeted to substrates of specific transporters.   
 Through a systematic evaluation of labeling patterns of GH206, PV139 and FFN7122 in 
the mouse brain tissue, we discovered that FFN7122 was a suitable synaptic marker for 
dopaminergic and glutamatergic presynaptic terminals. FFN7122 appeared to be excluded from 
GABAergic dendrites in the CA1 of the hippocampus. Furthermore, FFN7122 was released in 
response to stimulation with high K+ in both the dorsal striatum and hippocampus. FFN7122 
showed a 50% decrease in the number of puncta in VGLUT1 KO mice in comparison to WT 
littermates.  
 Based on our data, we propose two hypotheses for the uptake of FFN7122 into 
presynaptic terminals.  
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Hypothesis 1: FFN7122 is a VGLUT1 substrate and residual uptake of the probe in VGLUT1 
KO animals is due to the expression of VGLUT2.  
Hypothesis 2: FFN7122 is a lipophilic weak base that crosses cell membranes via passive 
diffusion and enters presynaptic vesicles where it gets protonated and sequestered due to the 
acidic environment of the vesicles. To understand this scenario, it is important to consider the 
protonated states of the two amines in FFN122. At physiological pH (7.4), the amine belonging 
to ethylamine group would be protonated (pKa ~ 9, based on the known pKa of 
phenylethylamine52) and the 7-amino group would be in its neutral state (pKa ~ 6, based on the 
known pKa of aniline53). As such, FFN7122 would carry only a single cationic charge at pH 7.4, 
which would not render it polar enough to prevent its permeation across the cell and vesicular 
membrane. At the lower pH of the vesicles (~5.5), the 7-amino group would be protonated. 
Consequently, FFN7122 would carry two cationic charges, rendering the molecule too polar to 
cross the cell membrane. This would cause FFN7122 to get sequestered in acidic compartments.   
In order to address the first hypothesis, we propose to perform experiments on adult 
(older than 6 weeks) VGLUT1-KO mice since the expression of VGLUT2 in the adult 
hippocampus is known to be negligible43. If residual FFN7122 uptake is indeed due to VGLUT2, 
it should be drastically decreased in the adult hippocampus where no VGLUT2 is likely to be 
found. It should be noted however, that studies characterizing VGLUT2 expression in the 
developing hippocampus have only been performed in WT mice, not VGLUT1-KO mice. To our 
knowledge, only indirect evidence exists to support similar patterns of VGLUT2 expression in 
the developing hippocampus of WT and VGLU1-KO mice. Therefore, we will perform 
immunohistochemistry in the adult hippocampus of VGLUT1-KO mice in order confirm the 
absence of VGLUT2 in this region.    
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 Furthermore, cell-based assays could also be used to address whether FFN7122 is indeed 
a VGLUT1 substrate. For example, HEK cells transfected with VGLUT1. Alternatively, PC12 
cells that over express VGLUT1 which have been developed by Wilson et al.54 could also be 
used.  
 In order to address the second hypothesis, we compared the labeling of FFN7122 with 
that of AO, a cell permeant lipophilic weak base. We found that AO could not be used to 
visualize synaptic vesicles in the CA1 of the hippocampus. This was in direct contrast to 
FFN7122 which reliably stained presynaptic terminals in the dorsal striatum, hippocampus and 
motor cortex. This indicates that either the probes stain structures via disparate mechanisms 
and/or that their photophysical properties differ in the acidic vesicles of presynaptic terminals.   
Regardless, these experiments showed that FFN7122 is superior to AO as a marker of 
presynapitc terminals in the mouse brain slice.  
 Currently, our combined data from the VGLUT1-KO mice and the AO experiments does 
not rigorously exclude either hypothesis 1 or hypothesis 2.  
In order to further characterize FFN7122 as a general marker for presynaptic terminals, 
we will study its ability to label a third subtype (besides dopaminergic and glutamatergic) of 
terminals, namely, GABAergic terminals. This study will be performed by carrying out 
colocalization experiments between FFN7122 and a genetic marker for presynaptic GABAergic 
terminals, mGAT1-GFP55. 
  The GABA transporter 1 (GAT1) is the predominant plasma membrane GABA 
transporter that is responsible for the uptake of GABA after its release from presynaptic 
vesicles56. GAT1 is particularly abundant in areas rich in GABAergic neurons, such as the 
hippocampus, neocortex, cerebellum, and retina57. Furthermore, GAT1 is localized in 
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GABAergic axons and nerve terminals and in some brain regions, is expressed on the surface of 
astrocytes58. In the aforementioned transgenic mice, which we will use as a marker for 
presynaptic GABAergic terminals, a knock-in strategy was used to develop animals that express 
an mGAT1–GFP fusion protein in place of the WT GAT1 protein.  
 In P29 and older mGAT1–GFP mice, fluorescence was expressed in GABAergic axons 
and synapses throughout the hippocampus. At higher magnifications, the stratum oriens layer 
displayed a clear staining pattern of axons and boutons. Such clear labeling of synaptic structures 
was not observed in the pyramidal cell layers of the CA1 and CA3 or granular cell layer of the 
dentate gyrus. The authors55 concluded that this could be attributed to the high levels of astroglial 
expression in these regions, which caused high background fluorescence and reduced the 
resolution of individual synapses.  Since GABAergic presynaptic terminals were distinctly 
labeled in the stratum oriens layer, we will explore the labeling of FFN7122 in this region of the 
mGAT1–GFP mice. Furthermore, since GABAergic terminals do not express VGLUTs, this 
experiment will help to weigh in on the hypotheses regarding the uptake of FFN7122.   
 FFN7122 represents the first FFN to successfully label presynaptic terminals outside of 
the dopamine system in the mouse brain tissue. It serves as a marker for glutamatergic 
presynaptic terminals, particularly in the CA1 region of the hippocampus. The study of its 
release via electrical stimulation of the SC pathway will shed light on several important aspects 
of glutamatergic neurotransmission. In this regard, FFN7122 could be a valuable tool to study 
LTP at the excitatory synapses between the CA3 and CA1 pyramidal neurons. Although LTP has 
been extensively studied at these synapses, the basic question as to whether LTP results from 
changes in presynaptic or postsynaptic function remains controversial59. One approach to resolve 
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the uncertainties about the presynaptic contribution to synaptic plasticity during LTP would be to 
directly image presynaptic function using a tool like FFN7122.   
 In the future, we will investigate the in vivo applications of FFN7122. This will be done 
using a thinned-skull cranial window technique that allows for long-term imaging in the cortex 
of live mice.  Since FFN7122 densely labels presynaptic terminals in the mouse cortex, it will be 
well suited for this technique. 
Eventually, we envision using FFN7122 for in vivo imaging in primates by adapting it for 
use in Positron Emission Tomorgraphy (PET) imaging (for PET imaging, see Chapter I, Section 
VII). PET-FFN7122 will be developed by incorporating radioisotopes such as 11C or 19F into the 
FFN design. This will unlock new opportunities for directly imaging synaptic function in the 
brain. In particular, PET-FFN7122 will be useful for studying the synaptic activity of 
glutamatergic neurons. The study of glutamatergic neurotransmission via PET imaging is a 
growing area of interest. In this regard, [11C]ABP68860, a PET radioligand for the metabotropic 
glutamate receptor 5 (mGluR5), has been developed. This PET probe has demonstrated excellent 
in vitro and in vivo properties and has already been used to study mGluR5 distribution in 
humans61.  
Eventually, we anticipate that FFN7122 will be embraced as a useful complement to 
other optical techniques such as calcium imaging in order to deconvolve neural activity into its 






IV. EXPERIMENTAL  
IV.1 Preparation of Probe Stock Solutions 
 GH206 was synthesized, purified and characterized by Dr. Gang Hu in the Sames 
Laboratory. PV139 was synthesized, purified and characterized by Dr. Paul Vadola in the Sames 
Laboratory. FFN7122 was synthesized purified and characterized by Dr. Paul Vadola and 
Andrew Kruegel in the Sames laboratory. GH206 and PV139 were used as their free bases and 
FFN7122 was used as its HCl salt. Stock solutions of 20 mM in DMSO were prepared for each 
probe and stored at -80oC. 
IV.2 Slice Preparation 
 Unless otherwise noted, animals used were 2 to 4 month old male WT C57BL/6 mice 
which were obtained from the Jackson Laboratory. Animal protocols were approved by the 
Institutional Animal Care and Use Committee of Columbia University. 
Corticostriatal Slices: These were prepared as described in Chapter III, Section IV 
(Experimental). All corticostriatal slices were cut in the coronal plane.  
Hippocampal Slices: Mice were decapitated by cervical dislocation and 300 µm thick horizontal 
slices were cut on a vibratome in oxygenated [95% O2, 5% CO2 (vol/vol)] artificial cerebrospinal 
fluid (ACSF) kept at 4°C containing the following (in mM): 10 NaCl, 2.5 KCl, 25 NaHCO3, 0.5 
CaCl2, 7 MgCl2.6H2O, 1.25 NaH2PO4.H2O, 10 glucose, 180 sucrose (pH 7.2–7.4, 292–296 
mOsm/L). Slices were allowed to recover for 30 minutes at 32°C in oxygenated [95% O2, 5% 
CO2 (vol/vol)] ACSF containing the following (in mM): 125 NaCl, 2.5 KCl, 25 NaHCO3, 2 
CaCl2, 1 MgCl2 .6H2O, 1.25 NaH2PO4 .H2O, 10 glucose (pH 7.2–7.4, 292–296 mOsm/L). Slices 
were then transferred to another container with the same ACSF composition that was at 32°C, 
and allowed to cool to room temp over another 30 minutes before use. Note the difference in the 
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cutting solution used for preparation of corticostriatal slices and hippocampal slices. Cutting 
solution with lower calcium (0.5 mM as opposed to 2 mM in the experimental ACSF) was used 
for the hippocampus slice preparation to prevent excitotoxicity generated in hippocampal slices 
during cutting.  
IV.3 Loading and Imaging of Probes in the Brain Slice  
 
 All loading and imaging of probes was done following procedures mentioned in Chapter 
III, Section IV (Experimental), with minor modifications. Since PV139 and FFN7122 were 
found to be brighter in the tissue slice as compared to GH206 and FFN200, they were used at 5 
µM or 2 µM (specified in each experiment) instead of the concentration of 10 µM that was used 
for the latter two compounds. 5 µM PV139 and FFN7122 was used for all colocalization 
experiments with genetic markers as well as for experiments with VGLUT1-KO mice. 2 µM was 
used for KCl release experiments as well as FFN7122 cell body staining experiments. A slightly 
lower concentration was used for the KCl release experiments because of concerns that the 
lipophilicity of the probe may interfere with the release of the compound at 5 µM. Additionally, 
the KCl release experiments and their corresponding controls were performed on the Prairie 
Ultima Multiphoton Microscopy System which had more sensitive fluorescence detectors in 
comparison to the Leica SP5 microscope on which the colocalization experiments were carried 
out. Thus, a lower concentration of 2 µM was better suited for the KCl destaining experiments.  
 Images were acquired on a Leica SP5 microscope with titanium-sapphire MaiTai laser 
(Spectra Physics) equipped with 40x 0.8 NA (Olympus, Tokyo, Japan; TH-GFP co-localization 
experiments) or a 63x 0.9 NA (Leica Microsystems, Wetzlar, Germany; comparison of puncta 
labeling patterns for FFNs and acridine orange staining) water immersion objective.  
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 For all other experiments (KCl stimulation, VGLUT1-KO and FFN7122 cell body 
staining) slices were imaged on a Prairie Ultima Multiphoton Microscopy System (Prairie 
Technologies, Middleton, WI) equipped a Spectra-Physics titanium-sapphire MaiTai laser 
(Newport Corporation, Irvine, CA) and a Coherent titanium-sapphire Chameleon laser (Coherent 
Inc., Santa Clara, CA) and a 60x 0.9 NA water immersion objective (Olympus, Tokyo, Japan). 
 On both microscope setups, slices were placed on a QE-1 imaging chamber (Warner 
Instruments, Hamden, CT) and held in place with a custom-made platinum wire and nylon holder 
(Wong et al., 2011), where they were constantly superfused (2-3 ml/min) with oxygenated 
ACSF. All images were taken at a depth of at least 30 µm. 
 GH206 was excited at 740 nm and the emission was visualized between 440 to 490 nm. 
On the Leica SP5 microscope, PV139 and FFN7122 were excited at 760 nm and their emissions 
were visualized between 450 to 500 nm. Images were collected at a resolution of 512X512 pixels 
(41 µm X 41 µm). Images were acquired as an accumulation of two frames and an average of 4 
lines at a speed of 200 Hz. On the Prairie Ultima Multiphoton Microscopy System, FFN7122 
was excited at 770 nm and its fluorescence emission was detected between 440 to 500 nm. 
Images were acquired as single frames at a resolution of  512X512 pixels (38 X 38 µm) using a 
dwell time/pixel of 10 µs.  
IV.4 Colocalization of PV139 and FFN7122 with TH-GFP, VGLUT1Venus and GAD65-
 GFP 
 
 Colocalization experiments with the FFNs and GFP-based genetic probes were performed 
as described in Chapter III, Section IV (Experimental) and thus are not elaborated upon here. For 
all transgenic mice, males between the ages of 1 to 3 months were used, with an exception being 
the GAD-65 GFP mice that were used between the ages of 4 to 5 months. VGLUT1Venus mice 
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were a gift from the laboratory of Dr. Etienne Herzog at Universite Pierre et Marie Curie 
(UPMC), Pathophysiology of Central Nervous System Disorders, Paris, France.   
 The only modifications from the previous procedure were the excitation and emission 
wavelengths used for the FFN channel. PV139 and FFN7122 were excited at 760 nm and their 
emission was visualized between 450 to 500 nm. All fluorescent proteins were excited between 
910-920 nm and visualized between 510 to 600 nm. The excitation wavelength for the 
fluorescent proteins was varied in order to minimize crosstalk between the two fluorophore 
channels.  
IV.5 Stimulation of FFN7122 with 40 mM KCl 
 
 KCl induced release was achieved by exposing slices labeled with 2 µM FFN7122 to a 
solution of ACSF containing 40 mM KCl (solution prepared by isotonic replacement of NaCl). 
The addition of KCl to the slice is harsh stimulus and generates movements in the xy and z 
planes and can sometimes distort the field of view. In order to account for shifts in the xy and z 
plane due to addition of this high concentration of KCl, images of 5 µm z-stacks were taken over 
time. As a control, z-stack images of slices not perfused with high KCl were also acquired. To 
confirm calcium-dependent release, slices were treated with 200 μM CdCl2 in ACSF for 20 min, 
followed by perfusion of ACSF containing 40 mM KCl and 200 μM CdCl2.  
 Within each z-stack 5 images were collected at intervals of 1 µm. The dwell time/pixel 
and image resolution was adjusted so that each z-stack was ~15 seconds. Thus, a field of view of 
38 X 38 µm at 512 X 512 pixel resolution was used with a dwell time/pixel of 10 µs. A total of 
36 z-stacks (36 cycles) were collected resulting in a time-lapse experiment lasting for nine 
minutes. The first 20 cycles (5 minutes) were baseline time points. The perfusion was switched 
to KCl at cycle 20. It took approximately 1-1.5 minutes for the effect of KCl to be visualized in 
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the slice. This accounts for the time it took for KCl to travel within the perfusion live to the slice 
as well as for KCl to penetrate the slice. As such, the effect could be visualized by a movement 
in the field of view at ~ cycle 26. After this, images were taken for another 2.5-3 minutes.  
IV.6 Uptake of FFN7122 in VGLUT1 Knock Out Mice 
 
 VGLUT1 KO mice we a gift from Robert Edwards at the University of California, San 
Francisco. Since these animals do not survive beyond P18, they were used between P10 and P17. 
Specifically, experiments were done at P11 and P15. The WT littermate was sacrificed first and 
three to four slices were imaged. Then, a homozygous KO mouse from the same litter was 
sacrificed and imaged using the same conditions. For each experiment, the WT littermate and 
KO mouse were imaged on the same day. Horizontal hippocampal slices were prepared and 
incubated in 5 µM FFN7122 for 30 minutes, washed for 20-30 minutes in a 40 mL jar, 
transferred to the imaging chamber, and imaged in the stratum radiatum layer of CA1. Imaging 
conditions (laser power, dwell time/pixel etc.) were kept constant between both animals. These 
experiments were performed on the Prairie Ultima Multiphoton Microscope using imaging 
conditions as described previously for this system.  
IV.7 Cell Body Labeling with FFN7122 and Acridine Orange in CA1 Region of 
Hippocampus 
  
 For FFN7122, horizontal sections of the hippocampus were prepared and incubated with 
2 µM probe for 30 minutes, washed for 20-30 minutes and imaged on the aforementioned Prairie 
Ultima Multiphoton Microscope.  
 For Acridine Orange, horizontal sections of the hippocampus were prepared and 
incubated with 4 µM probe, incubated for 30 minutes and washed for 15 minutes. Images were 
collected on the Leica SP5 microscope. Acridine orange was excited at 910 nm and its emission 
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was detected in the range of 530 to 600 nm. Images were acquired using a frame accumulation of 
two and a line average of 4 with a speed of 100Hz.  
 All cell body images were gathered at depths of greater than 35 microns in the slice.  
IV.8 Image Analysis  
 Image analysis was performed using either Volocity version 4.4 software by Improvision 
or an open source version of MacBiophotonics ImageJ (NIH), Fiji. For images analyzed in 
Volocity, raw images were imported into Volocity as “.liff” format (from the Leica LASAF 
software). The pixel size was adjusted to 0.080 µm/pixel after images were imported into 
Volocity. Presynaptic terminals were identified as objects in each of the images using the same 
protocols as previously mentioned in Chapter III, Section IV (Experimental). For images 
analyzed in Image J, images were imported into ImageJ as 512 X 512 8-bit “.tiff” and puncta 
were selected using a plugin called the DTP_multiple_thresholdsMacro, version 4.2. created by 
Damon Poburko at Simon Frasier University 
(http://rsb.info.nih.gov/ij/macros/Mulitple_Thresholds.txt). This macro uses a multiple 
thresholding method that can be used to form masks over puncta without having to specify a 
minimum brightness intensity. This macro allows certain critical parameters to be determined for 
puncta selection. These parameters are explained below.  
(1) Number of Standard Deviations (SDs) – This parameter specifies the number of SDs of 
intensity above the mean intensity that is needed for an object to be selected as a Region 
of Interest (ROI).  
(2) Number of Thresholds or Step Size – This parameter enables objects with varying 
intensities to be selected as ROIs. An increase in the number of thresholds roughly 
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corresponds to an increase in the sensitivity of the program towards picking both bright 
and dim puncta.    
(3) Minimum and Maximum Puncta Size – This can be specified by the user by limiting the 
minimum and maximum number of pixels that must be counted in an ROI.  
(4) Minimum Circularity of Puncta – This parameter ranges from 0 to 1 and can be specified 
based on the shapes desired for selection.  
(5) Radius of Background Subtraction – This background subtraction method is the same as 
ImageJ’s “rolling ball” background subtraction method (Process/Subtract 
background/Create background). 
(6)  Exclude ROIs from edges – This parameter specifies the number of pixels from the 
edges of the image that should be excluded while selecting puncta.  
 Upon visual inspection, it became clear that the selection of puncta by ImageJ was more 
accurate in terms of size and intensity of objects picked, as compared to Volocity. Therefore, 
images that were analyzed by ImageJ were not subjected to manual inspection and no puncta 
were manually discarded. The parameters used in this Macro are specified within each 
experiment.  
Quantification of Colocalization Between FFNs and Genetic Markers  
 All colocalization experiments were analyzed using parameters specified for 
colocalization experiments in Chapter III, Section IV (Experimental). The parameters for 
fluorescent puncta selection for the coumarin probes PV139 and FFN7122 were similar to that 
used for AH180 in Chapter III. The same is applicable for identification of puncta for the 
fluorescent proteins used as genetic markers.  
Quantification of FFN7122 KCl Release in the Hippocampus   
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 ImageJ (NIH) was used to analyze KCl-induced destaining of FFN7122 puncta. Image 
sequences were imported into ImageJ and organized into hyperstacks with 36 time points and 5 z 
sections. Since KCl produces xy and z shifts in the slice, images in time points after the KCl 
reached the slice (~ cycle 26) were analyzed by eye in order to match them as closely as possible 
to the field of view before KCl reached the slice. The appropriate z section in each time point 
was selected to form a continuous time sequence. Slices in which maximum information in the 
xy and z plane was captured after KCl stimulation were analyzed. In these slices, the time point 
at cycle 20, and cycle 30/31/32 (~1.5 Min after KCl reaches the slice) were analyzed for 
differences in puncta number. Due to the shifts in the xy and z planes and sometimes a distortion 
within the slice, it is not possible to track the destaining of individual puncta. Therefore, the 
differences in the number of puncta in cycle 20 and cycle 30/31/32 represents only a crude 
estimate of the effect of KCl on the destaining of FFN7122.  The number of puncta was analyzed 
using ImageJ. The parameters specified in the DTP_multiple_thresholds Macro Version 4.2 were 
as follows: 
(1) Number of Standard Deviations (SDs): 0.2 
(2) Number of Thresholds or Step Size: 40 
(3) Minimum and Maximum Puncta Size: Min 25 and Max 150 pixels 
(4) Minimum Circularity of Puncta: 0.6 
(5) Radius of Background Subtraction: -1 (this is the default value to indicate no background 
subtraction)  
(6) Exclude ROIs from edges: none 
Quantification of Genetic Inhibition Using VGLUT1-KO Mice 
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 ImageJ was used to analyze the images from this experiment. The parameters specified in 
the DTP_multiple_thresholds Macro Version 4.2 were as follows: 
(1) Number of Standard Deviations (SDs): 0.6 
(2) Number of Thresholds or Step Size: 20 
(3) Minimum and Maximum Puncta Size: Min 25 and Max 150 pixels  
(4) Minimum Circularity of Puncta: 0.6  
(5) Radius of Background Subtraction: 15 
(6) Exclude ROIs from edges: Less than 5 pixels  
IV.9 Statistical Analysis of Data   
Differences in puncta number and mean fluorescence intensity between WT and KO slices were 
calculated using GraphPad Prism software. Two tailed unpaired t-tests with 95% confidence 
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